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Abstract
The nuclear receptor PPARγ is a lipid-dependent transcription factor which
regulates many pathways in lipid metabolism. Due to functions in adipogenesis,
glucose uptake and insulin sensitivity it has been a target of type II diabetes
mellitus therapeutics since the 1990s. Due to a poorly understood antiinflammatory pathway it is also an emerging target in neurodegenerative disease.
Despite extensive research the majority of the structural mechanism underlying
the regulation of this proteins’ function is poorly understood. It is often thought
that nuclear receptors function in a simple two-state model with defined on and
off states. This model only considers one region of the protein, the coregulator
interaction surface. In this mechanism ligands function only to modulate the
equilibrium population of the active and inactive states. In this work we examine
the conformational ensemble of PPARγ in response to the binding of a wide
variety of structurally and functionally diverse ligands and find clear evidence
that this model is only correct for the most efficacious activating ligand. In all
others the ligand induced conformational ensemble is highly diverse and contains
multiple populations. Additionally, the mechanisms of inverse agonism and
agonism are examined. Through this a novel mechanism of inverse agonism is
determined. As well we demonstrate that the mechanistic underpinnings of
agonism are not strictly through the coregulator interaction surface. The most
efficacious ligands also make important interactions in other regions of the
protein which are often disregarded. Among the most interesting findings is the
identification of a highly conserved motif on helix 4 of the ligand binding domain
of nuclear receptors. We demonstrate that this motif is responsible for a large
degree of the specificity observed in coactivator interactions. This provides a
substantial amount of insight into the mechanism by which these proteins function
as it had previously been observed that coactivator recruitment was exceptionally
specific, but no mechanistic reason was known. Through this work we have
gleaned a deeper understanding of the mechanism of specific ligand-dependent
conformations in this important protein. This fundamental understanding allows
for more efficient and intelligent design of drugs which target PPARγ and other
nuclear receptors.
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Chapter 1 Introduction
1.1 Nuclear Receptors
The nuclear receptors (NR) are a diverse family of transcription factors
that regulate a wide variety of signaling pathways. In the human genome there are
48 recognized NR proteins in this superfamily which make up the largest group of
known transcription factors1,2. These proteins are highly sequence divergent but
structurally conserved3. All members of this superfamily share a very modular
fold wherein they contain an N-terminal intrinsically disordered region known as
either the A/B domain or the activation factor 1 region (AF-1). This domain has
very low homology between nuclear receptors and like many intrinsically
disordered regions appears to function primarily in the recruitment of regulatory
proteins. Though there is an emerging role for this domain in the modulation of
drug response. Thus far this has only been reported with estrogen receptor alpha
(ERα)4,5 but this may also be true for other members of this superfamily. The next
domain is the C domain or DNA-binding domain (DBD). This approximately 80
residue domain is highly conserved between nuclear receptors, ~80%, and
contains two tetra-cysteine zinc fingers. This domain mediates the interaction
with the respective response element for each of the NR. Receptors will bind to
their response element as either heterodimers, most often dimerized with retinoid
x receptors (RxR), homodimers or as half-site binders. This leads to highly
divergent sequences for the response elements, but they are most often direct
repeats for heterodimeric binding proteins or an inverted repeat if the receptor
binds as a homodimer. The next domain, D, is the flexible hinge region of
approximately 20 residues which connects the DBD to the following domain and
allows conformational freedom between the domains of the protein. For many
nuclear receptors the E domain or ligand-binding domain (LBD) is the C-terminus
of the protein. This domain has a very conserved fold made up of approximately
12 α-helices and a single region which typically contains three β-sheets. Not all
nuclear receptor LBDs have exactly 12 helices, but they are numbered as if they
do. The LBD contains the ligand binding pocket as well as the major coregulator
1

interaction surface known as the activation factor 2 (AF-2). In some receptors,
primarily the hormone receptors, there is an additional F domain which is
moderately structured and makes up the C-terminus of the protein. The role of the
F domain is not known but has been shown in some receptors such as ERα or
glucocorticoid receptor (GR) to be essential for protein stability. Recent data in
ER α and β indicates this domain may also be required for agonist behavior of
certain ligands6,7.

Figure 1. Conserved structure of nuclear receptors. A: Primary structure of nuclear receptors
showing the four conserved domains seen in nuclear receptors. Domain F is unique to hormone
receptors and is not present in the majority of nuclear receptors. B: Crystal structure of the DBD of
GR bound to a response element of DNA (PDB 1GLU). C: Crystal structure of the LBD of GR
bound to a peptide of the coactivator TIF2 (PDB 1M2Z). Both the DBD and LBD have a
conserved fold in nuclear receptors, so the representative structures shown will be very similar to
those of other nuclear receptors. Figure was adapted from Carter et al8.

These receptors are primarily divided into three families (NR1, NR2 and
NR3) which respond to different types of ligands. The NR1 family is primarily
lipid-dependent and binds either fatty acids or cholesterol metabolites. The NR2
2

family is by majority vitamin-dependent and binds a variety of essential vitamins
such as retinoic acid (vitamin A). There are exceptions to this however, as the
vitamin D receptor (VDR) is a member of the NR1 family while the orphan
receptor testicular receptor 4 (TR4) which has no known ligands specific to this
protein but can bind peroxisome proliferator-activated receptor gamma (PPARγ)
synthetic ligands is a member of NR2. The NR3 family is composed primarily of
hormone receptors and include heavily studied receptors such as GR or ERα.
There are three additional small families which are the NR0, NR4 and NR5
families. These are all orphan receptors, with no known ligands, and several,
including all members of the NR4 family, are considered to be constitutively
active and ligand-independent9,10. This is based on crystallographic observations
that these proteins do not contain a true ligand binding pocket due to impingement
by helix 3 and a large number of bulky hydrophobic side chains in the ligand
binding pocket9. However, a recent paper examining the LBD of Nurr1, NR4A2,
showed that the residues around what would be the ligand binding pocket are
highly plastic11. This may indicate that what is observed in crystal structures is
only one of several accessible conformations in this region and that in some
accessible conformations there is a properly formed ligand-binding pocket. The
NR0 family is also interesting, these proteins have lost the AF-1 and DBD
through the evolutionary process and now function more in the manner of a
coregulator. They still form heterodimers with other nuclear receptors but due to
the lack of their own DBD they are almost exclusively transrepressive12,13.
1.2 Mechanism of transcriptional regulation
Nuclear receptor function is regulated through the recruitment of
coregulator complexes. These occur through direct interactions between the
nuclear receptor and either a coactivator or a corepressor protein in a liganddependent manner. The binding of a coregulator to a NR will then nucleate the
formation of a large complex which regulates the transcription of downstream
genes in a variety of ways. It is generally thought that in an apo state of the
nuclear receptor it is almost exclusively bound with corepressors and when bound
3

to an endogenous ligand or a synthetic agonist, corepressors are displaced and
coactivators are recruited. These interactions are primarily mediated by small
motifs on the coregulator protein. In a coactivator this interaction motif is
comprised of an LxxLL sequence known as an NR box14–16 (In this work referred
to as an LxxLL box to avoid confusion with the abbreviation for nuclear
receptor). For a corepressor this motif is a somewhat longer and there is less
clarity in what makes up the sequence, but it is postulated that this motif contains
at least I/LxxI/VIxxxF/Y/L, LxxxL/IxxxL/I or L/VxxI/VI and is referred to as a
CoRNR box17–20. The LxxLL or CoRNR box interacts most often on the AF-2
surface of the nuclear receptor in a conserved manner where the interaction is
mediated primarily by a single α-helix of the coregulator protein. These
interactions are exceptionally specific with each NR binding only certain
coregulators and often only specific LxxLL or CoRNR boxes within a
coregulator. Currently, little is known of how these interactions are specific but in
chapter three of this work we present evidence for a helix 4 motif on the AF-2
surface of nuclear receptors which appears to be responsible for the majority of
the specificity observed in coactivator binding.
What is known about coregulator recruitment is almost completely in the
context of coactivators. It has been shown that the AF-2 surface of a nuclear
receptor has a hydrophobic cleft which allows a docking event between the
leucine residues in the LxxLL box and the nuclear receptor21. Following this
docking the most common hypothesis for interaction is from the “mousetrap
model” of the charge clamp. The charge clamp is made up of a glutamate on helix
12 and a lysine on the C-terminus of helix 3 which are conserved in almost all
nuclear receptors22. In this model helix 12 relocates into a conformation where it
is more proximal to the coactivator LxxLL box. This moves the coactivator into a
conformation where it is located near both charge clamp residues and allows for
the formation of extensive hydrogen bonds between the charge clamp residues
and the peptide backbone of the LxxLL box. These interactions have been shown
experimentally to convey the bulk of the binding energy for the coregulator but as
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stated earlier confer no selectivity since they are to a conserved region of the
peptide backbone of the coactivator.
Additionally, there are several nuclear receptors which have been shown
to interact with coregulators through the intrinsically disordered AF-1 region23,24.
The nature of this interaction is not well understood. The hypothesis for how this
binding leads to a functional output is by driving a self-association between the
AF-1 and the LBD which is required for activity, but why this is required for
activation is not currently clear. This often leads to coregulators binding to both
the AF-1 and AF-2 surface simultaneously25,26. It has been demonstrated that
these spanning interactions are important for function but the structural reason
why remains unclear. In the case of a small number of nuclear receptors, the NR4
family and the testicular receptors (TR2 and 4)27,28, the AF-2 surface is degenerate
and unsuitable for coactivator binding, so all coactivator interactions are mediated
purely through the AF-1. For the NR4 proteins this is primarily thought to be due
to a reversal of the charge clamp residues. In all three members of this family the
helix 12 charge clamp residue is instead a lysine and the helix 3 charge clamp
residue is a glutamate. This is in contrast to all other nuclear receptors which have
the conserved lysine on helix 3 and the glutamate on helix 12. It is not totally
clear why this change prevents coactivator recruitment on the AF-2 as these
residues are only involved in non-specific hydrogen bonds to the backbone of
coactivators but it has been shown experimentally that only the AF-1 contributes
to coactivator binding in Nur77 and that the presence of the LBD actually lowers
coactivator affinity29. For the other nuclear receptors which do not bind
coactivators through the AF-2, TR2 and TR4, the reason appears to be due to a
change in the polarity of the normally hydrophobic cleft where the leucines in the
LxxLL box interact. In these proteins this cleft is much shallower and more polar
which creates an unfavorable environment for these hydrophobic interactions27,28.
Interestingly, in at least Nurr1, NR4A2, it has been found that not only do
coactivators not bind in the AF-2 region but corepressors may also bind in a novel
position which is located in a cleft between helices 11 and 1230.
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1.2.1 Transcriptional activation through the recruitment of coactivator
complexes

Coactivator proteins recruit large complexes which depending on the
coactivator have distinct functionality and regulate different pathways31. The
largest family of coactivator proteins is the p160 family32. This includes the most
commonly studied coactivator proteins nuclear receptor coactivator 1 and 2
(NCoA 1 and 2), also commonly known as SRC 1 and 2, as well as several other
proteins. These proteins function primarily through the formation of histone
acetyltransferase (HAT) complexes which covalently modify histone proteins and
lead to the release of DNA thereby making it more accessible for transcription33.
Other common coactivators such as p300 and creb-binding protein (CBP)
nucleate the formation of similar HAT complexes34. There is significant crosstalk
between the NCoA proteins and CBP or p300 as it has been shown for each they
are often in the complexes assembled by the other35 leading to a synergistic
activation. In addition, the yeast HAT protein GCN536, closely related to the
human analog KAT2A, has been shown to directly bind some nuclear receptors in
a drug dependent manner as a coactivator. This implies that the formation of large
complexes may not always be necessary for coactivator function, but it should be
stated that it is not clear that if these HAT proteins were directly recruited they
would not nucleate larger complexes as well.
Not all coactivators are dependent on histone modification for function.
Two examples of this are the mediator of RNA polymerase II transcription
subunit 1 (MED1, also known as TRAP220 and DRIP205) and PPARγ
coactivator 1α (PGC1α)37–39. With these coactivators the mechanism operates
through a direct interaction with the promoter rather than through the recruitment
of HAT proteins. Both of these proteins function in the same manner where upon
binding of the nuclear receptor they assemble the 33-protein mediator complex.
This complex will then interact directly with the promoter of the gene to be
transcribed and facilitate the assembly of the RNA polymerase II holoenzyme.
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There may also be other activity with two specific coactivator proteins,
NCoA140 and MED141. These have been shown in cell-based assays to increase
gene expression when overexpressed. The mechanism of this is not fully clear as
it occurs in the absence of stimulation of any ligand for receptors which interact
with these proteins. The most likely hypothesis for this observation is that the
higher concentration of overexpressed MED1 or NCoA1 led to more instances
where the NR was bound to the coregulator even in the absence of ligand. This is
consistent with the observation that NR have an innate low affinity for
coactivators when the NR is in the apo state. However, this hypothesis has not
been experimentally validated.

7

Figure 2. Nuclear receptor activity is mediated by coregulator recruitment. Nuclear receptor
regulated transcription of downstream genes is mediated by the recruitment of coregulators. For
most nuclear receptors depending on the ligand bound state either coactivator complexes (top) will
be recruited to drive transcription. Alternatively, when bound to an inverse agonist or in the apo
state there is a preference for corepressor binding which will downregulate the transcription of
most downstream genes (bottom). Figure was adapted from Parissi et al42.

1.2.2 Transcriptional repression and corepressor complexes
Nuclear receptor corepressors are a much less diverse group. In humans
there are two primary corepressors, nuclear receptor corepressor 1 and 2 (NCoR 1
and 2, NCoR2 is often referred to as SMRT)43,44. These are both structurally
similar large proteins, approximately 2500 residues, which are primarily
intrinsically disordered. They share a mechanism of action whereby they nucleate
the formation of complexes which contain one or more histone deacetylase
(HDAC) proteins. The activity of HDAC will induce compression of genomic
DNA and thereby reduce transcription of nearby genes. It is generally thought that
the resting state of nuclear receptors in the absence of ligand is bound to one of
these corepressors. Due to somewhat high structural similarity and a similar
mechanisms of action it is often thought that these proteins are redundant and
perform the same role. However, this seems unlikely mostly due to the high cost
of producing such large and complex proteins. If these two NCoR proteins did not
have discrete roles it is likely that one would have since been selected against and
become a pseudogene. As well, there is some literature that suggests that one
cannot compensate for the absence of the other. For instance, it was shown in
mouse adipocytes that the selective ablation of NCoR1 created a phenotype very
similar to that seen with treatment by a PPARγ activating drug45. If it were the
case that NCoR1 and NCoR2 were redundant than it would be expected that the
ablation would have had minimal effect due to compensation through NCoR2.
There is a third less well understood corepressor, nuclear receptor
interacting protein 1 (NRIP1). This protein is particularly interesting as it does not
contain a CoRNR box like the other corepressors but rather contains the LxxLL
8

box seen in coactivators46,47. It has been shown to bind in a ligand-dependent
manner with a binding preference for agonist bound receptors. It has similar
corepressor activity as is seen with NCoR1 and SMRT arising primarily through
the assembly of corepressor complexes containing HDAC proteins. However, it
also has been shown to have some coactivator characteristics. This mechanism is
not well understood but it is thought that the regulation of NRIP1 activity as either
a coactivator or corepressor is regulated through post-translational modification of
the NRIP1 protein or by the sequence of the DNA the nuclear receptor is bound
to. The presence of an LxxLL box instead of a CoRNR box would also suggest
this protein would have a distinct binding mode from the NCoR proteins. This is
due to the fact that the CoRNR box has a much larger footprint on the nuclear
receptor and binding is thought to require either displacement of helix 12 or as has
more recently been shown a relocation of helix 1248. This implies that despite
primarily having corepressor activity this protein likely binds in a manner similar
to coactivators.
1.3 Peroxisome proliferator-activated receptor gamma (PPARγ)
The work in this project focuses on the nuclear receptor PPARγ. This
protein along with PPAR α and δ (PPARδ is also referred to as PPARβ) make up
the NR1C family. All the PPAR proteins function as lipid-dependent transcription
factors and regulate a variety of pathways related to fatty acid metabolism49. The
PPAR proteins like other fatty acid receptors transactivate as obligate
heterodimers with the retinoid x receptors (RxR α/β/γ) through the binding of
direct repeat sequences of five nucleotides with a single nucleotide spacer, known
as PPAR response elements (PPRE)50. It is generally thought the PPAR proteins
have a preference to interact with RxRα but recent in cell data showed that
PPARγ was actually most often interacting with RxRβ51. The PPAR proteins
regulate a number of pathways related to lipid metabolism and differ primarily in
tissue distribution. Particularly PPARα and PPARδ appear to have very similar
functions but differ in tissue distribution with PPARα being most heavily
expressed in the liver52 and PPARδ having highest expression in skeletal
9

muscle53. Both these proteins are involved in signaling which leads to the
metabolism of lipids as an energy source. Due to this there has been significant
research on PPARα as a therapeutic target for dyslipidemia leading to the fibrate
family of FDA approved drugs54. There has been significantly less research on
PPARδ as a therapeutic target. Some experimental ligands have been created but
none were suitable for human use55,56.
PPARγ is expressed at low levels ubiquitously in almost all tissue types.
There are two common isoforms which exist, PPARγ1 and PPARγ2, these
isoforms differ only by the presence of an additional 28 residues on the Nterminus of the protein in PPARγ2, in mice PPARγ2 contains an additional 30
residues. For the purpose of clarity in the introduction all PPARγ residue numbers
will be referred to in the form PPARγ1 #/ PPARγ2 # since both numbering
systems are used extensively in literature. There are no currently known
differences in the activity of the two isoforms of this protein. They do however
differ significantly in tissue distribution. PPARγ1 is expressed at low levels in the
majority of tissues while PPARγ2 is expressed almost completely in adipose
tissue57. It has been shown that a high fat diet (HFD) in mice will lead to the
expression of PPARγ2 in other tissues58,59. Depending on the tissue there appears
to be distinct pathways for this protein which will be explained in greater detail
below.
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Figure 3. Tissue specific expression of PPARγ in mice. The relative abundance of the PPARγ
mRNA in a wide variety of tissue types shows highest expression in adipose tissue and the colon
but some expression in almost all tissue types. Figure was adapted from Lee et al60.

1.3.1 Function of PPARγ in adipose tissue
The activity of PPARγ was first determined through its induction during
adipogenesis61,62. The function of this protein is best understood through the roles
it plays in adipogenesis and lipogenic pathways. As stated above the majority of
PPARγ is expressed in adipose tissue. Adipose PPARγ has been shown to act as
the master regulator of adipogenesis. This was first observed from PPARγ null
mice which were completely unable to generate any adipose tissue63. Later
experiments demonstrated that PPARγ knockout mouse embryonic fibroblasts
were unable to be differentiated into adipocytes consistent with this protein
playing an essential role in adipocyte differentiation64. Interestingly, it was also
found through the selective ablation of PPARγ in mouse adipocytes that this
protein is also required for maintenance as ablated cells died within a few days65.
PPARγ was also identified as playing a role in the self-renewal of adipose
tissue66. This was determined through the identification of a niche of adipocyte
progenitor cells in the adipose vasculature which heavily expressed PPARγ and
11

could be differentiated into adipocytes by treatment with a PPARγ ligand unlike
similar cells obtained from other tissues. Interestingly, adipose tissue is also the
only location where PPARγ2 is expressed to significant levels in healthy animals.
The specific role this isoform plays is not well understood as this tissue also
heavily expresses PPARγ1.
A function unique to PPARγ in adipose tissue is the “beiging” of white
adipose tissue (WAT)67. This leads to a phenotypic shift which makes this tissue
behave more similarly to brown adipose tissue (BAT). It had been thought that
humans lack this tissue type, but recent research determined that there is a
somewhat small reservoir of BAT in humans and like other adipose cells PPARγ
was essential for its differentiation and maintenance68. This tissue unlike WAT is
highly metabolically active and consumes lipids through uncoupled mitochondrial
respiration to generate heat69. There has been significant research into this
“beiging” phenomenon as due to the uncoupled oxidation of fatty acids this could
be exploited for weight loss or the treatment of certain metabolic conditions. Thus
far this “beiging” has only been observed following treatment with strong PPARγ
activators and the exact mechanism is not fully clear70. The current hypothesized
pathway is through stabilization of PRDM16, a transcription factor linked to BAT
development. It has been found that the activation of PPARγ leads to an increased
half-life for PRDM1671. This is supported by findings that deacetylation of
PPARγ on two lysine residues, 240/268 and 265/293, leads to an association
between PPARγ and PRDM1672. These findings have led to research to determine
if this pathway is PPARγ transactivation independent and whether a ligand can be
found which will preferentially increase this “beiging” without leading to
canonical PPARγ signaling.
1.3.2 Whole body signaling of PPARγ expressed in adipose tissue
As well as regulating adipogenesis PPARγ also has important roles in
adipose tissue which regulate glucose homeostasis. PPARγ activity increases the
expression of the glucose transporter Glut473,74 and the c-cbl associated protein
(CAP)75. Both of these proteins play important roles in insulin signaling. There is
12

also thought to be function in increasing insulin sensitization through the
modulation of the release of cytokines and adipokines. It has been shown that
PPARγ activation increases the release of adiponectin76. This adipokine is
important in insulin signaling through signaling an increase in glucose uptake and
a decrease in gluconeogenesis. Another important adipokine that is downregulated
is leptin which is important in the regulation of the hunger response77,78. A
significant amount of the PPARγ induced insulin sensitivity also comes from the
reduction of pro-inflammatory molecules. For instance, high circulating glucose
levels are highly inflammatory and have been linked to insulin resistance. As well
PPARγ activation has been shown to reduce the expression of the proinflammatory cytokine TNF-α79. This cytokine is also implicated in insulin
resistance when at high levels and is frequently upregulated with type II diabetes
mellitus (T2DM)80.
Due to these strong effects in insulin sensitization PPARγ has been studied
extensively as a medicinal target for T2DM. This has led to the development of
multiple drugs which have been approved for human use by the FDA.
Unfortunately, all of these drugs have been tied to severe negative side effects
leading to the restriction or recall of some. Medicinally relevant ligands of PPARγ
will be covered in more detail below in the section on synthetic ligands with the
FDA approved ligands covered in the section on full agonists.
1.3.3 Negative effects of PPARγ activation
As stated earlier, PPARγ is expressed to low levels in the majority of
tissue types. In many tissues this leads to beneficial effects such as are seen in
adipose tissue. PPARγ activation in skeletal muscle81, the pancreas82,83 or the liver
all leads to insulin sensitizing effects similar to those seen in adipocytes. Though,
in the liver it is hypothesized that PPARγ activity leads to steatosis, a damaging
accumulation of adipocytes84. However, literature also exists that suggests that
PPARγ reduces liver steatosis85,86. So, the overall effect on liver health is unclear
at this point. There is also the observed effect of a pronounced decrease in
inflammation in the brain. This has been of great interest in recent research
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towards the treatment of neurodegenerative diseases. This will be covered in
greater detail later in the section on anti-inflammatory effects. However, in some
tissue types there are severe effects related to the activation of PPARγ which give
rise to the negative side effects that have caused the recall or restriction of drugs
targeting this protein.
The best understood of these is a decrease in bone strength. This is caused
by a decrease in osteoblastogenesis, the formation of bone tissue, and an increase
in osteoclastogenesis, the resorption of bone cells. It has been found that the
activation of PPARγ inhibits bone formation through a reduction in differentiation
of osteoblasts87,88. To support this, it has also been shown that PPARγ-null
embryonic stem cells will spontaneously differentiate to osteoblasts unlike normal
embryonic stem cells89. As well, PPARγ-null hematopoietic mouse lineages are
deficient in osteoclastogenesis90. This data indicates that the loss in bone integrity
with PPARγ ligands occurs through the downregulation of osteoblastogenesis and
upregulation in osteoclastogenesis. There is also evidence that PPARγ ligands can
cause spontaneous differentiation of osteoblast precursors to adipocytes and lead
to fat deposits forming in bone further decreasing bone integrity91. This was
observed to lead to a large increase in hip fracture particularly in older women.
Another common side effect seen with drugs targeting PPARγ is weight
gain. This was originally thought to be due to the increase in adipogenesis caused
by the activation of PPARγ. However, later work in two independent studies
performed in mice implicated that this was actually due to the activation of
PPARγ in the brain. This was determined in mice using both pharmacological and
genetic methods92,93. Such findings were somewhat surprising as it was not
thought that PPARγ ligands were capable of crossing the blood-brain barrier.
These findings suggest that to understand the overall physiological ramifications
of activating this protein it is not prudent to consider only the adipose tissue
where these ligands have their most pronounced effect.
There are other severe side effects with major ramifications regarding
cardiac health. The first of these arises from PPARγ activity in the kidneys. It has
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been shown that treatment with PPARγ agonists helps improve the pathogenesis
of diabetic nephropathy (kidney damage)94, but this treatment also leads to edema.
This arises due to an altered sodium and fluid reabsorption in the kidney. But, the
exact mechanism is not totally clear as multiple studies on this topic have reported
conflicting results95–97. Additionally, there are cardiac issues which occur from the
activation of PPARγ in the heart98. In a healthy individual PPARγ is expressed to
very low levels in the heart but with individuals who have metabolic disorders
such as T2DM, heart PPARγ levels are greatly increased. Treatment with PPARγ
ligands has been shown to increase the mass and fat content of the heart in mice99.
As well, mice treated with PPARγ ligands have mitochondrial damage in the heart
and develop cardiac myopathy100.
1.3.4 Medical Ramifications
Given the findings outlined above it is clear that PPARγ is a medicinal
target of high value. This is particularly true for metabolic disorders such as
T2DM and atherosclerosis. However, the current system of treatment does not
appear to be optimal due to the negative side effects caused by increased activity
of this protein. This has led research to shift to more selective modulators which
activate the protein only fractionally but may give beneficial results through other
signaling pathways. Unfortunately, the mechanisms which lead to such selective
activation are incompletely or in some cases very poorly understood. This
indicates that significantly more research is needed into specific mechanisms of
PPARγ ligands which would allow for more intelligent drug design which could
avoid or reduce negative side effects while retaining a majority of the desired
therapeutic outcome.
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Figure 4: Effect of PPARγ activation in different tissues. The activation of PPARγ leads to
beneficial effects (Green arrows) in certain tissues but also very negative effects in other tissue
types. Figure was adapted from Ahmadian et al101.

1.4 Endogenous ligands of PPARγ
There is some debate as to the natural ligands of PPARγ. It is technically
classified as an orphan receptor but several endogenous lipids which can bind to
PPARγ have been identified. The concern with these natural ligands is that the
identified fatty acids which bind PPARγ have very poor affinity, usually >10µM,
this raises the concern that under physiological conditions these are never at a
high enough concentration to bind. Additionally, they only function as partial
agonists and it is thought that a more efficacious endogenous ligand should exist.
The majority of these fatty acids which bind to PPARγ do so in a covalent manner
to C285/313 on helix 3. Such a ligand would circumvent the low affinity. Only at
the initial non-covalent binding step would concentration of the lipid have to be
very high and then once the covalent bond is established there would be no risk of
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ligand release due to low affinity. That has raised some concern as this would
reduce the temporal control of signaling from this protein. This can be
rationalized by the fact that many synthetic ligands likely have very low off rates
due to their high affinity and would be bound for prolonged periods. Additionally,
PPARγ has a relatively short half-life so the covalent binding of a ligand would
not have too prolonged an effect102,103.
All of the postulated endogenous ligands that have been identified thus far
are polyunsaturated fatty acids (PUFA). The first ligand to be identified in 1995 is
prostaglandin D2 with metabolites in the Prostaglandin J2 pathway having stronger
effects. 15-deoxy-Δ12,14-Prostaglandin J2 (15d-PGJ2) showed the greatest effect
by a fairly large margin, approximately 65% of the efficacy of the synthetic full
agonist rosiglitazone104,105. This fatty acid requires the presence of C285/313 for
function, though it will still bind at low affinity when this residue is mutated but
ligand activity is abolished. Crystallography revealed this dependence on
C285/313 to be due to the formation of a covalent bond between one of the sites
of unsaturation and this cysteine residue in PPARγ106. The affinity is very poor
with a transcriptional reporter assay failing to plateau at a concentration of 10µM.
This may indicate that this lipid could activate the protein to a greater degree and
the level seen is a function of only partial binding. However, when dealing with
an endogenous ligand the likelihood of micromolar concentrations being present
is very low. Particularly for a lipid such as this which can readily bind to a variety
of proteins and will have very poor water solubility.
Later work examined the effect of the binding of several other PUFA to
PPARγ and was able to identify three new eicosanoid lipids which were able to
activate PPARγ to some degree107. These were examined in both a hydroxy and
an oxo state to determine if covalent attachment was necessary for function, since
the hydroxy state is unable to form a covalent bond to cysteine. From this they
observed that the covalent interaction was not actually necessary for the PUFA to
act as an agonist but in the absence of a covalent bond significantly higher
concentrations were required to observe the same response. Even with the
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covalent PUFA micromolar quantities were still required to reach the EC50 in a
transcriptional reporter assay, between 6-10µM. These concentrations seem
physiologically unlikely indicating that these many not be relevant in a biological
system. Another criticism is that the transcriptional reporter assay contained no
reference ligand, so it is very difficult to say to what level these lipids actually
increased transcription. Due to variability in the experimental system a reference
synthetic ligand of well-characterized behavior is typically included to more
accurately determine the effect of ligand binding. The most interesting finding in
this is that with one of the PUFA, 13-S-HODE, the authors were able to obtain a
crystal structure of PPARγ bound to two molecules of the lipid. This was one of
the first reports of PPARγ binding two ligands simultaneously108. This
phenomenon has recently been more thoroughly studied with synthetic ligands
and it does appear that the co-binding of endogenous lipids with synthetic ligands
may be a phenomenon which modulates the ligand behavior. The author in this
work postulated that these PUFA may not be the endogenous ligand but that it
may be a related lipid. They suggest that the more common metabolites of
arachidonic acid, 5-oxo-EPA and 5-oxo-ETE could readily reach sufficient
concentration in peripheral blood mononuclear cells for binding109. However, they
do not make it clear if the concentrations they report, 10-150µM, are total
concentration for these lipids which would suggest that a large percentage of this
lipid would likely be bound in membranes and inaccessible for binding to PPARγ.
It is worth noting that one of these postulated PUFA has been demonstrated to
bind to PPARγ in cancerous cell lines and arrest the cell cycle thereby promoting
apoptosis110.
With these findings it is still unclear if PPARγ is an orphan receptor or if
the endogenous ligand has been discovered. Given the low affinity seen in the
postulated endogenous PUFA ligands it seems likely that none of these would be
suitable ligands for signaling in a cellular environment. But to fully demonstrate
this will require further research and it is possible that the exact endogenous
ligand has not been identified but that the endogenous ligand may be closely
structurally related to those which have been identified. It also should be noted
18

that the majority of research postulates that there is a single endogenous ligand.
This is true for some nuclear receptors such as RxR and other vitamin receptors.
However, PPARγ is lipid-dependent and expressed in a wide variety of tissues.
Different tissues have markedly different lipid profiles, so it may well be that
there is not a single endogenous ligand for this protein but several that are tissue
dependent and may regulate pathways which are more relevant in that tissue. To
provide insight as to their structure several lipids which have been identified as
putative PPARγ ligands are shown in figure 7.
1.5 Synthetic ligands of PPARγ
Due to the medicinal importance of PPARγ a very large number of
synthetic ligands have been made for this protein. Interestingly they are not very
structurally conserved. There are some moieties which are relatively common in
structures, such as a central indole, but the only thing which is completely in
common is an amphipathic nature. These ligands must be somewhat amphipathic
as the ligand binding pocket of PPARγ is intended to bind fatty acids and is
therefore relatively hydrophobic. Due to the large size of the ligand binding
pocket22, ~1500Å3, it can be difficult to exploit all potential interactions, but there
are important residues which can be utilized to drive hydrogen bonding and
therefore increase affinity and specificity111. A very common example of this is
S342/370 in the β-sheet region. This residue forms hydrogen bonds either through
the side chain or more commonly the backbone to a very large number of ligands
which are structurally and functionally distinct. Due to this bonding event not
being correlated with ligand function it is likely only significant as a potential
target to increase selectivity and affinity. There are other residues which are
frequently involved in hydrogen bonding that are distinct to the ligand class which
will be discussed in more detail later.
Another interesting characteristic of the binding of synthetic ligands to
PPARγ is the so-called alternative binding site. This was discovered in 2015
through the binding of two separate ligand molecules to a single protein112. This
binding does not occupy the standard binding pocket but instead the ligand binds
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in a region between the N-terminal region of helix 3 and the Ω-loop. It was
originally thought that this binding only occurred as a result of a second ligand
binding event and could explain some of the odd behavior seen with some partial
agonists at high concentration. The second binding event is typically only
observed with partial agonists and typically occurs at very low affinity, EC50
values of approximately 10µM. However, since then there have been cases where
ligands appear to preferentially occupy the alternative site. The partial agonists
S35 and SR1664 (PDB 5DWL) have both been crystallized bound only to the
alternative site in the absence of other ligand molecules. It was suggested in the
original paper on S35 that in solution this ligand had a preference to bind the
alternative site almost exclusively113.
A more in-depth discussion of synthetic ligands by their effect on the
functional behavior of PPARγ will follow below.
1.5.1 Ligand nomenclature used in nuclear receptors
In the nuclear receptor field, ligand function is named based on their effect
on transcriptional reporter assays. The most commonly performed of these is the
GAL4-fusion transactivation assay. In this assay the LBD of the nuclear receptor
of interest is fused to the DBD of the yeast protein GAL4. A vector with a GAL4UAS reporter, generally some form of luciferase, is also transfected to provide a
readout. Based on the ligand binding state of the nuclear receptor LBD the
endogenous coregulator proteins will be recruited to the reporter plasmid and
regulate transcription of the reporter gene. This system has the advantage that the
GAL4-DBD binds to DNA as a monomer so this circumvents the necessity of a
dimer partner114. However, this has the limitation that only the LBD of the
nuclear receptor is being considered. Generally, ligand function is regulated
primarily by the LBD but there are rare instances whereby the DBD or the
unstructured AF-1 region will affect the activity of a ligand115. It appears likely
that the relative scarcity of such reports is due to the almost exclusive use of the
LBD of nuclear receptors for both in vitro and cell-based assays. The primary
reason for this appears to be the simplicity of the system. This is particularly
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troublesome for in vitro assays since full-length nuclear receptors are not very
stable and will readily undergo proteolysis. This eventually leads to all protein
degrading to the LBD state which adds uncertainty to the assay due to the
presence of partially degraded protein which is functionally different than fulllength.

Figure 5. Schematic diagram of a luciferase transcriptional reporter assays. Diagrams
showing the mechanism of either a GAL4 transactivation assay (left) or a PXRE transactivation
assay (right). The PXRE reporter is analogous to the PPRE reporters used with PPAR proteins.
Figure was adapted from Luckert et al116.

A variant of the above technique is the yeast two-hybrid assay117. This is a
similar technique but instead of a fusion of the GAL4-DBD to the nuclear
receptor LBD two expression plasmids are used. On the first is a fusion of the
GAL4-DBD with an interacting protein of interest, usually the NR. The second
contains a fusion of the coregulator of interest with the active domain of GAL4.
Thereby when the two proteins bind transcription of a reporter gene is activated
and through titration of a small molecule a ligand-dependent affinity can be
determined. This has since been expanded into mammalian cell lines and is more
commonly performed in this manner and referred to as a mammalian twohybrid118. The only major difference in the mammalian system is that the GAL4
active domain is unsuitable in a mammalian cell line so the active domain of a
viral protein, VP16, which is constitutively in an active state with high coactivator
affinity is used instead.
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As the DNA recognition of nuclear receptors began to become better
understood a similar assay grew in popularity. This is commonly referred to as the
PPRE transcriptional reporter. In this assay, instead of relying on a fusion of the
LBD, full-length PPARγ is overexpressed and the reporter plasmid has PPRE
enhancer sequences upstream of the promoter119.
Both of these systems have the same drawbacks which are not
straightforward to overcome. The first is that in these systems you do not know
what coactivators or corepressors are being recruited. As stated before different
coactivators control very different pathways in the cell and the ability to ascertain
if a ligand could preferentially recruit specific coactivators, similar to the biased
agonists seen in GPCR proteins121,122, would be of great value. Additionally, since
the transcriptional machinery endogenous to the cell is not being overexpressed
this sets a cap to the response that can be observed. Due to this limitation it is not
currently clear if different full-agonists show different efficacy since any full
agonist will eventually saturate the response.
Based on transactivation assays described above, ligand function has been
broken up into three primary groups. The first is the full agonists, which strongly
drive transcription and have historically been the most studied ligands for
medicinal purposes. The next are the non/partial agonists. These either do not
drive transcription at all or show only a fraction of the response of the full
agonists. With recent discoveries non/partial agonists have become one of the
leading areas in PPARγ medical research but come with the caveat that they are
structurally diverse, and their mechanism of action is poorly understood. The last
group is the antagonists/inverse agonists. These two types of ligands are
indistinguishable in transactivation assays but induce very different outcomes.
The antagonist ligands function by having a portion of the ligand, often a bulky
hydrophobic group such as a tert-butyl, that sticks directly out of the AF-2 surface
and thereby disrupts the very specifically organized hydrophobic cleft required for
any coregulator interaction. On the other hand, the inverse agonists are thought to
specifically drive the recruitment of corepressor proteins while reducing affinity
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for coactivator proteins. There is some thought that the inverse agonist behavior
observed is not in fact due to a direct function of the ligand and instead occurs
through a displacement of endogenous lipids bound to the protein. PPARγ is
capable of binding a wide variety of fatty acids in the cell and even some as
simple as nonanoic acid have been shown to have partial agonist character.
Because of this, there is some argument whether or not inverse agonism is
actually occurring in PPARγ, but recent data suggests that it is123.
1.5.2 Alternate functional assays to determine ligand class
There has been increasing use of in vitro assays to characterize ligands
since the mid-2000s. Typically these assays utilize fluorescence-based techniques
to look at coregulator binding to a purified NR protein as a function of the ligand
bound. One flaw in these assays is the large size and unstable nature of most
coregulators which are at least partially intrinsically disordered. As such,
recombinant expression of the entire coregulator protein is usually not possible.
Because of this most assays rely on a peptide containing only a single known
LxxLL or CoRNR box. Some work has been done using the receptor interaction
domain (RID) of coregulators such as SRC-2 but these are not as popular as these
domains are still not trivial to purify to any significant yield124 and show only
minor differences with assays utilizing the small peptides containing a single
interaction motif. Another restriction is that at least one coregulator which binds
with decent affinity must be known to perform these assays. Generally, for most
nuclear receptors at least a portion of the coregulator interactome is known but
specific affinity data is rare. Additionally, many coregulators contain multiple
LxxLL125 or CoRNR126 boxes that bind different proteins with significantly
different affinities which further complicates these studies since most of the
interaction data was obtained from cells and the exact interacting motif is often
ambiguous. There are two main forms of this assay which will be outlined below.
The first form of this assay performed to any great extent was based on
Fӧrster resonance energy transfer (FRET) often performed in a time-resolved
(TR-FRET) fashion to reduce noise127–129. For simplicity, all FRET assays will be
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referred to in this form, TR-FRET, for this work. In such an assay a fluorescently
modified NR protein, most often through labeling with a fluorescently modified
antibody, is pre-mixed with a fluorescently labeled coregulator peptide, often
covalently modified with a fluorophore. To this mixture can then be titrated a
solution of the ligand of interest and the change in FRET ratio can be fit to
estimate binding of the coregulator to the NR. There are multiple downsides to
this technique. The first is the very practical matter of cost, having to utilize
multiple fluorophores and antibodies makes this a relatively expensive assay. The
second more significant downside is that the data are somewhat challenging to
interpret and relate to other data. Since the ligand is being titrated the EC50 value
obtained from the fit is really only representative of the ligand’s affinity for the
NR protein and not the affinity of the NR for the coregulator. To look at that
relative affinity you instead have to examine the FRET window between
unliganded and ligand bound and relate the fold-change in FRET ratio to estimate
the affinity of the NR for the peptide. As well these assays are not exceedingly
reproducible, relative effects seen in ligand behavior remain constant, but other
properties such as FRET ratio or window are somewhat different between runs
making in depth interpretation difficult.

Figure 6. Fluorescence polarization binding assays. A schematic diagram of the fluorescence
polarization assay. This technique is frequently used in NR through titrations to determine Kd
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values of coregulator peptides. Figure was adapted from Fluorescence Polarization Assay to
Quantify Protein-Protein Interactions in an HTS Format130.

Once the technique became suitably adapted to a high-throughput assay
the use of fluorescence polarization or anisotropy to look at binding events of NR
with coregulators became popular, e.g. VDR131, THRb132, SRC1133. This system is
much simpler as it requires only modifying either the protein or peptide with a
fluorophore. This is typically done by the covalent addition of a fluorophore to the
peptide. With the fluorescently modified component held at a fixed concentration
the other protein can then be titrated in either pre-loaded with the ligand of
interest or with a fixed ligand concentration in each well. The second method with
a fixed ligand concentration is somewhat less common due to the low water
solubility of nuclear receptor ligands. Given this poor solubility at low protein
concentrations where the majority of the ligand is unbound there are concerns that
the ligand will fall out of solution or aggregate and thereby have unforeseen
effects. As the complex binds and the molecular mass increases the tumbling rate
will lower increasing the polarization or anisotropy of the fluorophore. This
increase can then be fit to determine a dissociation constant, Kd, for the
coregulator and NR in each ligand bound state. This technique has become
increasingly popular due to the low cost and relatively high throughput. It also
allows for a more sensitive way to interpret the behavior of full agonists and
inverse agonists than the cell-based assays.
In 2009 a high throughput modification of the TR-FRET protocol was
developed by Pamgene. In this protocol 53 peptides are immobilized on a chip
and GST-fusion NR proteins can be titrated in with ligands bound36. A
fluorescently modified anti-GST antibody is then added and the binding affinity
can be determined from a non-linear regression. This technique is quite interesting
but has not generated a lot of use in academic research most likely due to the cost.
At this point only two papers can be located that utilize this first-generation
technique. The first is the initial methods paper from the company and the other is
looking at coregulator binding patters in estrogen receptor alpha (ERα) obtained
from tumor cells134. The same group released a newer version of the technology in
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a paper from February 2018 which reported an increase i the number of
coregulator peptides to 154 and looked at changes in coregulator affinity with
both the apo state and a reference full agonist ligand135. However, the results
reported in this paper were not entirely consistent with results from their previous
paper and with some of our own data, so there may be some issues in this newer
technique. There are a couple of publications using this newer technology in the
orphan receptor NR2E1 (TLX)136 or with ERα4 which showed robust results so
the inconsistencies in this method may be more of an issue with PPARγ and not a
problem for all NR. The previous generation of the Pamgene assay does seem
robust and we have found good agreement with their results and our own
coregulator recruitment data.
1.5.3 Full agonist ligands of PPARγ
Many full agonist ligands for PPARγ were developed as potential
therapeutics of type II diabetes. A significant number of these ligands have gone
into clinical or preclinical trials but relatively few have been found to be suitable
for human use. This unsuitability is due to a wide variety of negative side effects.
Some of these arise as an effect of canonical PPARγ activation which has been a
concern in the development of therapeutic agents which target this protein.
However, there are a number of other severe side effects that occur from full
agonists of PPARγ where the mechanism is unclear. Despite this, full agonist
ligands of PPARγ are still an active area of study, though more modern
compounds have been designed to not activate the protein as significantly as prior
drugs. Through this the impact of side effects has lessened but is still a very
significant concern.
Full agonism is the best understood mechanism of action in PPARγ.
Almost all full agonists share the same core mechanism which consists of a direct
hydrogen bond from the ligand to Y474/501 on helix 12137,138. This interaction
stabilizes helix 12 in a conformation which is appropriate for interaction with the
LxxLL motif on coactivators. These ligands also make other conserved hydrogen
bonds within the protein to S289/317 on helix 3, H323/351 on helix 5 and
26

H449/477 on helix 11139. These aid in stabilizing other portions of the AF-2
region in a suitable conformation to interact with coactivators. NMR studies have
also shown that full agonists reduce the available conformational ensemble more
so than the other ligand classes140. The significance of this is not understood but it
is hypothesized that limiting the plasticity of the protein will lock the protein in a
conformation suitable for coactivator recruitment and thereby help to lower the
energetic penalty associated with coactivator binding, which will increase binding
affinity. Our own data, which will be shown in chapter 3, support this hypothesis
and also indicates that it is not only the overall stability of the protein which is
important for full agonist function but that the stabilization of the β-sheets, the Ωloop and helix 5 in particular are important for the highest efficacy in agonism.
Interactions in these regions are important in an optimal orientation of the AF-2
residues for productive interactions with the coactivator peptide. Additionally,
these data illustrate that the AF-2 surface is not defined solely by interactions on
helix 3 and helix 12 but that there are important interactions, both selective and
general, arising from residues in helices 3’ and 4.
Two major classes of full agonist ligands for PPARγ exist. These are the
glitazones which contain an thiazolidinedione (TZD)141 head group which
mediates the important interactions with the AF-2 region and the glitazars which
are derivatized from L-tyrosine142. Interactions are more complex with the glitazar
ligands than with the glitazone ligands. This is due to the fact they are typically
significantly more structurally complex than the glitazones and while the AF-2
interactions do arise from the conserved carboxylate within the tyrosyl moiety this
group is frequently located in the central region of the molecule. Such greater
structural complexity allows the glitazar ligands the ability to interact more
extensively in significant regions than the glitazones, particularly around the Ωloop and β-sheets. This greater degree of interactions appears to lead to higher
affinity than is seen for the glitazones and in some cases greater agonist efficacy.
It should be stated however, that higher efficacy is not a hallmark of the glitazar
ligands as some including saroglitazar and aleglitazar only act as partial agonists
for PPARγ. Unfortunately, the glitazar ligands have been strongly linked with
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very negative side effects and only a single member, saroglitazar which is a panPPARα/γ ligand, has been approved for human use and is only approved in
India143. There has been greater success with ligands from the glitazone family.
Of these three have been approved for human use by the FDA (troglitazone,
rosiglitazone and pioglitazone) and an additional one is approved for human use
in Canada and the European Union, edaglitazone.
The first of the FDA approved full agonists was troglitazone (Rezulin).
This drug was approved for human use in 1997 but within one year of use a
severe side effect was observed. This side effect had not been apparent in either
preclinical animal or human testing. It was found that in a small percentage of
people taking this drug severe liver damage was occurring in some cases leading
to liver failure. Due to this negative side effect the drug lost approval for human
use in 2000. It is still not entirely clear what the cause of this side effect was but
there is some evidence that, in mice with dysfunctional oxidative stress responses
in the mitochondria of liver hepatocytes, liver damage is induced by troglitazone.
This suggests that troglitazone may be causing liver damage through an increase
in oxidative stress in hepatocyte mitochondria144,145. However, this damage is
relatively mild which is inconsistent with the side effect observed in humans.
Research continued into this ligand family and the next compound to be
approved for human use was rosiglitazone (Avandia) in 1999. This ligand also
induced severe side effects including edema, weight gain, increased bone fracture
in women and cardiac issues. There were a number of reports of heart failure
associated with this medication146–148 which led in 2007 to the addition of a black
box warning which severely limited the availability in the U.S. Around the same
time this medication was completely banned for human use by the European
Medical Association (EMA). Since this time the black box warning has been
lifted in the U.S. following a large randomized study by the manufacturer which
showed the initial studies indicating heart failure were not reproducible, but this
medication remains banned in Europe. Following this a similar medication,
pioglitazone (Actos), was approved which carried much milder cardiac risks and
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in some research has actually been shown to improve cardiac health in type 2
diabetes patients149. This medication unfortunately has been linked to bladder
cancer risk leading to its ban in portions of Europe150. Additionally, it carries the
same side effects seen in rosiglitazone with the exception of the cardiac issues.
These shared side effects (edema, bone fracture and weight gain) appear to occur
as a consequence of PPARγ signaling and so may occur with any full agonist
drug.
Due to severe side effects, research has begun to shift away from these full
agonists towards less efficacious partial agonists. Many of these compounds have
gone into clinical or preclinical trials but as yet none have been approved for
human use. What is known about partial agonists will be covered in greater detail
below.
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Figure 7. Chemical structures of representative ligands of PPARγ. A-D: The structure of four
endogenous lipids which have been shown to bind PPARγ with an approximately 10μM affinity.
All of these except 9-S-HODE bind covalently to C285/313. E-G: Structures of three inverse
agonist ligands. T0070907 and GW9662 are both covalent and appear to act through a distinct
mechanism to SR10221. H-K: The structure of 4 partial agonist ligands of PPARγ. These range in
activity from no transactivation activity, SR1664, to fairly high activity, INT-131. I-O: Structures
of four representative full agonist ligands. Troglitazone, Pioglitazone and Rosiglitazone are all
TZD ligands which have been FDA approved for human use. GW1929 is a glitazar ligand which
shows higher activity then the TZD ligands but is unsuitable for medical use.

30

1.5.4 Inverse agonists and antagonists of PPARγ
Comparatively few inverse agonists or antagonists have been explored in
literature relative to the other ligand types. Typically, these are not thought to
have a wide variety of medicinally useful effects, which limits research interest.
There have been some reports of the covalent inverse agonists T0070907151,152
and GW9662153,154 having an anticancer effect by arresting the replication of
human cancer cell lines. The issue in this research is that both of these ligands
have rather strong off target binding, GW9662 can bind PPARα with a Kd of
approximately 20nM155 and T0070907 can do the same with a Kd of around
1µM156, both of these concentrations are much lower than were used in these
studies. The Kd values estimated for these two ligands are somewhat based on
assumption since they are both covalent, they have no koff value and so the Kd
reflects only a contribution from the kon. As well the mixed agonist/antagonist
BADGE was able to promote apoptosis in cancer cells, but this was only at
concentrations in excess of 50µM. This would suggest that the observed effects
are almost certainly due to off target binding and not due to PPARγ signaling157.
The mechanism of inverse agonism has been of some interest. A lot of this
interest comes as a comparator to other NR where inverse agonists are of more
value (e.g. ERα where the antagonist tamoxifen is the leading breast cancer
medication). It is thought the mechanism of inverse agonism is shared among
nuclear receptors so a greater understanding in one system should be of use in
studies of a different NR. Typically, inverse agonists are thought to function
through the displacement of helix 12 from the AF-2 surface158. This hypothesis is
based on crystal structures of various other nuclear receptors bound to the
corepressor SMRT in which helix 12 is never resolved and the helix 11- helix 12
loop points into space159. This is further supported by a pair of dominant negative
NR, Rev-Erb α and β which completely lack a helix 12. The lack of this helix is
thought to be what makes these proteins dominant negative due to its importance
in coactivator interactions. That would be consistent with the observation that the
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CoRNR box has a larger footprint when bound to the nuclear receptor then the
LxxLL box so some conformational change must occur to prevent a direct steric
clash with helix 12. Such a clash can be observed when a corepressor peptide
from a crystal structure is docked on an apo PPARγ structure. Unfortunately, no
crystal structure of a corepressor bound to PPARγ has been published as of yet.
There are a small number of inverse agonist or antagonist ligands that have been
crystallized bound to PPARγ. Recent structures of the antagonists SR10171 and
SR11023 indicate that helix 12 is being pulled away from the AF-2 surface and
towards the N-terminus of helix 348. This conformational change would generate
the additional space needed for the CoRNR box interaction but is surprising given
that typically helix 12 appears to be pushed off the surface in other nuclear
receptors not pulled to a different portion of the protein.
Our own data, which will be presented in chapter 4 of this work, indicates
that there are two distinct mechanisms of inverse agonism in PPARγ. The first is
the displacement of helix 12 which occurs with bulky ligands that appear to
directly make sterically unfavorable interactions with helix 12 and lead to
displacement of this helix from the AF-2 surface. The second which is unique to
the comparatively small covalent inverse agonists appears to be driven by a
relocalization of helix 12 to a position lower relative to helices 3 and 4 than it is in
a partial agonist or agonist bound state but oriented in the same fashion as it
would be in an agonist bound state. Such a mechanism leads to helix 12 actually
making productive binding interactions with corepressors. It appears likely that
these productive interactions with helix 12 are what make T0070907, one of the
covalent inverse agonists mentioned above, the most efficacious known ligand of
its class. Some example structures of representative inverse agonists can be seen
in figure 7.
1.5.5 Partial agonist ligands of PPARγ
Recently the partial and non-agonists have become the most heavily
studied group of PPARγ ligands160. The difference between these two groups is
not well defined and many works will refer to the same ligand as either a partial
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or non-agonist. For the purpose of brevity in this work all ligands from these
groups will be referred to as partial agonists. Partial agonists are synthetic ligands
that activate PPARγ transcription to only a small fraction of the full agonist
response. These responses range from very weak: SR1664161 or nTZDpa162 have
almost no transcriptional effect, to somewhat marked effects: Int131 activates up
to approximately 40% the level of a full agonist163. This group is the most
structurally diverse and therefore it has been difficult to determine what
interactions are significant for their effects. Additionally they make relatively few
direct interactions with the protein which further complicates a mechanistic
understanding at an atomic level.
The mechanism of action for partial agonists is very poorly understood. It
has been shown that they function in a manner independent of helix 12
conformation which is unsurprising as they do not form direct hydrogen bonds to
Y473/501 as the full agonists do164. Rather they make extensive contacts on helix
3, some contacts to the Ω-loop and direct hydrogen bonds to S342/370 in the βsheet region165. Particularly during the second or alternative binding event they
make no contacts at all on the AF-2 surface. Additionally, they do not stabilize the
protein as is seen with the full agonists. In complexes bound to partial agonists,
the protein appears to remain highly plastic with a similar amount of rigidity as is
seen in the apo state, when assayed by 2-dimensional NMR techniques. This is
consistent with our own observations that the binding of partial agonist ligands
does not restrict the conformational ensemble of either helix 3 or helix 12 of the
AF-2 region, these data are presented shown in chapters 2 and 3. Despite this, a
large number of these ligands still drive coactivator recruitment in in vitro assays
and are seen to drive transcription through either transactivation assays or qPCR.
How exactly they have this agonist behavior is not understood at this point.
While the mechanism remains elusive it has been seen that many partial
agonists increase insulin sensitivity in cell-based assays or in model animals.
They also carry far less side effects than seen with full agonists which often cause
weight gain, edema or bone fracture. This reduction in side effect severity is
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thought to be due to the lesser transactivation of PPARγ seen with this ligand
family160. Some of these ligands, particularly SR1664166 and MRL24167, were
observed to increase insulin sensitivity to almost the level seen with the full
agonists. Due to this several of these ligands have gone into clinical or preclinical
trials for type II diabetes treatment but as yet none have been approved for
human use.
1.6 Other significant areas in drug design for PPARγ

Figure 8. Post-translational modifications of PPARγ. A representation of PPARγ showing
identified post-translational modification sites and their functional outcome. Figure was adapted
from Ahmadian et al101.

1.6.1 Post-translational modifications of PPARγ
Several post-translational modifications occur of PPARγ which have
significant effects on the functional outcome. This includes a phosphorylation
event on the AF-1 at S84/112 which has been well demonstrated to reduce the
activity of PPARγ168,169. A sumoylation event on K79/107 has been shown to
downregulate PPARγ activity. Interestingly an association with ubiquitin ligases,
PIASxβ or Ubc9, at this site upregulates PPARγ activity in a manner independent
of sumoylation170. As well, it was found that preventing this sumoylation event
lead to insulin sensitizing effects in mice but no increase in adipogenesis171. This
34

may be a future avenue of drug discovery but this finding was only made this year
so as yet no further research has been published. The deacetylation of PPARγ by
SIRT1 has been determined to be important for the so-called “beiging” of adipose
tissue which can be induced by PPARγ ligands. Acetylation of PPARγ was shown
to directly inhibit association with PRDM16 which is essential for this observed
behavior72. One of these modifications, sumoylation of K367/395, is suggested to
be important for the anti-inflammatory effects seen with PPARγ172. However,
there is debate as to whether this actually occurs with other literature directly
stating that this residue is in fact not a target of sumoylation173. The most recently
discovered post-translational modification is the phosphorylation of S245/273
which will be covered in significant detail below due to the fact it is the leading
area of active drug development research.
1.6.2 Regulation of the phosphorylation of S245/273
The mechanism of increased insulin sensitivity seen with partial agonists
remained elusive until 2010 when a post translational modification was
discovered in the work of Choi et al174. This modification is a phosphorylation of
S245/273 in a unstructured loop proximal to the β-sheets. The phosphorylation of
this residue was confirmed by an alanine mutation which increased the expression
of several proteins dysregulated in obesity. It was found that the phosphorylation
of this residue almost completely abolished the insulin sensitizing effects seen
with PPARγ ligands. This phosphorylation also seemed to lead to an overall
downregulation of expression of PPARγ regulated genes. PPARγ contains a site
which matches four of the five residues for a cyclin-dependent kinase 5 (CDK5)
recognition motif175 in a loop between the first of the β-strands and helix 2’. As
such this appeared to be the mediating kinase176. The role of this kinase was
demonstrated by the addition of a specific inhibitor of CDK5 or RNAi of CDK5
which strongly reduced the phosphorylation. Tracking levels of this kinase
showed that mice fed a high fat diet (HFD), 60% fat, had greatly increased levels
of CDK5 in adipose tissue. This suggests that the upregulation of this kinase and
phosphorylation of PPARγ could be an important cause of dysregulation of many
PPARγ controlled genes.
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It was also found that the addition of PPARγ specific drugs significantly
reduced this phosphorylation event. The addition of rosiglitazone to an in vitro
kinase assay showed a 50% reduction in phosphorylation at 30nM, relatively
close to the IC50 value for this ligand, though large doses of approximately 3µM
were required to prevent phosphorylation. A much stronger effect was seen with
the partial agonist MRL24 which was able to block most phosphorylation at a
level of only 30nM. However, this ligand has a sub nanomolar IC50 value, so it is
not clear if the difference is due to ligand behavior or merely an artifact of the
fraction bound. Further examination of other partial agonist ligands which
function well in insulin sensitization showed they also efficiently prevented this
phosphorylation event. In fact the ligands most effective at preventing this
phosphorylation were all partial agonists with the exception of a single full
agonist, farglitazar. Other glitazars were not utilized in this study so it is not clear
if other ligands of this class such as saroglitazar or GW1929 might also be very
effective at blocking this post-translational modification. The authors postulate
this reduction is due to a stabilization of this loop as evidenced by reduced
hydrogen deuterium exchange of this loop and the neighboring β-sheet region.
Later work by the same group suggests that thyroid receptor associated protein 3
(THRAP3) is recruited to PPARγ through this phosphorylated residue and that
this is the root cause of dysfunction in gene expression caused by CDK5177.
Based on these findings research into PPARγ therapeutics has shifted
towards partial agonist ligands which can effectively block phosphorylation. The
performance of ligands in an in vitro phosphorylation assay has become
somewhat of a gold standard in papers covering novel ligands and their potential
value in insulin sensitization. One concern with this assay however is that it seems
to only perform well in a western blot178. Western blotting gives rise to
complications as to quantification. Typically, these must be quantified through
pixel counting which is not the most precise measurement and can have a smaller
dynamic range than other techniques. The development of fluorescent indicators
or automated systems which utilize chemiluminescent signals have greatly
improved the potential accuracy in quantifying a blot but are not as commonly
36

used as the traditional horseradish peroxidase (HRP) colorimetric indicator and
pixel counting179. In a few papers an ADP-Glo assay is used to measure
phosphorylation through the consumption of ATP but this is not used
commonly180. A single methods paper exists which outlined a protocol to perform
this assay through enzyme-linked immunosorbent assay (ELISA)181 which would
improve the accuracy of quantification, but this method does not seem to have
been adopted by the research community. Our own efforts to reproduce this assay
have been unsuccessful.
1.6.3 Anti-inflammatory effects in nervous system
It has previously been observed that a number of PPARγ ligands have
moderately strong anti-inflammatory effects. Interestingly these are observed to
relatively similar levels in both full agonists such as rosiglitazone182 or
pioglitazone183 as well as with partial agonists such as MRL24, UHC1178 and
INT131. The exact mechanism of this behavior is currently not well understood. It
has been shown that this effect is independent of PPARγ DNA binding184 and is
therefore postulated to be due to a poorly understood transrepressive activity or
possibly to occur through the S245/273 phosphorylation. The most common
hypothesis for how these anti-inflammatory effects occur is through PPARγ
binding to the NFκB subunit p65185. This interaction has been demonstrated to
occur in cells via immunoprecipitation assays. The majority of anti-inflammatory
effects observed with PPARγ ligands occur through the downregulation of NFκB
signaling186–188. Due to this observation it is postulated that in a ligand dependent
manner PPARγ associates with NFκB and prevents the transcriptional activity of
this pro-inflammatory transcription factor. It is not clear if this is occurring in a
manner similar to NFκBIB proteins which sequester NFκB and thereby
downregulate activity or if possibly this effect may be due to PPARγ binding to
NFκB which is bound to DNA in a repressive manner. Such transrepression has
been reported with other nuclear receptors such as glucocorticoid receptor (GR)189
but has not been seen to occur with this protein.
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Figure 9. PPARγ activation leads to a variety of anti-inflammatory effects. Activation of
PPARγ by agonist ligand introduction leads to a pronounced anti-inflammatory effect through a
largely unknown pathway. These effects manifest in a variety of cell types and have been found to
be exploitable to reduce chronic inflammation in the nervous system. Figure was adapted from
Ohshima et al190.

Due to their anti-inflammatory effects, several PPARγ synthetic ligands
have been shown to have potential therapeutic value in treatment of
neurodegenerative disease183,191,192. These conditions all cause a chronic
inflammatory state and these ligands are thought to have beneficial effect through
this transrepressive pathway. Examples of these effects include a reduction in
insoluble Aβ42 load in rat brains with pioglitazone treatment183. Pioglitazone has
also been shown to have beneficial effects on animal models of Parkinson’s
disease192,193. These effects are not explicitly due to full agonism. Multiple partial
agonist ligands have been shown to be of benefit in therapy of neurodegenerative
disease. In 2016 the partial agonist INT131, which has previously entered clinical
trials as a type 2 diabetes therapeutic, began a new clinical trial as a potential
therapeutic for multiple sclerosis. This has potentially opened a new pathway in
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therapy for currently untreatable neurodegenerative diseases. However, as
promising as some of the results observed may be there is still a large amount of
work to be done before such a therapy would be suitable for human use.
1.7 Objectives of this work
The goal of this work is to gain a better understanding of the various
mechanisms of PPARγ ligands at the molecular level. This information is
incomplete for all PPARγ ligands and for certain ligand classes such as partial
agonists almost nothing is known of their mechanism of action. Mechanistic
information gained would be of great use in more intelligent drug design which
could lead to the creation of therapeutics which retain beneficial effects while
reducing negative side effects. The future goal would be to gain enough of an
understanding of differential coregulator recruitment, coregulators are a highly
diverse group which often lead to very different functional consequences, to
develop so-called “biased ligands” which would preferentially recruit specific
coregulator proteins. Biased ligands were first designed for the GPCR proteins
and function through a preferential signaling of a single pathway instead of all
outcomes of activation. Thus far they have shown great promise in providing
similar therapeutic benefits as existing therapies but with significantly reduced
side effects. To add to understanding of the conformational mechanisms of
PPARγ ligands three projects were completed.
In the first project, which will be covered in chapter 2, the conformational
effects of ligand binding on the C-terminal helix, helix 12, were examined. This
helix is the most functionally significant portion of the AF-2 region in terms of
overall coregulator affinity. So, a better understanding of how this region changes
with the binding of a wide group of structurally and functionally distinct ligands
is important to the understanding of how the protein is primed for coregulator
binding. This study also allowed for better determination of the role of this helix
in coregulator recruitment. For a long-time helix 12 has been the primary portion
of the protein to be studied but it is clear that it is not the only significant region
of the protein for activity.
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The second project, described in chapter 3, had two goals. The first and
most important was to identify a region of the protein that conveys the extreme
selectivity seen in nuclear receptor and coactivator interactions. This is
fundamental in the idea of creating a biased ligand since such bias would require
the preferential recruitment of specific coactivators. As well the mechanism by
which full agonists have differential efficacy was examined. The purpose of
examining full agonism was not as much to understand full agonism, as this does
not appear to be the optimal therapeutic pathway due to side effects. Rather the
goal was to identify other regions of the protein where a particularly efficacious
agonist might interact besides the direct helix 12 interaction. This could
potentially allow the design of therapeutics that induce a more modest response in
terms of protein activation and thereby have less deleterious side effects
The third project, described in chapter 4, examines one of the mechanisms
of inverse agonism in PPARγ. To this point only a single mechanism is thought to
occur leading to inverse agonism in nuclear receptors which involves the
displacement of helix 12 from the AF-2 surface. This work identifies a novel
mechanism which actually conveys greater inverse agonist efficacy, higher
corepressor affinity, than the ligands which operate through the more standard
pathway. Currently inverse agonists have not been studied much for their
therapeutic value but there is some evidence they may be useful as cancer
therapeutics through the arrest of the cell cycle. While these data may not be
immediately useful for PPARγ research there may be value due to the high
structural similarities among NRs. Which makes it quite possible that these
mechanisms are conserved. This knowledge could be then utilized with other NR
where inverse agonists are of great medical significance. If this is the case than it
could lead to an entirely new route in drug design for these proteins.
Through the completion of this work and other work which can build on
findings established herein it is hoped that a more fundamental understanding of
this medicinally significant protein can be gained. This would allow for the design
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of better therapeutic strategies for the treatment of the metabolic and
neurodegenerative diseases in which PPARγ is directly or indirectly involved.
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Chapter 2. Defining a conformational ensemble that
directs activation of PPARγ
Ian M. Chrisman, Michelle D. Nemetchek, Ian Mitchelle S. de Vera, Jinsai Shang,
Zahra Heidari, Yanan Long, Hermes Reyes-Caballero, Rodrigo Galindo-Murillo,
Thomas E. Cheatham III, Anne-Laure Blayo, Youseung Shin, Jakob Fuhrmann,
Patrick R. Griffin, Theodore M. Kamenecka, Douglas J. Kojetin, and Travis S.
Hughes

Results in this chapter have been published in Nature Communications, | DOI:
10.1038/s41467-018-04176-x

2.1 Abstract
The nuclear receptor ligand-binding domain (LBD) is a highly dynamic
entity. Crystal structures have defined multiple low-energy LBD structural
conformations of the activation function-2 (AF-2) coregulator binding surface yet
it remains unclear how ligand binding influences the number and population of
conformations within the AF-2 structural ensemble. Here, we present a nuclear
receptor coregulator binding surface structural ensemble in solution, viewed
through the lens of fluorine-19 (19F) nuclear magnetic resonance (NMR) and
molecular simulations, and the response of this ensemble to ligands, coregulator
peptides and heterodimerization. We correlate the composition of this ensemble
with function in peroxisome proliferator-activated receptor gamma (PPARγ)
utilizing ligands of diverse efficacy in coregulator recruitment. While the
coregulator surface of apo and partial agonist bound PPARγ is characterized by
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multiple thermodynamically accessible conformations, the full and inverse
agonist bound PPARγ coregulator surface is restricted to a few conformations
which favor coactivator or corepressor binding, respectively.
2.2 Introduction
Nuclear receptors are ligand-regulated transcription factors that mediate
the transcriptional actions of lipophilic endogenous ligands, including steroid
hormones and lipids194, and are the target of ~13% of US FDA approved drugs195.
The binding of these natural ligands, as well as synthetic ligands and FDAapproved drugs, to the nuclear receptor ligand-binding domain (LBD) affects the
recruitment of transcriptional coregulator proteins to target gene promoters, which
influences chromatin remodeling and gene transcription196. Crystal structures of
nuclear receptor LBDs have revealed in exquisite detail the molecular contacts
created between the receptor and ligand, as well as low energy “active” and
“inactive” conformations of helix 12197–200. Helix 12 is a critical regulatory
structural element in the activation function-2 (AF-2) coregulator interaction
surface of many nuclear receptors201. Over 100 crystal structures have been solved
of the peroxisome proliferator-activated receptor gamma (PPARγ) LBD bound to
ligands of various scaffolds and pharmacological activities202. Surprisingly, the
backbone conformations of these structures, in particular the conformation of
helix 12, are all very similar despite the fact that PPARγ is bound to ligands that
produce a diverse range of functional outputs. Thus, it is difficult to understand
the structural mechanism of action by which the binding of ligands with diverse
activities affect helix 12 conformation from crystallography data alone. One
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hypothesis is that helix 12 consists of a dynamic ensemble of conformations, and
not one single or “static” conformation in the presence or absence of a bound
ligand138,203. However experimental evidence describing this ensemble is lacking
and it remains poorly understood how binding of pharmacologically distinct
ligands affects the ensemble of coregulator binding surface and helix 12
conformations.
Solution structural methods indicate prevalent, ligand dependent helix 12
movement. Hydrogen deuterium exchange mass spectrometry (HDX-MS)
demonstrates a relationship between helix 12 stability and agonist binding for
nuclear receptors161,204–206. NMR studies implicate movement on the
microsecond-millisecond (µs-ms) time scale between two or more conformations
over a large portion of the apo and partial agonist bound PPARγ LBD. These
movements result in very broad or unobserved NMR resonances that prohibit
structural analyses. Full agonists robustly diminish these dynamics140,207–209.
Furthermore crystal structures, HDX-MS, and protein NMR have provided
complementary information revealing a relationship between structure and
function for PPARγ (e.g. the presence or absence of critical hydrogen bonds
between ligand and helix 1222) however a direct observation of the ligand
dependent ensemble implied by these data is lacking. This raises the question: are
there multiple long-lived conformations that correlate with functional efficacy
(e.g. coregulator affinity) in nuclear receptors?
It remains challenging to quantify the number, relative population and
kinetics of exchange between the conformations that compose this putative
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ensemble and how the ensemble is influenced by binding small molecules and
coregulators. 19F (fluorine-19) NMR spectroscopy is exceptionally sensitive to
structural and environmental changes, can reveal structural information from
regions of a protein that are unobserved via 2D/3D NMR210, and can be used to
probe how ligands affect the conformational ensemble of proteins211–215. Here,
using 19F NMR combined with biochemical coregulator interaction analysis and
molecular simulations, we define the ligand dependent conformational ensemble
of the coregulator interaction surface, including helix 12, which controls the
transcriptional activity of PPARγ. The data presented here indicate that helix 12
and the coregulator binding surface of apo and partial agonist bound PPARγ is
found in a broad energy well with multiple local minima of similar potential
energy separated by relatively small kinetic barriers, allowing exchange on the μs
to ms time scale. In contrast, when PPARγ is bound to a full agonist or inverse
agonist, helix 12 and the coregulator binding surface occupies narrow energy
wells with fewer thermodynamically accessible conformations. In addition,
simulations define some of the probable structures that compose these ensembles.
These data better elucidate how ligands induce functional effects via nuclear
receptors.
2.3 Results
2.3.1 Diverse activities of synthetic PPARγ ligands
We assembled a set of 16 pharmacologically distinct PPARγ ligands that
we and others developed or previously characterized in cellular and structurefunction studies (Supplementary Fig. 16). The set of ligands includes full and
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partial agonists that robustly or mildly enhance transcriptional activation;
antagonists/non-agonists that block activation or maintain constitutive basal
cellular transcriptional activity; and inverse agonists that repress transcription
compared to the basal receptor activity. In a time-resolved fluorescence resonance
energy transfer (TR-FRET) coregulator interaction assay, full agonists such as
GW1929 and rosiglitazone that induce robust PPARγ transcription142,216, increase
binding of a peptide derived from Mediator of RNA polymerase II transcription
subunit 1 (MED1) coactivator (Figure 1a), and decrease binding of a peptide
derived from the nuclear receptor corepressor 1 (NCoR1) referred to herein as
NCoR (Figure 1b). In contrast, ligands that function as inverse agonists such as
T0070907 and SR10221 lower PPARγ transcriptional responses relative to basal
cellular activity156,161,217, increase binding of NCoR (Figure 1b), and decrease
binding of MED1 (Figure 1a). Crystal structures of ligand-bound PPARγ LBD
typically show a non-crystallographic dimer configuration containing two chains,
A and B (Supplementary Fig. 2a). The main difference between the two chain A
and chain B protein molecules involves helix 12, which adopts distinct
conformations commonly referred to as “active” and “inactive”. The “active”
conformation is assumed to be the conformation in solution when bound to a full
agonist that induces increased transcription. Notably, these “active” and
“inactive” helix 12 conformations are both influenced by crystal contacts
(Supplementary Fig. 2b).
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Figure 1. Differences in nuclear receptor coregulator interaction differentiates
pharmacologically distinct synthetic PPARγγ ligands. TR-FRET biochemical assay shows the
effect of the compounds on the interaction between PPARγ LBD and peptides derived from the (a)
MED1 coactivator and (b) NCoR corepressor, plotted as TR-FRET ratio (665 nm/620 nm) vs.
ligand concentration (n=2, standard deviation). The data shown represents technical replicates
from a single experiment and the experiment was repeated four times with similar results. The
window of efficacy in these data is representative of ligand induced changes in coregulator affinity
for PPARγ. An increase in TR-FRET ratio indicates a strengthening of affinity for MED1/NCoR
compared to apo while a decrease indicates a ligand induced weakening of affinity for the
coregulator. The effect of vehicle (DMSO) is negligible (Supplementary Fig. 5), furthermore the
DMSO concentration is constant across the titration both in this figure and all other TR-FRET data
presented.

2.3.2 NMR-detected coregulator binding surface structural ensemble
To facilitate 19F NMR studies of the coregulator binding surface, which is
composed of portions of helix 3, 4 and 12, we introduced a cysteine residue on the
C-terminus of helix 12 at several locations (K502C, Y505C and Q498C) and on
helix 3 (Q322C) of the PPARγ ligand binding domain (LBD) to allow covalent
linkage of 3-Bromo-1,1,1-trifluoroacetone (BTFA), a small molecule containing a
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trifluoromethyl (–CF3) group. Q498C caused protein instability, whereas BTFA
attached to Y505C did not show pronounced ligand induced changes to the 19F
NMR spectra of the PPARγ LBD, presumably due to its position at the
unstructured C-terminus of helix 12 (Supplementary Fig. 1). However, Q322C
and K502C yielded well-functioning protein with pronounced ligand inducible
changes; we used these mutants to probe the conformational ensemble of the
PPARγ coregulator binding surface (i.e. the AF-2 surface).
Molecular simulations indicate that K502 (wild-type residue) and K502CBTFA (modified residue) are both solvent exposed in the “active” helix 12
conformation and are not likely to sterically hinder coregulator binding in this
“active” conformation (Figure 2, Supplementary Fig. 3). Control experiments
indicate that the introduced cysteine on helix 12 (C502) is preferentially labeled
over the only native cysteine (C313), which could be because C313 points into the
ligand binding pocket (Supplementary Fig. 4). We refer hereafter to BTFA
labeled PPARγ K502C protein as PPARγK502C-BTFA, we also use PPARγK502CBTFA with a C313A mutation (referred to as PPARγC313A,K502C-BTFA) for
comparison, as this protein can only be labeled on helix 12. 19F NMR signals in
these labeled proteins could conceivably arise from BTFA labeled co-purified
protein impurities, however, the spectrum of PPARγC313A, which lacks all
cysteines, reveals no detectable signal from impurities (Supplementary Fig. 5).
Next, we determined the effects of mutations and labeling on the function
of the PPARγ LBD. First, we measured ligand Ki values using a competitive
ligand displacement assay to determine if the mutations and BTFA label affects
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ligand affinity. Compared to wild-type, the PPARγK502C-BTFA and
PPARγC313A,K502C-BTFA proteins exhibit a 5- and 11-fold median reduction in
ligand affinity respectively (Supplementary Table 1) however, only four ligands
(GQ-16, BVT.13, ciglitazone and troglitazone) are predicted to be at less than
93% occupancy in our samples under the conditions used for the NMR
experiments reported here (Supplementary Table 2). Second, we measured
coregulator recruitment efficacy and EC50 using TR-FRET. As expected from the
calculated Ki values, PPARγK502C-BTFA has a 2- and 5-fold median reduction in
EC50 and PPARγC313A,K502C-BTFA has a 1- and 9-fold median reduction in EC50 in
recruiting MED1 and NCoR respectively compared to wild-type PPARγ
(Supplementary Table 3). Importantly, ligand induced coregulator recruitment
efficacy is highly correlated for PPARγK502C-BTFA and WT indicating that
PPARγK502C-BTFA is functionally similar to wild type PPARγ LBD (R2=0.8 for
NCOR and R2=0.98 for MED1; Supplementary Fig. 6d and 6f). In contrast, the
relative NCOR recruitment efficacy differs between PPARγC313A,K502C-BTFA and
WT, while the relative MED1 recruitment efficacy is comparable to WT in this
labeled mutant (R2=0.11 for NCOR and R2=0.8 for MED1; Supplementary Fig.
6d and 6f). We also found that the mutations and labeling had little effect on
recruitment efficacy and EC50 of a coactivator peptide derived from CREBbinding protein (CBP) for both labeled forms of PPARγ (Supplementary Fig. 6b
and 6e and Supplementary Table 4).
In addition, we compared mutant and WT PPARγ affinity for fluorescein
isothiocyanate (FITC) labeled NCoR, MED1 and a peptide from the silencing
49

mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor
utilizing fluorescence polarization (FP). Labeling did not significantly affect
affinity of NCoR or MED1 for the four tested PPARγ-ligand complexes
(Supplementary Fig. 7) and consistent with the TR-FRET data, PPARγK502CBTFA affinity for NCOR and MED1 correlated most closely with WT PPARγ.
Both labeled PPARγs affect SMRT peptide affinity, although PPARγK502C-BTFA
does so to a lesser extent, indicating that the label may directly interfere with
SMRT binding (Supplementary Fig. 7). In general, these data indicate that the
relative coregulator affinities are consistent between WT and especially
PPARγK502C-BTFA. Given these data we focused on PPARγK502C-BTFA to
correlate structure with function and utilize PPARγC313A,K502C-BTFA to confirm
specific labeling of PPARγK502C-BTFA and in cases where increased signal to
noise is required. PPARγK502C-BTFA is incompletely labeled (Supplementary
Fig. 4d) to avoid labeling C313 (Supplementary Fig. 4a-c), which decreases the
NMR signal. In addition, PPARγK502C that is not labeled with BTFA is not TRFRET active (Supplementary Fig. 4e) but has the same affinity for coregulators
as PPARγK502C-BTFA (Supplementary Fig. 7b), therefore any unlabeled portion
of PPARγK502C-BTFA should not affect FP or TR-FRET results.
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Figure 2 | 19F NMR analysis of PPARγK502C-BTFA bound to 16 pharmacologically distinct
ligands. (a) Location of covalently attached BTFA tag. (b-s) 19F NMR spectra (medium grey
lines) of PPARγK502C-BTFA (b-q) bound to ligand and ordered according to mean weighted
19
F chemical shift or (r) delipidated and (s) non-delipidated apo-protein. Fitted peaks are colored
according to fitted 19F chemical shifts; deconvoluted spectra and residuals are shown in black and
light grey lines, respectively. Some of these spectra have been replicated (Supplementary Fig.
10) (t) Plot of the full width half max (FWHM) of the major fitted peaks (only peaks that comprise
>5% of the spectrum area are included) versus fitted chemical shifts. Clusters were detected by
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bivariate kernel density estimation (purple contours) with weighted mean 19F chemical shift values
annotated on top of the plot. Computational simulations were run of labeled PPARγ (PPARγK502CBTFA) bound to one of these 16 ligands (GW1929) that demonstrate that the tag stays on or near
the surface of the protein (Supplementary Fig. 3)

We collected 19F NMR spectra of PPARγK502C-BTFA bound individually
to each of the 16 synthetic ligands (Figure 2b–q), as well as spectra of apoprotein with and without delipidation (Figure 2r,s). Bacterially expressed PPARγ
often contains fatty acids, which can have functional effects218 and therefore we
remove these lipids, additional data regarding the effects of delipidation on
structure and function are presented below. 19F NMR provides a time-averaged
view of the conformational ensemble of helix 12, thus long-lived major
conformations (>ms lifetime) show up as distinct peaks, while conformations with
lifetimes on the µs-ms timescale show up as a broad single peak. A single
conformation (i.e. fast exchange among minor conformational variants) produces
a single narrow peak. We used an objective deconvolution219 method to determine
the number of peaks and corresponding peak line widths that compose the
recorded spectra. The line widths of the peaks obtained from the objective
deconvolution are consistent with measured NMR lifetimes of the 19F (T2) that we
obtained for several liganded states (Supplementary Table 5). Bivariate kernel
density estimation of all the deconvoluted spectra revealed two primary clusters
of peaks, or conformations and a third lowly populated cluster (Figure 2t). In
general, ligands known to be efficacious or strong agonists (e.g. GW1929,
rosiglitazone, pioglitazone, and troglitazone) populate the most upfield (right)
group of the narrowest peaks in cluster 1. Ligands of other pharmacological types,
including partial agonists and inverse agonists are found in cluster 2, which is
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composed of wider peaks, indicative of ensembles composed of multiple
conformations. A third lowly populated cluster of downfield chemical shifts and
relatively narrow peak widths, cluster 3, occurs for T0070907 and GW9662
ligands that covalently bind to C313 in the canonical ligand-binding pocket and
function as inverse agonists in cell-based assays156,217. These covalent ligands do
not attach to the introduced cysteine on helix 12 (C502; Supplementary Fig. 5ab). PPARγC313A,K502C-BTFA loaded with or without the same 16 ligands show
very similar 19F NMR spectra to PPARγK502C-BTFA, except for ligands which
covalently bind to C313, which as expected look similar to ligand-free/apoprotein because PPARγC313A,K502C-BTFA lacks C313 (Supplementary Fig. 8).
Overall these data indicate a diverse ligand dependent helix 12 conformational
ensemble.

A contribution to the ligand-dependent differences in 19F NMR chemical
shift values could be the relative solvent exposure of the BTFA probe –CF3 group,
which can be determined by collecting 19F NMR spectra as a function of D2O
concentration. When increasing amounts of D2O are added to the sample, a large
upfield shift (i.e., to the right) of the 19F NMR peak indicates high solvent
exposure of the BTFA probe while a smaller shift indicates low solvent
exposure215, for example a solvent exposed 5-fluorotryptophan shifted 0.217 ppm
upfield in 90% D2O buffer220. The chemical shift of free BTFA, which has high
solvent exposure, has nearly the largest chemical shift change of any measured
here (0.115 ppm upfield), whereas the solvent protected MRL24 ligand CF3
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group, which is buried deep in the ligand binding pocket, moves in the opposite
direction with increasing D2O concentrations (Figure 3 and Supplementary Fig.
13). Given the solvent protected position of MRL24 CF3 in the ligand binding
pocket221, the movement in the opposite direction of the MRL24 ligand CF3 group
likely indicates interaction between the ligand CF3 group and the protein that is
perturbed upon addition of D2O32. GW1929 bound PPARγC313A,K502C-BTFA has
the largest upfield chemical shift (0.116 ppm; Figure 3), which is consistent with
molecular simulations that show that K502 and C502 both have considerable
solvent exposure in the “active” conformation (Supplementary Fig. 3). These
data indicate full agonists primarily populate the “active” crystalized
conformation in solution, while apo, partial agonists and inverse agonists are
found in other distinct conformations.

54

Figure 3 | Helix 12 solvent exposure is distinct for the “active” helix 12 conformation, apoprotein and inverse agonist-bound conformations. (a) 19F NMR spectra of delipidated apoPPARγC313A,K502C-BTFA bound to 0.2 molar equivalent of GW1929 (left); and T0070907-bound
PPARγK502C-BTFA with excess free BTFA; at the indicated concentrations of D2O. Due to the
high binding affinity of GW1929 (4 nM), all three expected peaks (two apo-protein peaks and one
GW1929 peak) are present in slow exchange on the NMR time scale, allowing analysis of the
three conformations simultaneously. (b) D2O solvent isotope-induced changes, plotted as % D2O
versus change 19F NMR chemical shift values for various peaks; a dotted grey line is shown to
highlight no D2O-induced change in 19F NMR chemical shift. These experiments were performed
once.

PPARγ protein expressed in bacteria can pull down medium chain fatty
acids, which function as weak partial agonists218. In agreement, non-delipidated
(native) apo-protein that is partially bound to endogenous E. coli lipids (Figure
2s) afforded 19F NMR spectra with two peaks of similar chemical shift to
delipidated apo-protein (Figure 2r) along with several other lowly populated
peaks. Comparison of 2D NMR spectra of delipidated and non-delipidated
PPARγ LBD and PPARγC313A,K502C-BTFA in apo form or bound to ligands
indicate that E. coli lipids have relatively minor effects on helix 12 and backbone
structure (Supplementary Fig. 9a-b). In addition, TR-FRET data collected using
non-delipidated or delipidated PPARγ-LBD shows essentially the same ligand
dependent coregulator recruitment potency and efficacy (Supplementary Fig. 9c
and 9d). In separate protein preparations we did observe some variation in
T0070907 bound spectra (Supplementary Fig. 10c) which could be due to
variable amounts of residual co-bound lipids remaining after delipidation as
PPARγ has a very large ligand binding pocket that can accommodate more than
one bound ligand208. Overall, these data indicate that some inverse agonists do
more than simply displace activating lipids, but instead induce a distinct PPARγ
LBD state with higher affinity for corepressors than delipidated apo protein.
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We probed ligand induced changes in another region of the PPARγ
coregulator binding surface using a Q322C mutation, which is located in helix 3,
generating PPARγC313A,Q322C-BTFA. The fluorine probe in this variant is solvent
exposed in the “active” conformation and maintains wild type like recruitment of
coregulators (Figure 4 and Supplementary Fig. 11). The chemical shift
difference induced by ligands is relatively small; however, just as with the helix
12 probe, ligands decrease the conformational diversity of this region with the
strongest agonists (rosiglitazone and GW1929) yielding the narrowest peaks
indicative of a single main conformational ensemble. Similar to apo PPARγK502CBTFA (Figure 2r), apo PPARγC313A,Q322C-BTFA produces a spectrum with two
main wide peaks, indicative of two sub ensembles composed of multiple
conformations with slow exchange between the sub ensembles (Figure 4). These
data indicate that the ligand free coregulator binding surface is composed of two
main structurally diverse (i.e. wide NMR peak) ensembles in slow exchange.
Alternatively, one of the peaks could be PPARγ bound to residual E.coli lipids,
however this unlikely given that the spectra is stable over time (Supplementary
Fig. 11) whereas E.coli lipid bound PPARγK502C-BTFA spectra change with time
(Supplementary Fig. 10a). The exchange rate between these two apo NMR
peaks is discussed below.

56

Figure 4 | A helix 3 probe on the coregulator binding surface confirms agonist induced
reduction in conformational complexity of the coregulator binding surface. a) Fluorine NMR
spectra of PPARγC313A,Q322C-BTFA bound to the indicated ligands. The small sharp left shifted
peak in all the spectra is free BTFA. b) Trajectory frame from a simulation of PPARγC313A,Q322CBTFA bound to a coactivator peptide (MED1; green) with 322C-BTFA shown in orange as
spheres (fluorine atoms are turquoise). These experiments were performed once.

2.3.3 Slow exchange between ensemble structures
A single well populated 19F NMR peak is observed for BTFA probes
placed in two areas of the coregulator binding surface (helix 3 and 12) when
PPARγ-BTFA is bound to a strong agonist such as GW1929 or rosiglitazone.
However, for less efficacious ligands, multiple-well populated 19F NMR peaks are
observed in slow exchange on the NMR time scale indicating that the peaks
represent distinct coregulator binding surface conformations with lifetimes on the
order of milliseconds or longer.
To confirm the apparent slow exchange between different conformations,
we performed 19F chemical exchange saturation transfer (CEST) NMR
experiments on PPARγ where multiple peaks, or conformations, are present
(Figure 5a and Supplementary Fig. 12). Of the five ligands and apo protein
studied, four ligands and apo protein show obvious slow chemical exchange
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between a well-populated minor resonance and the most abundant resonance. In
the case of T0070907, exchange was difficult to detect, likely because exchange
rates less than ~0.4 s-1 are too slow to be effectively detected using this method
under our experimental conditions (Supplementary Fig. 12a and 12b).
We next quantified the exchange rate between peaks. PPARγK502C-BTFA
bound to GW9662 and troglitazone each showed very slow exchange between
peaks, making precise measurement difficult (0.3 and 0.4 s-1; Supplementary Fig.
12d). However, for pioglitazone and ciglitazone, the exchange between the two
prominent peaks is 1.2 and 1.4 s-1 (95% CI 1.1 to 1.3 s-1 for pioglitazone and 1.3
to 1.5 s-1 for ciglitazone; Figure 5b). In addition, we found exchange of 1.0 s-1
(95% CI 0.9 to 1.1 s-1) between the two resolved apo peaks of PPARγC313A,Q322CBTFA (Supplementary Fig. 12c). These slow exchange rates are consistent with
the notion that the detected conformations originate from larger scale movements
involving many atoms223, indicating helix 12 and the coregulator binding surface
exchanges between two or more distinct conformations. Almost all of the signal
in the ligand bound spectra do not overlap with the apo spectrum, thus implying
that exchange between conformations is occurring while bound to ligand. These
data raise the possibility that these ligands are found in at least two functionally
distinct main conformations exchanging on the seconds time scale. This idea is
consistent with the fact that the PPARγ non-agonist/antagonist SR1664 has been
crystalized in two distinct conformations161,224.
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Figure 5 | Chemical exchange saturation transfer indicates slow exchange between liganded
states with multiple helix 12 conformations. (a) A selective Gaussian pulse was used to saturate
the 19F spectra bound to the indicated ligands at locations indicated by pink circles. The height of
the pink circles indicates the height of the peak indicated by the black arrow when the selective
pulse was carried out at the chemical shift of the pink circle. If exchange is occurring between the
two peaks the pink dots should mirror the spectrum. (b) A selective Gaussian pulse was used to
saturate the spectrum at an on resonance (a; orange box arrow) and off resonance (a; blue box
arrow) location, the peak height of the most abundant resonance (a; black arrow) was monitored as
a function of the duration of the saturation pulse, and the resulting peak intensities were fit to
extract the exchange rate. 95% confidence intervals for the fit of the calculated exchange rates are
shown in parentheses. PPARγK502C-BTFA was used for these data except for ciglitazone which
used PPARγC313A,K502C-BTFA for increased signal to noise. These experiments were performed
once.

2.3.4 Connecting the helix 12 structural ensemble to function
To test whether the 19F NMR detected helix 12 conformations correlate to
function within our set of 16 ligands, we compared the weighted mean 19F NMR
chemical shift values to ligand efficacy for recruitment of MED1 (coactivator),
NCoR (corepressor) and for a subset of these ligands, CBP (coactivator) in the
TR-FRET coregulator interaction assay. For PPARγK502C-BTFA there is a
correlation between mean ligand induced 19F NMR chemical shift and ligand
induced MED1, CBP and NCoR recruitment efficacy (Figure 6a). There are
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similar correlations for PPARγC313A,K502C-BTFA (Supplementary Fig. 14) but not
for PPARγC313A,Q322C-BTFA. In addition, we used fluorescence polarization (FP)
to measure the affinity of a subset of PPARγ-ligand complexes for coregulators
(MED1, NCoR, and SMRT) and compared these to labeled and wt PPARγ and
found that ligand specific affinity correlates with NMR chemical shift (Figure 6b
and Supplementary Fig. 14). The most efficacious agonist for MED1 and CBP
binding in our ligand set (GW1929) induces the most upfield mean chemical shift
of the PPARγK502C-BTFA probe. Similar trends are observed for other agonists,
including the right shifted peaks of thiazolidinedione (TZD/glitazones) ligands. In
contrast, downfield mean chemical shifts are prevalent in apo-protein and inverseagonist (T0070907) bound PPARγK502C-BTFA, which show the highest efficacy
and affinity for NCoR and SMRT binding (Figure 6). These data indicate that the
conformations detected by 19F NMR are functionally distinct.
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Figure 6 | Ligand-directed helix 12 ensemble dictates PPARγγ-coregulator interaction. (a) Plot
of mean 19F NMR chemical shift values (PPARγK502C-BTFA) versus TR-FRET endpoint data for
the recruitment of MED1, NCoR and CBP peptides to PPARγK502C-BTFA (top panels) and wt
PPARγ LBD (bottom panels) for the set of 16 pharmacologically distinct synthetic PPARγ ligands
and apo-protein (select ligands for CBP). Error bars are relatively small for end point TR-FRET
values (Figure 1 and Supplementary Figure 6) and excluded for clarity b) Plot of mean 19F NMR
chemical shift values (PPARγK502C-BTFA) versus MED1, NCoR and SMRT peptide dissociation
constant (Kd) for PPARγK502C-BTFA (top panels) and wt PPARγ LBD (bottom panels) as
measured by fluorescence polarization for a subset of the ligands in panel a. Linear regression fit
is shown as a solid line and the correlation coefficient (R2) for the fitted line is indicated. The
ligands with the highest efficacy for MED1 and NCoR recruitment for PPARγK502C-BTFA are
highlighted. Error bars represent standard deviation of two (K502C-BTFA Kd and wt SMRT Kd)
or three (wt MED1 and NCoR Kd) independent experiments.

2.3.5 Coregulators shift the conformational ensemble
The data above demonstrate that ligands of different pharmacological
activities can stabilize functionally distinct coregulator binding surface
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conformations. To determine how coregulator binding influences these ligand
dependent conformational ensembles in solution, we performed 19F NMR with
and without coactivator (MED1 and CBP) and corepressor (SMRT and NCoR)
peptides; and in the absence or presence of the most efficacious agonist
(GW1929) or inverse agonist (T0070907) and a less efficacious inverse
agonist/antagonist (GW9662) (Figure 7a). Similar to strong agonists, addition of
coactivators to apo-protein induces an upfield (right) shifting of the spectra. In
contrast, similar to inverse agonists, addition of corepressors to apo-protein
induces a downfield (left) shifting of the spectrum. Notably, corepressor cobinding to T0070907/PPARγK502C-BTFA results in smaller perturbations to the
fluorine spectra than coactivator co-binding. The opposite is observed for
coregulator co-binding to GW1929/ PPARγK502C-BTFA. Apo-protein and
GW9662 bound PPARγK502C-BTFA are almost equally changed by addition of
coactivators or corepressors (Figure 7c). These data suggest that the
GW1929/PPARγ and T0070907/PPARγ coregulator binding surface structural
ensembles are near ideal for MED1/CBP and NCoR//SMRT binding,
respectively. In contrast, the apo-protein and GW9662 structural ensembles are
not ideal for binding any of these coregulators.
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Figure 7 | Coregulator binding shifts the helix 12 conformational ensemble in a manner
predicted by ligand induced shifts to the ensemble. (a) Deconvoluted 19F NMR spectra of apoPPARγC313A,K502C-BTFA and PPARγK502C-BTFA bound to GW1929 or T0070907 in the absence
and presence of MED1 coactivator or NCoR corepressor peptides. The percent of total signal area
found in the left sharp peak is shown for T0070907 and GW9662 spectra. The small sharp peak at
~-83.3 ppm is free BTFA. (b) Mean weighted chemical shift values from the plots in (a). (c)
Fraction of the total peak areas in the four colored boxed regions in (a), which roughly correspond
to the clustered spectral regions from Figure 2; with the two middle regions corresponding to the
two peaks observed for apo-protein. Agonist bound PPARγ is changed little by MED1 binding,
whereas NCoR binding changes the spectrum drastically and vice versa for inverse agonist
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(T0070907) bound PPARγ. *SMRT induced mean chemical shift in GW1929 bound PPARγK502CBTFA is the same as NCoR. These experiments were performed once.

2.3.6 RXRα heterodimerization shifts the inverse agonist ensemble
PPARγ binds enhancer regions on DNA and affects gene expression
primarily as a heterodimer with RXRα225. We therefore performed experiments to
determine the effect of RXRα heterodimerization on the conformational ensemble
and on coregulator recruitment. Other than the expected broadening and
consequently decreased signal from the larger molecular weight complex, RXRα
heterodimerization has a relatively small effect on the 19F spectra of
PPARγC313A,K502C-BTFA when co-bound to GW1929 (agonist), MRL24 (less
efficacious partial agonist) and apo. RXRα binding to PPARγK502C-BTFA cobound to T0070907 (inverse agonist) induces a large change in the spectrum,
decreasing the relative population found in the left shifted peak (Figure 8a),
which is expected to disfavor NCoR binding. Consistent with the change in 19F
NMR spectrum, NCoR binding is decreased and MED1 recruitment is increased
by RXRα heterodimerization with the T0070907/PPARγ complex (Figure 8).
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Figure 8. | Heterodimerization of PPARγ LBD with RXRα LBD favors MED1 binding,
disfavors NCOR binding. (a) 19F NMR of PPARγK502C-BTFA bound to T0070907 and
PPARγC313A,502C-BTFA bound to MRL24 or GW1929 or with no ligand bound was performed in
the presence (orange) or absence (black) of RXRα LBD. These experiments were performed once.
(d) The 19F NMR signal from the MRL24 ligand. Broadening and consequent reduction in signal
intensity is expected as a consequence of the increased rotational correlation time of the
heterodimer complex. (b-c) TR-FRET was used to measure interaction between wt PPARγ LBD
and MED1 or NCOR in the presence or absence of equimolar concentrations of RXRα. Error bars
represent standard deviation of two technical replicates within a single experiment. The
experiment was repeated twice and gave similar results each time. (e) Heterodimerization favors
MED1 binding (p=0.0017) and disfavors NCOR binding (p=0.0076) to apo PPARγ. In addition,
visual and statistical comparison of NCOR and MED1 recruitment to PPARγ LBD saturated with
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ligand (4 highest concentrations of ligands) indicates that RXRα affects coregulator recruitment to
T0070907 bound PPARγ (NCOR p=0.0042; MED1 p=0.0027) more than GW1929 (NCOR
p=0.44; MED1 p=0.34) or MRL24 (NCOR p=0.0141; MED1 p=0.061). All p values are derived
from a two-tailed t test.

2.3.7 Simulations suggest a diverse ligand dependent ensemble.
The extreme broadening observed in apo PPARγ alone or bound to NCoR
peptide originate from multiple conformations exchanging every μs to ms. We
reasoned that we could sample some of these conformations in independent longtime scale simulations of apo alone or apo bound to NCoR. We also simulated
inverse agonist (T0070907) bound PPARγ LBD with and without co-bound
NCoR to gain additional insight into how this ligand changes the coregulator
binding surface conformational ensemble. We built simulation models using
crystal structures with helix 12 in an “inactive” chain B conformation
(Supplementary Fig. 2d) to avoid steric clash with bound NCoR peptide. We ran
simulations at 37°C (NMR was run at 25°C) and with the TIP3P water model
(TIP3P is much less viscous than actual water226), to speed relaxation to a local or
global energy minimum (i.e. stable conformation) given that this chain B
“inactive” conformation may be in a higher energy conformation. These
simulations were allowed to run until reaching a structure that remained
reasonably stable for at least 5 μs as judged by consistent helix 12 RMSD relative
to the starting structure (Supplementary Fig. 15). These stable conformations are
representative of a local or global free energy minima. Three of four independent
simulations of PPARγ LBD alone (apo) relaxed to a cluster of distinct but similar
conformations that are somewhat similar to the starting chain B crystal structure,
while the fourth does not appear to stabilize to the same degree and goes to a
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distinct conformation. These results are consistent with the broad ligand free (apo)
PPARγ 19F peaks observed which indicate exchange between two or more
conformations (Figure 9a) and are also consistent with previous free energy
calculations that indicated the “inactive” chain B crystal structure is very similar
to low energy apo structures227. Addition of NCoR to apo PPARγ LBD results in
up to 12 μs of relative instability (Supplementary Fig. 15b) before finally
relaxing to several different stable conformations that are consistent with the idea
that NCoR pushes helix 12 away from the coregulator binding surface, yielding a
diverse collection of conformations that are consistent with the observed broad
helix 12 19F NMR peaks observed for this complex (Figure 9b). All three
simulations of T0070907 bound to PPARγ LBD relax to very distinct
conformations (Figure 9c). Addition of NCoR to T0070907 bound PPARγ
provides a path to one dominant energy minima as all three simulations in this
complex reach conformations similar to an “active” conformation but with helix
12 shifted to accommodate the longer LXX I/H IXXX I/L helix of corepressors
compared to the LXXLL motif of coactivators42. These data are consistent with
our 19F NMR data that demonstrate that NCoR binding to the T0070907 PPARγ
LBD complex induces a shift towards one particular conformation from several
conformations (Figure 9d).
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Figure 9 | Microsecond timescale molecular simulations point to a diverse ligand dependent
ensemble and a possible NCoR bound structure. (a-d) Root mean square deviation (RMSD) of
helix 12 relative to an “inactive” (1PRG chain B) structure and an “active” conformation (1PRG
chain A) for helix 12 in four different simulated complexes. Helix 12 from these “inactive” and
“active” structures is shown in all panels (grey pipe). SMRT bound to PPARα (PDB code: 1KKQ)
was aligned to 1PRG chain A and the SMRT helix is shown in panels b and d (grey pipe).
Fourteen independent simulations of (a) apo PPARγ LBD, (b) apo + NCoR corepressor, (c)
inverse agonist (T0070907) bound PPARγ LBD, and (d) PPARγ LBD co-bound to T0070907 and
NCoR corepressor were carried out for 10 to 30 μs and the last 5 μs were analyzed (4 each for apo
simulations and 3 each for T0070907 simulations). Colors on the RMSD plots indicate relative
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number of frames; red indicates the most prevalent and blue the least. Representative structures
from the centroid of the major clusters are shown with helix 12 highlighted in color (4 apo, 4 apo
+ NCOR, 3 T0070907 and 3 T0070907 + NCoR). Helix 12 disassociates from the LBD in one apo
+ NCoR simulation. The cluster for this simulation (centered at 21.3Å (x) and 23.8Å (y)) is not
shown, however a representative structure is shown in light blue. Corresponding 19F NMR data
from Figure 7 are shown in each panel. (e) A model for helix 12 conformational diversity based
on simulation and experiment. Apo or partial agonist bound PPARγ helix 12 is found in many
similar conformations of varying helical structure producing broad NMR peaks and rapid
hydrogen deuterium exchange, while full agonist is found in a tighter cluster of conformations.
Co-binding of the inverse agonist T0070907 and the corepressor NCoR produces one main
conformation similar to an “active” conformation, but with helix 12 shifted. Fuzziness implies
intermediate exchange (μs to ms) between the conformations.

2.4 Discussion
The data presented here for the first time explicitly reveal the
conformational ensemble of the coregulator binding surface, including helix 12,
of a nuclear receptor and the effects of ligands on that ensemble. A model of
nuclear receptor activation arises from these data and previously published work,
which indicates that nuclear receptors and other proteins are found in ensembles
of structures and not a single structure207,211–213,228,229. The structural variance
around this primary structure varies from protein to protein, however for nuclear
receptors this variance appears to be considerable140,207,230. The data presented
here indicate that the coregulator binding surface, including helix 12, exchanges
relatively quickly (i.e. μs to ms lifetimes) between many conformations of similar
free energy in a broad rough energy well for apo PPARγ, partial agonist bound
PPARγ, and apo PPARγ bound to NCoR. Furthermore, agonist and inverse
agonist binding reduces the complexity of the apo ensemble and forms distinct,
narrow energy well(s) increasing the population found in structurally distinct
“active” or “inactive” state(s) which favor coactivator or corepressor binding
respectively (Figure 7 and 9e). Very slow exchange (seconds) across high kinetic
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barriers is observed for some agonists and inverse agonists, indicating that these
ligands hold helix 12 in narrow and deep energy wells with rare exchange
occurring between sub-ensembles (Figure 5). Consistent with these data, free
energy calculations indicate that helix 12 in apo-PPARγ is found in two broad
energy wells with conformations similar to both “active” and “inactive” apoPPARγ helix 12 crystal conformations, whereas helix 12 in rosiglitazone-bound
PPARγ is found in one deep narrow well with a conformation similar to the
“active” chain A conformation227. Importantly, these data reveal a correlation
between ligand efficacy and the prevalence of at least three distinct structural
ensembles using a diverse set of 16 pharmacologically distinct PPARγ ligands.
The long time-scale simulations presented here are qualitatively consistent
with the experimental results. Simulations started from an “inactive” chain B
structure PPARγ relax to multiple different structures depending on the ligand and
coregulator that are bound to PPARγ (Figure 9). Apo PPARγ LBD relaxes to
conformations similar to the starting “inactive” chain B structure, while addition
of NCoR binding pushes helix 12 into various different structures, consistent with
the idea that NCoR does not interact productively with helix 12 in apo PPARγ. In
contrast, simulations of NCOR and T0070907 co-bound to PPARγ relax to two
very similar structural clusters, which are consistent the idea that helix 12
interacts productively with NCoR in this complex. In addition, simulations of
GW1929 bound to PPARγ starting with helix 12 in an “active” chain A
conformation remain in a similar helix 12 conformation throughout the simulation
(Supplementary Fig. 3), indicating that as expected this is the dominant
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conformation for agonist bound PPARγ in solution. In addition to movement of
helix 12 between different positions relative to the rest of the LBD these
simulations indicate that the length and helicity of helix 12 can weaken in some
conformations (Figure 9), which could contribute to broad 19F NMR peaks and
increased exchange rates in HDX-MS161. Overall it is encouraging that these nonconverged simulations qualitatively agree with 19F NMR and provide a glimpse of
possible conformations that comprise a portion of the observed 19F NMR spectra,
however quantitative comparison between the 19F NMR spectra and converged
simulations remains a future challenge.
This view of the coregulator binding surface, including the number and
relative populations of conformations and sub-ensembles that comprise the
ensemble is made possible by using a single fluorine probe which provides high
sensitivity, a single signal which obviates the need to transfer spin between
residues, and a total lack of background signal. 19F NMR requires mutation and
labeling of PPARγ which perturbs corepressor affinity (especially SMRT) but has
less effect on NCoR interaction and little effect on coactivator affinity as
measured by TR-FRET peptide recruitment and FP affinities for corepressor
(NCOR and SMRT) and coactivator (MED1 and CBP) peptides (Supplementary
Fig. 7). Based on these observed functional effects, we propose that any effect
from the mutations would likely shift inverse agonist bound mean NMR chemical
shifts toward the center decreasing the population found in the inverse agonist
conformational state (cluster 3). Depending on the chemical shift difference and
rate of exchange between the conformations this will result in movement of a
71

peaks chemical shift and/or a decrease in population of the cluster 3 (left cluster).
For example, a left shifted narrow peak at a chemical shift typical of inverse
agonism (cluster 3) and a broad peak at a chemical shifts typical of
antagonist/partial agonist (cluster 2) are observed for PPARγK502C-BTFA bound
to the inverse agonist T0070907156,217 and less efficacious inverse
agonist/antagonist GW9662 (Figure 2 and 7). Addition of NCOR or SMRT shifts
the population from cluster 2 to cluster 3, while the mutations and labeling may
shift the equilibrium population in the opposite direction toward the
antagonist/partial agonist cluster (cluster 2). Thus, it may be that helix 12 of WT
PPARγ LBD bound to T0070907 is found in a conformation represented by the
“inverse agonist” cluster (cluster 3; left shifted narrower peak) to a larger degree,
than detected by PPARγK502C-BTFA.
This work adds detail to how ligands in general control the activity of
nuclear receptors. Our data not only confirm that helix 12 and the coregulator
binding surface exists as a ligand specific dynamic structural ensemble, but also
indicate the relative populations of sub-ensembles that comprise the overall
structural ensemble and correlate function with this ensemble. Further definition
of the conformational ensemble of the entire protein and the kinetics and
thermodynamics of exchange between the members of the ensemble will build an
accurate model of how ligands produce functional outputs via nuclear receptors
and allow greater control of their function via ligands.
2.5 Methods
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2.5.1 Protein purification
A pET-46 plasmid carrying the genes for ampicillin resistance and Nterminally 6xHis tagged PPARγ containing a tobacco etch virus nuclear inclusion
protease (TEV) recognition site between the His tag and protein of interest was
transformed into chemically competent E. coli BL21(DE3) Gold cells. Cells were
grown in either ZYP-5052 autoinduction media or terrific broth (TB). Cells grown
in TB at 37 °C were induced at an OD600 of approximately 0.8 by the addition of
0.5mM IPTG and the temperature lowered to 22 °C. Induction proceeded for
16 hours prior to harvesting. Harvested cells were homogenized into 50 mM
Phosphate (pH 8.0), 300 mM KCl, 1 mM TCEP and lysed using a C-5 Emulsiflex
high-pressure homogenizer (Avestin). Lysates were then clarified and passed
through two Histrap FF 5 ml columns in series (GE Healthcare). Protein was
eluted using a gradient from 15-500 µM imidazole. Fast protein liquid
chromatography (FPLC) was performed on either an NGC Scout system (Biorad)
or an ÄKTA Start (GE Healthcare). Eight mg of recombinant 6xHis tagged TEV
was added to eluted protein followed by dialysis into 50 mM Tris (pH 8.0),
200 mM NaCl, 1 mM TCEP, and 4 mM EDTA. The protein was again passed
through HisTrap FF columns in order to separate cleaved protein from TEV as
well as the cleaved 6xHis tag. The cleavage step was only performed on protein
which would be used for NMR or fluorescence polarization, protein used for TRFRET did not have the 6xHis tag removed. The protein was then further purified
by gel filtration using a HiLoad 16/600 Superdex 200 PG (GE Healthcare). Size
exclusion was performed in 25 mM MOPS (pH 8.0), 300 mM KCl, 1 mM TCEP,
and 1 mM EDTA buffer. Protein was then dialyzed into 25 mM MOPS (pH 7.4),
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25 mM KCl, and 1 mM EDTA buffer. Protein purity in excess of 95% was
determined by gradient 4-20% SDS-PAGE analysis (NuSep). Protein
concentration was determined using ε280 = 12,045 M-1cm-1.
15

15

N labeled protein was grown in M9 minimal media containing 99%

NH4Cl (Cambridge Isotope Laboratories) as the sole nitrogen source. For this

growth cells were grown at 37°C and 180 rpm until an OD600 of approximately
1.0 was reached. At this point the temperature was dropped to 22°C for 1 hour.
Following cool down period protein expression was induced by the addition of
500 µM IPTG during induction cells remained at 22°C. Protein expression and
purification was then accomplished utilizing the same protocol as outlined above.
2.5.2 Delipidation of PPARγ
To delipidate PPARγ LBD, purified protein was diluted to 0.8 mg/ml and
batched with Lipidex 1000 (Perkin Elmer) at an equal volume. This mixture was
batched for 1 hr at 37 °C and 100 rpm. Immediately following this treatment,
protein was pulled through a gravity column by syringe. To increase yield, it was
found that speed of elution was important; protein could not remain on the resin at
room temperature in excess of 3 min. Two more column volumes of pre-warmed
25 mM MOPS, 25 mM KCl, and 1 mM EDTA were also pulled through in the
same manner. Quality of delipidation was then estimated by 19F NMR, loss of
lipid can be most easily detected by a reduction in the peak at -84.1 ppm. When
non-delipidated protein is used in this report it is labeled as bound to E. coli
lipids.
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2.5.3Site-directed mutagenesis
Mutations in PPARγ LBD were generated using the Quikchange
Lightning site-directed mutagenesis kit (Agilent). To generate each mutation the
following primers were used: K502C Forward 5’aggttaattattagtacaagtcgcagtagatctcctgcaggagcgg-3’, Reverse 5’ccgctcctgcaggagatctactgcgacttgtactaataattaacct-3’; C313A Forward 5’ccacggagcgaaactgagcgccctgaaagatgcgg-3’, Reverse 5’ccgcatctttcagggcgctcagtttcgctccgtgg-3’, Q322C Forward 5’catactctgtgatctcgcacacagcctccacggagc-3’, Reverse 5’gctccgtggaggctgtgtgcgagatcacagagtatgc-3’. The presence of expected mutations
and absence of spurious mutations was confirmed by Sanger sequencing
(Eurofins).
2.5.4 Preparation of NMR samples
NMR samples were prepared to a final concentration of 150 µM protein in
470 µL volume containing 10% D2O. Addition of ligand was done in two separate
injections of compound to reduce precipitation. Injections were spaced 30-60 min
apart to allow time for binding. All ligands were dissolved in D6dimethylsulfoxide (DMSO) with the exception of GQ-16 which was dissolved in
D7-dimethylformamide (DMF). Deuterated solvents were obtained from
Cambridge Isotope Laboratories Inc. and were at least 99% isotopically pure.
Final concentrations of ligand for samples of PPARγK502C-BTFA were 1.25x
ligand to protein (187.5 µM) with the exception of troglitazone, pioglitazone, and
ciglitazone, which were loaded to 2.0x (300 µM) due to poor binding affinity. In
samples of PPARγC313A,K502C-BTFA, ligand concentration was 1.1x to protein
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(165 µM) with the exception of troglitazone, pioglitazone, and ciglitazone, which
were loaded to 1.5x (225 μM). To decrease the likelihood of labeling the single
native cysteine (C313) in PPARγK502C-BTFA, we first loaded ligands into the
protein and then labeled with BTFA since bound ligands would restrict access to
C313 for all experiments involving PPARγK502C-BTFA. In both cases, the ligand
concentration in DMSO was controlled to maintain a constant volume of DMSO
or DMF addition to the sample (8.80 µL for PPARγK502C-BTFA and 7.76 µL for
PPARγC313A,K502C-BTFA) including for apo and E. coli lipid samples. For peptide
studies, 1 mM peptide in identical buffer to protein was added at a 2:1 molar ratio
(final concentration 300 μM peptide and 150 μM protein). For non-covalent
ligands, samples were labeled with 2.0x BTFA after addition of ligand. For
covalent ligands, samples were labeled with 10x BTFA following preincubation
of T0070907 or GW9662; and addition of 1.5 and 2 ligand molar ratios yielded
very similar spectra, indicating complete covalent modification of C313 and
likely no bonding to K502C (Supplementary Fig. 5). After addition of BTFA,
protein was incubated for 30-60 minutes and then buffer exchanged at least 100x
using 10kDa Amicon Ultra-15 concentrators (Merck Millipore) to remove excess
unbound BTFA. Following this buffered D2O was added.
Variable D2O NMR samples were prepared by buffer exchanging protein
samples greater than 100x into 25mM MOPS 25mM KCl 1mM EDTA pD 7.4
buffer prepared in either 50% or 100% D2O using Amicon Ultra-4 10kDa
centrifugal filters (EMD Millipore). 100% D2O buffer was adjusted to read pD 7.4
(pH 7.0231), and then mixed with appropriate amounts of H2O buffer that had been
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adjusted to read pH 7.4. Following this, ligands were added to the appropriate
concentration as usual. The samples which contained only 10% D2O were
prepared as usual with the standard addition of 10% buffered D2O to the final
sample. Samples of PPARγK502C-BTFA were already loaded with ligand and
labeled appropriately with BTFA prior to exchange into deuterated buffers.
2.5.5 Fluorescence Polarization (FP) assay
Fluorescence Polarization peptide binding assays were performed by
plating a mixture of 50 nM peptide with an N-terminal fluorescein (FITC) tag, 12point serial dilutions of PPARγ-LBD (wild-type, PPARγK502C-BTFA,
PPARγK502C, or PPARγC313A,K502C-BTFA), and PPARγ ligands from 50μM to
24nM. PPARγ-LBD and PPARγ ligands were added at a 1:1 ratio. This mixture
was added to wells of low-volume 384-well black plates (Grenier Bio-one,
catalogue number 784076) to a final volume of 16 μL. Peptides were synthesized
by Lifetein LLC (Somerset, NJ) for the for Mediator Complex Subunit 1 (MED1)
peptide, sequence: NTKNHPMLMNLLKDNPAQD; and the Nuclear Receptor
Corepressor 1 (NCoR) peptide, sequence: GHSFADPASNLGLEDIIRKALMG
(2251-2273). Other peptides were purchased from ThermoFisher (Waltham, MA)
for Mediator Complex Subunit 1 (MED1) peptide, sequence:
NTKNHPMLMNLLKDNPAQD (catalogue number PV4549); CREB-Binding
Protein (CBP) peptide, sequence: AASKHKQLSELLRGGSGSS (catalogue
number PV4596); and Silencing Mediator for Retinoid and Thyroid Hormone
Receptors (SMRT), sequence: HASTNMGLEAIIRKALMGKYDQW (catalogue
number PV4424). All dilutions were made in 25 mM MOPS (pH 7.4), 25 mM
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KCl, 1 mM EDTA, 0.01% fatty-acid free Bovine Serum Albumen (BSA) (EMD
Millipore, catalogue number 126575), 0.01% Tween, and 5 mM TCEP. Assay
titrations were performed in duplicate. Plates were incubated in the dark at room
temperature for 2 hr before being read on a Synergy H1 microplate reader
(BioTek). Fluorescence polarization was measured by excitation at 485nm/20nm
and emission at 528nm/20nm for FITC. Data was fit using nonlinear regression
(agonist vs response – variable slope 4 parameters) in Prism 7.0b. For FP, TRFRET and Fluormone competitive binding assays we did two technical replicates
and repeated these experiments independently in the lab for once (Fluormone) or
2 or more times FP and TR-FRET. We chose these number of technical replicates
and independent experiment replicates based on our experience with the limited
variability inherent in these biochemical assays

2.5.6 Time-resolved Förster resonance energy transfer (TR-FRET) assay
TR-FRET peptide recruitment assays were performed by plating a mixture
of 8 nM 6xHis-PPARγ-LBD (wild-type, PPARγK502C-BTFA or PPARγC313A,K502CBTFA), 0.9 nM LanthaScreen Elite Tb-anti-His Antibody (LifeTechnologies
catalogue number PV5863), 200 nM peptide (N-terminally biotinylated and Cterminally amidated), 400 nM streptavidin-d2 (Cisbio, catalogue number
610SADLB), and 12-point serial dilutions of PPARγ ligands from 50 μM to
1 pM. This mixture was added to wells of low-volume 384-well black plates
(Grenier Bio-one, catalogue number 784076) to a final volume of 20 μL. Peptides
were synthesized by Lifetein LLC (Somerset, NJ) for Mediator Complex Subunit
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1 (MED1) peptide; sequence: VSSMAGNTKNHPMLMNLLKDNPAQ; and
Nuclear Receptor Corepressor 1 (NCoR) peptide, sequence:
GHSFADPASNLGLEDIIRKALMG (2251-2273). All dilutions were made in
25 mM MOPS (pH 7.4), 25 mM KCl, 1 mM EDTA, 0.01% fatty-acid free Bovine
Serum Albumen (BSA) (EMD Millipore, catalogue number 126575), 0.01%
Tween, and 5 mM TCEP. Assay titrations were performed in duplicate. Plates
were incubated in the dark at room temperature for 2 hr before being read on a
Synergy H1 microplate reader (BioTek). TR-FRET was measured by excitation at
330nm/80nm and emission at 620nm/10nm for terbium and 665nm/8nm for d2.
Change in TR-FRET was calculated by 665nm/620nm ratio.
Data was fit using nonlinear regression (agonist vs response – variable
slope 4 parameters) in Prism 7.0b. Outliers were automatically detected using
Prism 7.0b’s implementation of the ROUT method232 and excluded from the
curve fitting (20 out of 2260 total data points were flagged as outliers). However,
all data points, including detected outliers were included in figure graphs. In cases
where curve fitting failed the TR-FRET value nearest the calculated free ligand
concentration in the NMR experiment was used, otherwise the TR-FRET value at
the calculated free NMR ligand concentration was calculated using the fitted
curve. These TR-FRET ratio values were used to correlate with NMR chemical
shift values. One ligand, nTZDpa, showed a biphasic TR-FRET curve. This could
be due to several factors including ligand aggregation233, absorption interference
in the TR-FRET assay (nTZDpa contains an indole group that could in principle
cause interference), or alternate site binding effects208; we therefore utilized the
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value of the TR-FRET ratio for nTZDpa based on a fit that did not include the last
two concentrations (10 and 50 μM), so as to exclude most effects of the second
transition. In addition, the 50 μM SR2088 point was not run because we did not
have sufficient ligand. All error bars are standard deviation.
2.5.7 Fluormone competitive binding assays
PPARγ ligand inhibition constants (Ki) were measured using a protocol
adapted from LanthaScreen TR-FRET PPARγ Competitive Binding Assay
(Invitrogen, catalogue number PV4894). Assay was performed by plating a
mixture of 8 nM 6xHis-PPARγ-LBD, 2.5 nM LanthaScreen Elite Tb-anti-His
Antibody, 5 nM LanthaScreen Fluormone Pan-PPAR Green (Invitrogen,
catalogue number PV4896), and 12-point serial dilutions of PPARγ ligands from
50 μM to 140 fM. This mixture was added to wells of low-volume 384-well black
plates (Grenier Bio-one) to a final volume of 16 μL. All dilutions were made in
25 mM MOPS (pH 7.4), 25 mM KCl, 1 mM EDTA, 0.01% fatty-acid free BSA
(EMD Millipore), 0.01% Tween, and 5 mM TCEP. Assay titrations were
performed in duplicate. Plates were incubated in the dark for 2 hr at room
temperature before being read on a Synergy H1 microplate reader (BioTek). TRFRET was measured by excitation at 330nm/80nm and emission at 495nm/10nm
for terbium and 520nm/25nm for Fluormone. Change in TR-FRET was calculated
by 520nm/495nm ratio. Nonlinear curve fitting was performed using Prism 7.0b
(Graphpad Software, Inc.) as described above for the TR-FRET data, including
manual exclusion of highest two concentrations for nTZDpa. 30 of the 1224 total
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data points for all three proteins (WT, PPARγK502C-BTFA and PPARγC313A,K502CBTFA) were automatically excluded by Prism in the fits.
2.5.8 Ki calculation
The inhibition constant for each PPARγ ligand was calculated by applying
a corrected Cheng-Prusoff (Kenakin, TP 1993 in Pharmacologic analysis of
drug/receptor interaction, 2nd ed., New York:Raven p. 483.)

=

+

−

+

−

where IC50 is the concentration of the ligand that produces 50% displacement of
the Fluormone tracer, Lo is the concentration of Fluormone in the assay (5 nM),
and KD is the binding constant of Fluormone to wild-type or the two BTFA
labeled mutants, Ro is the total receptor concentration and Lb is the concentration
of bound Fluormone in the assay with no addition of test ligand. The affinity of
Fluormone for the two BTFA labeled mutant proteins was determined via TRFRET by titration of fluormone into each mutant bound to Elite Tb-anti-His
Antibody. Dissociation constants of fluormone for wild-type was measured as
PPARγ LBD is 7.9 ±0.2 the variants were measured as 26 ±3 nM for PPARγK502CBTFA and 44 ±4 nM for PPARγC313A,K502C-BTFA and PPARγC313A 12 ±1 nM.
2.5.9 NMR spectroscopy
Acquisition of spectra was performed using a Bruker 700 MHz NMR
system equipped with a QCI-F cryoprobe. Chemical shifts were calibrated using
an internal separated KF reference in 20 mM KPO4 (pH 7.4) and 50 mM KCl
contained in a coaxial tube inserted into the NMR sample tube. KF was set to
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be -119.522 ppm, which is the shift of the KF signal with respect to the 19F basic
transmitter frequency for the instrument (658.8462650 MHz) at 298.2K, the
temperature at which samples were run. Routine 1D fluorine spectra were
acquired utilizing the zgfhigqn.2 pulse program (Bruker Topspin 3.5), which
consists of a 90° pulse followed by acquisition with proton decoupling
(acquisition=0.7 s). Settings were D1=1.2 s, AQ= 0.82 s. Approximately 500 to
4000 transients were collected. Saturation transfer experiments were carried out
using the stddiff pulse program. Settings were D1=1.6 s, AQ=0.6 s. For some
experiments the total duration of the saturating pulse (Gaus1.1000, 54.52 dB,
50ms) was 1.6 s (D2O) and the location of the saturating pulse was varied. In
other experiments, the duration of the saturating pulse was varied, with the
saturating pulse location held constant and the rate of exchange was fit using
equation 50 found in a previous publication234. An off resonance selective
saturating pulse was used to determine the peak intensity at time t=0 and R1 was
determined experimentally (Table 2). Fits of the saturation transfer data were
accomplished with a single free parameter using these experimentally determined
values for initial intensity and R1 (2.7s-1 used for all fits except GW9662 which
used 2.4s-1). Transverse and longitudinal relaxation lifetimes (T1 and T2) were
determined by fitting data acquired using an inversion recovery experiment
(Bruker pulse program t1ir) and cpmg pulse sequence (Bruker cpmg) in Prism
7.0b (Graphpad Software, Inc.) using standard formulas. Spectra were
deconvoluted in an objective manner with models chosen statistically by a fitting
program219. All fits were carried out in the same manner with the same settings in
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the fitting program, except where noted. Relative phase of fitted peaks was
allowed to vary slightly (π/50 radians) to accommodate imperfect phasing of these
broad signals. The fitting algorithm219 assumes Lorentzian lineshapes of similar
phase. Intermediate exchange effects and field inhomogeneity are likely present in
some of these spectra, which will result in inaccuracies in the fitted models;
however, notwithstanding these limitations, the deconvolution method provides
an objective view of the possible underlying spectral structure and populations.
Two-dimensional [1H,15N]-TROSY-HSQC NMR data were obtained using the
trosyf3gpphsi19.2 pulse program. Select NMR spectra were replicated in two
different ways. 1) Some NMR samples were measured via NMR initially and then
days to weeks later to determine if certain parts of the spectrum changed. Cs
would indicate that non-reversible processes contribute to that part of the signal,
such as unfolding or degradation of the protein. 2) Some spectra were run twice
utilizing protein from the same batch as utilized for the first spectra or from an
entirely different protein preparation.
2.5.10 Molecular dynamics simulations
Residues in our physical protein constructs used in NMR that were
missing in crystal structures (except the N-terminal glycine, which is an unnatural
vestige of the cleaved His tag) were added using the modeller235 extension within
Chimera236 and a PDB file was saved. This PDB file was then submitted to the
h++ server237 (http://biophysics.cs.vt.edu/H++) to determine the state of titratable
protons at pH 7.4, along with more realistic rotamers for some residues. This h++
PDB file was then given AMBER names for the various protonation states of
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histidine determined by h++ using pdb4amber (AmberTools14238). PDB files of
Cysteine-BTFA residue was created through modification of a cysteine residue in
Chimera. This PDB file was then submitted to the RED server239 for RESP240
charge derivation and geometry optimization. RESP values for the cysteine
backbone of these modified residues were constrained to match AMBER cysteine
residue values as part of the input to the RED server. In a manner similar to that
outlined in sections 2-3 in tutorial 5 on the ambermd.org site
(http://ambermd.org/tutorials/basic/tutorial5/), the output mol2 file was then used
to prepare an ac file and then a prepin file containing the same RESP derived
charges (Supplementary Methods) and two force modification files. The
AMBER parameter database derived frcmod file (Supplementary Methods) was
loaded after the GAFF241 parameter database derived frcmod file
(Supplementary Methods) within Tleap in order to use AMBER parameters
where possible for the Cysteine-BTFA residue. Tleap was then used to generate
parameter and coordinate files using both ff14SB242 and GAFF values. A
truncated octahedron solvation cell with boundaries at least 10 Angstroms from
any protein atom was built with TIP3P243 water. The system was neutralized with
Na+ ions and K+ and Cl- atoms were added to 50 mM. Joung and Cheatham ion
parameters244 were used. Minimization (imin=1) and equilibration was carried out
in nine steps with non-bonded cutoff (cut) set to 8 angstroms and with the
equilibrations carried out at 310 Kelvin. First, steepest descent minimization
(ntmin = 2) with strong restraints (restraint_WT = 5 kcal/mol Å2) on protein
heavy atoms for 2000 steps was used followed by NTV MD with shake, the same
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restraints and 1 fs steps for 15 ps. Next, two rounds of 2000 steps of steepest
descent minimization with progressively relaxed restraints (restraint_WT = 2 and
0.1 kcal/mol Å2) followed by a round without restraints. This was followed by
three rounds of NTP MD with shake (5ps, 10ps and 10ps in duration), and protein
heavy atom restraints of 1, 0.5 and 0.5 kcal/mol Å2. A final unrestrained NTP MD
simulation was then run for 200 ps with 2 fs steps. The final restart file from this
process was used along with a hydrogen mass repartitioned parameter file
(modified using parmed) to run new simulations with new randomized atomic
velocities using 4 fs steps at 310 Kelvin. Analysis was carried out using
CPPTRAJ245. All production simulations were carried out using pmemd.cuda or
pmemd.cuda.MPI.
The S enantiomer of GW1929, which was used in NMR and TR-FRET,
was built using Maestro (Schrödinger, LLC). The pyridine ring nitrogen of
GW1929 was the only atom with a predicted pKa near 7.4 (calculated 7.56 +/1.12) using the EPIK module (Schrödinger, LLC). We chose to model this
nitrogen as deprotonated. There is no crystal structure for GW1929 bound to
PPARγ, however there is for GI262570, which is bound to PPARγ LBD in the
1FM9 crystal structure. GI262570 is identical to GW1929 for about 2/3 of the
molecule. GW1929 was docked into the 1FM9 crystal structure with GI262570
removed using AutoDock Vina246. The best scoring docked binding mode
overlaid well with GI262570. In this docked model in the helix 12 interacting
region the two ligands themselves are identical. RESP charges for GW1929 were
derived using the RED server and force modification files generated using GAFF
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parameters. 1FM9 was modified (or not) to incorporate cysteine-BTFA
(parameterized as described above) in place of K502 and docked with GW1929 in
a similar way to that described above to build PPARγK502C-BTFA and PPARγ
bound to GW1929.
1PRG chain B was used to create the build for apo and 3BOR chain B was
used to build T0070907 bound PPARγ LBD. 3BOR contains GW9662 which
differs from T0070907 by one atom. T0070907 has a nitrogen in place of a carbon
atom in one of the ligand rings. This change was made in Chimera and the ligand
parameterized and incorporated into the structure as described above for BTFA.
NCoR (same sequence as used in NMR and TR-FRET including N-terminal
acetylation and C-terminal amidation) was added to these builds utilizing Chimera
using the following procedure. The core helix structure from NCoR (from 2OVM)
was aligned to SMRT on a PPARα SMRT structure (1KKQ), apo PPARγ chain B
(1PRG) was then aligned to PPARα and the PPARα/SMRT structure deleted
leaving the aligned NCoR on apo PPARγ chain B. A similar procedure was used
with the 3BOR structure to create T0070907 co-bound with NCoR on PPARγ.
These PDBs were then used to create the final solvated, minimized and
equilibrated structure in a manner similar to that described above.
All simulations were run with settings shown in Supplementary Methods
including utilization of SHAKE247, with variability in the frequency of writing
various files to disk. K-means clustering was performed and representative
structures from these structures were output by CPPTRAJ245.
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2.5.11 Data availability
Data files for TR-FRET, Fluormone competitive binding assays, and FP
are publicly available at https://osf.io/rqdpz/. Any other datasets generated during
and/or analyzed during the current study are available from the corresponding
author on reasonable request.
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Chapter 3: Helix 4 determines the specificity of
coactivator interactions in nuclear receptors
Ian M. Chrisman, Zahra Heidari, Trey Patton, Tung-Chung Mou and Travis S. Hughes

Data in this chapter is in final preparation for publication.

3.1 Abstract
Nuclear receptors are a diverse superfamily of transcription factors which
are the target of 13% of FDA approved drugs. These proteins function through the
recruitment of coregulator complexes which modulate transcription. These
coregulator interactions are exceptionally specific and regulate very different
pathways. The mechanism by which this selectivity arises is poorly understood. In
this work a helix 4 motif on the LBD of nuclear receptors is identified. Through
this motif specific interactions are made with coactivators which convey a large
degree of specificity. We find that the frequency of interaction between these
residues and coactivators is proportional to coactivator affinity in the nuclear
receptor peroxisome proliferator-activated receptor γ (PPARγ). The significance
of this motif is also verified via molecular dynamics simulations in the nuclear
receptor estrogen receptor α (ERα). Additionally, the mechanism by which full
agonists display differential efficacy in PPARγ is presented.
3.2 Introduction
The nuclear receptor (NR) superfamily of transcription factors regulates a
variety of important pathways in metabolism and development. This superfamily
is made up of 48 proteins in the human genome which makes up the largest group
of transcription factors1,2,248. Dysfunction in these transcription factors is linked to
a variety of disease states including cancers153,249–251, metabolic
syndromes46,49,53,146,252,253 and developmental disorders254–256. Thus far 20 of these
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proteins when modified at the genetic level have been linked directly to disease
states257–260. Due to this the NR family has been a focus of drug development with
approximately 13% of all FDA approved drugs targeting members of this
family261,262.
The activity of NR is controlled through the recruitment of coregulator
proteins. These coregulators are classified into either coactivators which through
their interaction promote transcription of regulated genes or corepressors which
reduce the expression of regulated genes263,264. The interaction of NR and
coregulators is highly specific often to the degree of interacting only with a single
motif inside a coregulator. These interaction motifs are the well characterized
LxxLL motif, NR box (referred to as LxxLL box in this work), seen in
coactivators16,265,266 or the less well understood motif in corepressors which
contain either (L/I)xxI(/V)I or Lxxx(I/L)xxx(I/L), referred to as the CoRNR
box17,267,268. These LxxLL or CoRNR boxes appear to be necessary and sufficient
for the interaction and in many cases only a single motif is needed for high
affinity binding to the LBD of an NR269,270.
NR-coregulator interactions can occur in one of two regions of the NR,
either the unstructured and very poorly conserved activation factor 1 (AF-1)
region of the protein29,271, or more often through the LBD of the NR via the
activation factor 2 (AF-2) region272,273. Current knowledge of the mechanism of
binding focuses on two major interactions. The first is a hydrophobic cleft present
in the NR LBD which allows for interaction with the conserved regions of either
the LxxLL or CoRNR box14,20,274. The second which is most significant for the
interaction of coactivators is the so-called charge clamp. This consists of a
conserved lysine at the C-terminal of helix 3 and a conserved glutamate on helix
1223,275. These two residues serve to anchor the coactivator through interactions
with the peptide backbone of the LxxLL motif in the mousetrap model of
coactivator binding138. However, neither of these interactions are specific to the
coactivator being bound as they interact with conserved motifs.
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In this work we identify a highly conserved motif on helix 4 of the NR
ligand binding domain (LBD) which makes direct coregulator interactions in the
large majority of NR-coregulator crystal structures. This eight-residue motif
makes highly selective coregulator interactions through the side chains of the first
and last residues in the motif. We propose that this motif leads to a large degree of
the observed selectivity in NR coregulator interactions. This hypothesis is verified
experimentally in the NR, peroxisome proliferator-activated receptor gamma
(PPARγ). From this we observe that the degree of helix 4-coactivator interactions
are directly related to the affinity of the complex. Additionally, we identify a
structural mechanism which gives rise to differential efficacy among full agonists
of this protein. Molecular dynamics driven analysis of NR-coactivator interactions
in both PPARγ and estrogen receptor alpha (ERα) indicate that this structural
mechanism of coregulator selectivity appears to be conserved among this
superfamily of proteins. This provides valuable insight into the currently
unknown mechanism by which NR selectively recruit specific coregulators and
better defines the functionally important AF-2 region of the NR LBD.
3.3 Results
3.3.1 Coregulator helix 4 interactions in NRs
A query of the protein data bank revealed that of the 48 NR in the human
genome 42 had crystal structures of the LBD. Of these, 27 had structures that
were solved bound to a coregulator peptide. From these structures we were able to
find 23 NR-coregulator complexes that resolved direct interactions between helix
4 residues on the NR and side chains of the coregulator peptide. Almost all of
these interactions arose from two residues on helix 4 spaced eight residues apart.
Examining the residues in this region we were able to identify a conserved motif.
Three of the residues in this motif were almost 100% conserved across all NR.
These are an aspartate at position two, a glutamine at position three and a leucine
in position six. A consensus logo of this motif is shown in Figure 1, other
consensus logos can be found in Figure S1. Additional interactions were seen in
some NR-coactivator structures originating from the residue immediately prior to
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this conserved motif (seen with FXR, LXRβ and all ROR proteins), as well as two
with interactions from an arginine located five prior to this motif in helix 3’ (in
structures of AR, CAR and GR). However, due to the scarcity of these
interactions it is not realistic to make inferences about their role, but they likely
are significant in selectivity of coactivator recruitment.

Figure 1. Conservation of the helix 4 motif sequence. A: Consensus logo of the primary
sequence for all nuclear receptors for the helix 4 motif. This omits three proteins (DAX1, GCNF
and TR2) of the 48 human nuclear receptors. This motif is degenerate and cannot be identified in
GCNF and TR2. In DAX1 this motif has expanded to nine residues and cannot be aligned due to
this. B: Example crystal structure of HNFα bound to SRC1 (PDB 1PZL) which shows direct
hydrogen bonding from the side chain of both helix 4 residues, D205 and R212. The consensus
logo was generated using WebLogo276.

Next, the 15 remaining NR with crystal structures were examined. Among
these this motif could be identified in all but one, Testicular receptor 4 (TR4). In
this case there is a similar sequence but among the three conserved residues in this
motif only the position 6 leucine is present. Further examination of the remaining
NRs based purely on primary sequence was performed. This identified a further
two proteins, testicular receptor 2 (TR2) and germ cell nuclear factor (GCNF),
which do not contain this motif. However, literature on these proteins indicate that
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such a lack may not be surprising as they are not known to bind coregulator
proteins on the AF-2 surface. For the purposes of examining this motif these three
proteins will not be considered due to the lack of consensus. The presence of this
motif gives insight into a mechanism through which NR LBDs preferentially bind
certain coactivators. Currently this is not well understood as the characterized
interactions, the hydrophobic cleft which interacts with the LxxLL box and the
charge clamp are conserved among NR.
Examining these sequences, we were able to determine several
characteristics of this eight-residue motif, this motif is shown for all 46 NR in
which it could be identified in Figure S2. The first residue is not heavily
conserved but is most frequently an acidic residue, 19 out of 39 cases, and is a
residue capable of hydrogen bonding in 79.5% of NR. When this residue is
capable of hydrogen bonding it is frequently observed to make interactions with
side chains of the coregulator peptide, 14 of 22 proteins crystallized in the
presence of a coregulator. The second residue is the fully conserved aspartate. It is
not clear what the purpose of this residue is as it is not properly aligned to interact
with a coregulator, but it may serve a structural role in the conserved fold seen
with NRs. The next residue is the fully conserved glutamine in position three.
This residue appears to predominantly make water mediated hydrogen bonds to
the carbonyl of one of the leucine residues in the LxxLL motif. It can however
hydrogen bond directly to the side chain of a residue in the peptide, but this is less
common. The fourth residue is poorly conserved but is a non-aromatic
hydrophobic residue (isoleucine, methionine or valine) in 89% percent of the
considered cases. Two proteins where this residue is changed are the NR0B
family (DAX1 and SHP) which function more like coregulator proteins than as
NRs. The other proteins where this residue has changed are the NR4A family
(Nur77, Nurr1 and Nor1) which have been shown to lack a normal coregulator
binding surface29,271 and have been found to bind corepressor proteins in a cleft
between helix 11 and helix 12, which is the opposite side of H12 from the normal
coregulator binding surface30. The fifth residue is very poorly conserved, but this
is unsurprising as it is oriented directly away from the peptide and does not appear
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to have any role in peptide recognition or binding. The sixth residue seems to play
no role in peptide binding but makes a large amount of hydrophobic contacts
which connect helices 4, 8 and 9. This suggests the conservation of this residue
has nothing to do with peptide binding and instead is important for proper folding
of NRs. The seventh residue is almost exclusively a leucine, in three cases is an
isoleucine (AR, MR and PGR) and appears to make non-specific hydrophobic
interactions to the leucine repeat in the LxxLL motif of the coactivator peptide.
The final residue again seems to make specific hydrogen bonds or salt bridge
interactions to the side chains of the peptide. This residue is not very conserved
but by majority is a basic residue, 68%, but can also be a glutamine, 18%, or a
glutamate, 15%.
Separating out these proteins by family reveals patterns relevant to
coregulator specificity profiles within subfamilies. The final residue seems to be
heavily conserved within NR families. In NR1 the motif exclusively ends with a
lysine while in NR2 all proteins have a motif ending in arginine with the
exception of PNR and TLX. However, both PNR and TLX are not well
understood proteins so this may indicate that these proteins share their coregulator
recruitment pattern more with the NR3 family than with the NR2 family. In the
NR3 family the final residue of this motif is less conserved and is just as likely to
be a glutamine or a glutamate. This may indicate that in these subfamilies there
are differences in preferential recruitment of coactivators. Also interesting is that
in the NR1 family the motif sequence is 100% conserved within subfamilies, with
the exception of NR1I where the vitamin D receptor (VDR) differs from the
consensus sequence of the other two. This is not seen in either NR2 or NR3 and
may indicate a greater similarity in coactivator recruitment for proteins from the
NR1 family. We further examined the conservation of this motif across several
nuclear receptors and species. From this it appears that this motif is 100%
conserved in mammals and begins to deviate slightly when more distantly related
species are examined. However, this deviation was only found in those nuclear
receptors which have a somewhat degenerate motif, TR4 and Nurr1 (Figure S3).
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3.3.2 Experimental confirmation of coactivator selectivity
There are relatively few NR proteins where the relative affinity of many
different coregulator peptides are known. However, there are three, PPARγ36,
TLX136 and ERα134, wherein the binding of a wide variety of coregulator peptides
have been examined using the PAMGENE system. As well there are some data
for relative coregulator affinities for VDR131 and THRβ132 but significantly fewer
coregulator interactions were examined. Due to a robust pool of synthetic ligands
and experience in this system we examined the significance of this motif in
PPARγ, which will serve to experimentally verify the importance of these helix 4
interactions and to determine if they are involved in the selective recruitment of
coactivator LxxLL boxes to the receptor. There are no published crystal structures
of PPARγ which show both helix 4 interactions expected from this motif, (i.e.
involving N312 and K319). However, both interactions can be seen
independently, the N312 interaction is seen in crystal structures with PPARγcoactivator 1 alpha (PGC1α) and the K319 interaction can be seen in crystal
structures with either steroid receptor coactivator 1 or 2 (SRC1 or SRC2). We
hypothesized that co-crystallization of PPARγ with the most efficacious available
full agonist and a high affinity coactivator peptide would reveal both these
interactions.
3.3.3 Agonist efficacy in PPARγ
There exist many full agonists for PPARγ including two which are
currently FDA approved for human use, rosiglitazone and pioglitazone, as well as
several experimental ligands of the glitazar or glitazone classes. However, it is not
clear which of these is the most efficacious in coactivator recruitment. Based on
in cell transcriptional reporter assays it is frequently assumed that these ligands
promote the same level of coactivator recruitment and the main differences
observed are due to ligand affinity or bioavailability277,278. However, this is
inconsistent with biophysical data obtained from fluorescence polarization (FP)
assays. As such we wished to look at a variety of structurally and functionally
diverse ligands, including inverse agonists, partial/non-agonists and full agonists,
to determine if there are reproducible differences. This was performed with three
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distinct biologically relevant high affinity peptides, PGC1α, CREB-binding
protein box 1 (CBP-1) and MED1-2 as well as a corepressor peptide of nuclear
receptor corepressor 1 box 2 (NCoR1-2). This will determine if differences in full
agonist efficacy could exist and if differences in coregulator peptide affinity are
reproducible. These assays were performed by means of FP whereby protein preloaded with ligand is titrated into a fixed concentration of fluorescently labeled
peptide, the increase in polarization upon binding can be fit to a non-linear
regression to determine a Kd of interaction. To simplify interpretation data are
represented as a heatmap representing the fold change in affinity with ligand
relative to the apo state (Figure 2a and b). Actual Kd values are shown in table
S1 and S2, curve fits and experimental replicates are shown in Figures S4 and
S5.
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Figure 2. Identification of the most efficacious full agonist of PPARγ. A-B: Fluorescence
polarization of either the heterodimer of the PPARγ-RxRα LBD or the full-length complex of
PPARγ2-RxRα-SULT2A1 PPRE. Data are shown as fold-change relative to the apo state. All data
shown represents two technical replicates from a single experiment. The experiment was
replicated independently a second time and those results are shown in figure S4. Curve fits for
these data are shown in figure S4. C: The crystal structure of the PPARγ LBD complexed with
GW1929 and the MED1-2 peptide. D: Crystal structure of the PPARγ LBD complexed with
GW1929. For both structures the direct protein-ligand interactions are shown in the inset. Protein
ligand interactions were determined using the Protein Ligand Interaction Profiler279. E-F: Blowup
of the ligand binding pocket for the crystal structures in C and D showing the large system of
highly ordered water molecules which form water-mediated hydrogen bonds between the ligand
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and the protein. The bonds originating from the ligand are shown in green while the fully water
mediated are in purple.

This assay was performed both in a heterodimer of the PPARγ-LBD and
the RxRα-LBD as well as the more biologically relevant form of the full-length
PPARγ2 and full-length RxRα bound to a PPAR response element from the
SULT2A1 gene. In both cases the same pattern was seen wherein the full agonist
GW1929 binding led to higher affinity for all studied coactivators than did the
other ligands. This demonstrates that full agonists of PPARγ do have different
levels of efficacy in coactivator recruitment contrary to the relative affinities
implied from in cell transcriptional assays. It is not completely clear why this is,
but we hypothesize that in transcriptional assays such as GAL4 the endogenous
transcriptional machinery is limiting, preventing differentiation of full agonist
behavior. This idea is supported by the phenomenon of squelching wherein
coregulator recruitment to reporter plasmids decreases expression from other
genes due to limiting supplies of endogenous coregulators such as components of
the mediator complex.
3.3.4 Crystallization of PPARγ
We selected mediator of RNA polymerase II transcription subunit 1
LxxLL box 2 (MED1-2) to attempt crystallization of a PPARγ structure where
both putative selective helix 4 interactions could be resolved as MED1-2 has not
previously been crystallized with PPARγ and has high affinity for PPARγ. This is
significant as existing structures of PPARγ include SRC1-1, SRC1-2, SRC2-2 and
PGC1α which do not have high affinity for PPARγ. Since GW1929 has not
previously been crystallized bound to PPARγ and induces the highest affinity for
MED1-2 of any tested ligand we set up trials to co-crystallize the PPARγ-LBD
with GW1929 as well as with GW1929 and the MED1-2 peptide, Figure 2c-f.
Both yielded high-quality crystals which diffracted to 1.9Å, crystallographic data
is tabulated in table S3. Initial analysis of the GW1929 bound PPARγ-LBD did
not reveal anything significantly different than seen previously in other full
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agonist bound PPARγ crystal structures. The ligand makes the same four
hydrogen bonds to the protein that are seen in many full agonist bound structures.
Hydrogen bonds are observed between GW1929 and protein residues S289,
H323, H449 and Y473280,281. Hydrophobic contacts are also similar to those seen
with farglitazar, a closely structurally related ligand, barring only two novel
contacts to helices 11 and 12281. This indicates the difference in efficacy with
GW1929 and other full agonists is likely not due to direct ligand-protein
interactions.
What is unique in this crystal is that even in the absence of coregulator
peptide it is monomeric which is uncommon for PPARγ structures; only three
other WT PPARγ structures are monomeric (3BC5, 3R5N and 4XLD).
Additionally, there are no gaps of electron density in the polypeptide chain,
including a fully resolved Ω-loop which is also somewhat unusual for a structure
of PPARγ. Previous literature suggests that stabilization of the Ω-loop is
important for agonism107, which would be consistent with observations here. The
most striking characteristic is the presence of a large system of water-mediated
hydrogen bonds which originate from the ligand. These bonds appear to anchor
together helices 3, 5 and the β-sheet region. Previously it has been shown that
rigidification of PPARγ is related to agonism140, so this large stabilizing network
may contribute to the increase in ligand efficacy seen with GW1929.
Examining the structure bound with MED1-2 almost no structural change
is observed with peptide binding, Figure 3a. The ligand still makes the same
interactions to the protein and the water-mediated hydrogen bond network is still
present, although the network of water-mediated hydrogen bonds has changed
slightly, contacting the Ω-loop in a stabilizing manner. The Ω-loop undergoes
aconformational change upon peptide binding. This may be because the structure
without peptide helix 3 contains one additional turn. No crystal contacts were
seen in the unit cell to the Ω-loop indicating that the stabilization observed here is
an effect of the ligand and not a crystallographic artifact. The one other region of
the protein where significant change relative to the peptide free structure is seen is
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the phosphorylation loop, residues 238-246, but this region does appear to have
significant contacts in the unit cell suggesting these differences may be due to
crystal packing forces. As hypothesized both singularly observed helix 4
hydrogen bonds, involving residues N312 and K319, were observed in the
GW1929 bound MED1-2 structure simultaneously. This is consistent with the
idea that these interactions are important in high affinity binding interactions and
are more likely to be observed in crystals representing such structures.
Due to the lack of observed conformational change in the PPARγGW1929 complex upon MED1-2 binding, it was of interest to compare it to
previously published structures of rosiglitazone with and without coactivator
peptide, Figure 3b. We attempted to co-crystallize PPARγ with rosiglitazone and
MED1-2 for a more useful comparison but were unsuccessful. For this
comparison the monomeric crystal structure of PPARγ bound to rosiglitazone,
PDB ID:4XLD, and a structure bound to rosiglitazone and a peptide of the
reasonably high affinity coactivator PGC1α were selected, PDB ID:3CS8.
Pairwise alignment and superposition of the peptide bound and free structures of
GW1929 and rosiglitazone reveal that the lack of conformational change observed
with GW1929 appears to be unique. In the rosiglitazone bound structures change
is observed in helices 3 and 4 with significant changes seen in helix 11. In
addition, the Ω-loop is not fully resolved in either structure, however the resolved
portion indicates different conformations in this region. We hypothesized that the
similarity of the GW1929 and GW1929+MED1 structures and the dissimilarity of
the rosiglitazone structures indicates that GW1929 binding restricts the protein to
a conformational state that is nearly identical to the coactivator bound state and
thereby would reduce any energetic penalties arising from conformational change
upon coactivator binding.
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Figure 3. GW1929 stabilizes PPARγ in a state similar to the coactivator bound state. A:
Right, crystal overlays of the GW1929 bound PPARγ-LBD in the presence (blue) and absence of
MED1-2 (tan). Left, crystal overlays of the rosiglitazone bound PPARγ-LBD in the presence (tan,
4XLD) and absence of PGC1α (blue, 3CS8). B: TROSY-HSQC of the PPARγ-LBD. Left, overlay
of the GW1929 and rosiglitazone bound states. Center, overlay of the GW1929-MED1 and the
GW1929 bound state. Right, overlay of the rosiglitazone-PGC1α and the rosiglitazone bound
states. C: 19F NMR of PPARγK474C-BTFA. D:19F NMR of PPARγQ294C-BTFA with 13 structurally
and functionally distinct ligands. An * denotes labeling of the native cysteine, C285. All NMR
samples were run once. Labels above indicate the synthetic ligand present in the NMR sample. In
panels B and C the text color matches the color of the corresponding spectrum.
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3.3.5 15N HSQC of PPARγ in the presence of coactivators
Because a crystal structure represents only a single low energy state of a
protein and we have previously observed PPARγ to be highly plastic we wished
to confirm these observations by NMR. Towards this end, we analyzed 15N
labeled PPARγ bound to either rosiglitazone or GW1929 in the presence and
absence of MED1-2 using TROSY-HSQC NMR, Figure 3c. This allows for the
observation of significant changes in the backbone conformation of PPARγ upon
peptide binding. Comparison of the peptide free rosiglitazone and GW1929 bound
states showed only minor differences. A few more resonances are observed in the
GW1929 bound state consistent with greater structural rigidity. While the
GW1929 bound state spectrum remains virtually unchanged upon MED-1
addition the rosiglitazone bound spectrum changes. Several new resonances are
observed upon MED1-2 addition which indicates that the protein is rigidifying.
Additionally, almost all peaks have an upfield shift in the 1H dimension. Taken
together this indicates that rosiglitazone does not induce or select a conformation
as conducive to coactivator binding as GW1929 does. MED1-2 binding to the
rosiglitazone PPARγ complex requires significant conformational
change/selection which requires energy and lowers affinity.
3.3.6 Probing the PPARγ AF2 conformational ensemble by 19F NMR
Using 19F NMR we focused on specific AF2 regions that contain the
charge clamps, which are crucial to coactivator recruitment to determine any
structural differences in these regions between full agonists. To accomplish this
PPARγ-LBD was irreversibly modified with a trifluoro group (3-bromo-1,1,1trifluoroacetone; BTFA), via an introduced cysteine as we have done
previously282. In this work we will utilize the helix 12 probe, PPARγ-BTFAK474C,
and a helix 3 probe near the helix 3 charge clamp, PPARγ-BTFAQ294C. The
PPARγ-LBD contains only a single native cysteine C285 which points into the
ligand binding domain and is largely blocked when ligands are bound to the
orthosteric site282, thus we BTFA label ligand bound PPARγ to avoid labeling the
native cysteine. In addition, we confirm all spectra seen in the PPARγ-BTFAQ294C
variant with a double mutant which removes the native cysteine, PPARγ102

BTFAC285A,Q294C. Both the single PPARγ-BTFAQ294C and PPARγ-BTFAC285A,Q294C
were tested for protein function by FP assays and found to have minimal effects
on peptide affinity (Table S4). Both labeled mutants had similar affinity for
coregulator peptides as wt PPARγ and appropriate ligand induced changes in
affinity for coregulator peptides (Table S4).
The helix 12 probe (PPARγ-BTFAK474C) produces nearly identical spectra
when bound to GW1929 or rosiglitazone (Figure 3d). Upon addition of MED1-2
both spectra shift upfield, although rosiglitazone shifts more. Thus, the
differential affinity for coactivators induced by these ligands may not arise
primarily due to helix 12 conformation. This is perhaps not surprising as both
ligands make direct hydrogen bonds to Y473 on helix 12 based on crystal
structures. Additionally, both ligands induce a similar loss in affinity for NCoR12, whose affinity is highly sensitive to the conformation of helix 12282.
Previously it was shown by hydrogen deuterium exchange mass
spectrometry (HDX-MS) that all analyzed PPARγ ligands stabilized helix 3 to
some extent, however the C-terminus of helix 3, which contains the charge clamp,
was not resolved164. More recently it was found that rosiglitazone did not
significantly stabilize the charge clamp region, however this was performed in the
PPARγ/RxRα heterodimer124. We performed fluorine NMR of PPARγBTFAQ294C, which contains a probe near the helix 3 charge clamp (K301), bound
to a wide variety of 11 apo or ligand-bound states ranging from inverse agonists
to full agonists to determine any correlation between spectra and ligand activity
(Figure 3e). All strong agonists induced a single narrow peak, indicating that they
are reducing the conformational flexibility in this region. Less efficacious
agonists and non-agonists produced broader or multiple peaks and apo state
produced three peaks. Chemical exchange saturation transfer (CEST) NMR and
apo WT PPARγ-BTFA spectra confirmed that the middle apo peak arises from
labeling of the native cysteine (Figure S6). Interestingly, all the highly
efficacious agonist ligands (rosiglitazone and pioglitazone) except GW1929
produced the same shift and peak structure. The GW1929 bound state of PPARγ103

BTFAQ294C also had a single narrow peak but a unique shift. These data suggest
that some of the difference in efficacy arises from a unique conformation of helix
3 when bound to GW1929. NMR with all ligands was replicated in PPARγBTFAC285A,Q294C which produced nearly identical spectra with some differences
observed for lower affinity ligands. These differences likely arise from labeling of
the native cysteine in the single mutant, which may be more accessible in low
affinity ligand PPARγ complexes (Figure S7).
3.3.7 Mutagenic analysis of PPARγ
Since the interactions from this motif seem to be related to high affinity
interactions and specificity of coactivator recruitment, we decided to test this
through mutagenesis. A series of mutations in PPARγ-LBD were made including
K301A, N312A, K319A and E499L which are the two charge clamp residues and
the two residues on helix 4 which interact with coactivators. We determined the
dissociation constant of MED1-2, CBP-1 and PGC1α derived peptides for WT
PPARγ-LBD and the point mutants with the full agonists rosiglitazone and
GW1929 using FP. These peptides vary in affinity for the PPARγ full agonist
complex. Due to anticipated low affinity due to mutation only full agonist ligands
were examined. CBP-1 has the highest affinity, MED1-2 has high affinity, while
PGC1α has moderate affinity. We attempted to measure affinity for SRC1-2 using
FP, however the affinity for WT PPARγ-LBD was too low to allow for
comparison with mutants (~37µM affinity for GW1929 bound PPARγ-LBD).
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Figure 4. The effect of removing helix 4 residues on coactivator affinity is proportional to the
affinity of the peptide. A: Fold change in peptide affinity relative to WT for either the GW1929
or rosiglitazone bound PPARγ LBD point mutants relative to WT. Boxes denoted with an *
indicate that the affinity is too low to be accurately determined, >50,000nM, while those marked
with NBD, no binding detected, indicates that there was no indication of binding at any
concentration used. Data shown is the average of two independent experimental replicates. The
PPARγ WT LBD affinity is shown for each complex in the leftmost column in nanomolar. Curve
fits and exact Kd values are shown in figure S8 and table S4 respectively. B: TR-FRET of WT and
point mutant PPARγ LBD with the MED1-2 peptide. C: TR-FRET of WT and point mutant
PPARγ LBD with the SRC1-2 peptide. Data shown in B and C represents four technical replicates
run in a single experiment. An experimental replicate is shown in figure S9 for each peptide as
well as results with other ligands for the MED1-2 data.

As expected, mutation of the charge clamp significantly effects all peptide
binding. Removal of the helix 3 charge clamp residue induces at least a 20-fold
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loss in affinity for all coactivators while the removal of the helix 12 charge clamp
almost completely ablates coactivator binding (Figure 4a). The effect of
mutations on helix 4 are more interesting. In the case of CBP-1 we see
approximately a 10-fold loss in affinity with the K319 mutation and over a 60fold loss in affinity with the N312 mutation. This indicates that for the very high
affinity peptide both these residues are highly important for binding. With the
somewhat lower affinity MED1-2 there is approximately a 10-fold loss in affinity
with either helix 4 mutation (Figure 4a). This indicates that both these residues
are still significant for this interaction but that the N312 interaction is less
important than for CBP-1. When examining the moderate affinity PGC1α either
helix 4 mutation has only a 2-fold loss in affinity despite all crystal structures of
PPARγ-LBD with this coactivator showing interaction with N312.
Since it was not feasible to examine SRC1-2 binding through FP we
utilized time resolved (TR)-FRET based binding assays to examine mutational
effects on the binding of this low affinity peptide. In this assay the FRET ratio,
which reflects the amount of SRC1-2 bound to PPARγ, was used as a proxy for
relative affinity. This assay was run at various SRC1-2 concentrations to ensure
reproducibility. Ligand induced changes in TR-FRET were measured for MED1-2
to determine if the results correlate with dissociation constants obtained using FP
(Figure 4b and c). TR-FRET data for MED1-2 with additional ligands and
experimental replicates are shown in Figure S9.
The MED1-2 results were consistent with the FP results for the E499L
mutation, which completely abolished binding for all complexes. Both helix 4
mutations reduced binding significantly. The PPARγK319A mutant had more of an
effect on FRET than PPARγN312A (Figure 4b), consistent with FP (Figure 4a).
The E499L mutation completely abolished binding of SRC1-2 similar to the other
coactivators tested using FP. In contrast, the helix 4 mutations had smaller or even
opposite effects on SRC1-2 binding when compared to the higher affinity
coactivators. The PPARγN312A mutant did not affect SRC1-2 binding and the
PPARγK319A mutant had increased binding of SRC1-2 compared to WT. This
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supports our hypothesis that these helix 4 interactions are important for high
affinity binding between nuclear receptors and coactivators and consequently for
coactivator specificity, that is they determine the coactivator binding profile for a
given nuclear receptor.
3.3.8 Molecular dynamics indicates this mechanism in shared in nuclear
receptors
After confirming the role the helix 4 residues plays in the selective
recruitment of coactivators to PPARγ, we questioned whether this mechanism is
shared across nuclear receptors. Towards this end molecular dynamics
simulations were employed in another NR with known relative coregulator
binding affinities, ERα134. Simulations were performed from crystal structures
deposited to the PDB, 3UUD and 5DX3, which were bound with low affinity
coactivator peptides, SRC1-2 and SRC2-2 respectively. Unfortunately, no crystal
structures existed which were bound to a high affinity peptide so the relatively
high affinity peptide SRC1-3 was docked in silico using existing SRC1 containing
structures. These simulations were performed in both the point mutant utilized in
crystallography, Y537S, as well as a WT protein where the mutation was
reversed. The Y537S mutant and WT ERα showed significantly different
behavior. It is not immediately clear why this is, but this mutation is proximal to
helix 12 and likely exerts a significant effect on the helix 12 conformational
ensemble. Thus we focus here on the results using WT ERα. Protein stability and
proper binding modes of the peptide were confirmed for through whole protein
RMSD and analysis of hydrogen bonding between the charge clamp residues and
the peptide, Figure S10.
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Figure 5. Molecular dynamics indicate the significance of this motif in ERα. A: Significantly
greater interaction is seen between the terminal residues of the helix 4 motif and a high affinity
coactivator, SRC1-3, peptide with ERα than is seen with two lower affinity coactivator peptides,
SRC1-2 and SRC2-2. Each point represents the fraction of hydrogen bonding or salt bridge
interactions between the indicated residue and coactivator peptide from a single monomer within
the homodimer of ERα. For each simulation the two data points along with the mean are shown.

These simulations showed higher prevalence of hydrogen bonding
between residues 1 and 8 of the helix 4 motif and the peptide for the high affinity
peptide (SRC1-3) than for the low affinity peptides (SRC1-2 and SRC2-2; Figure
5). The non-selective central residue in the helix 4 motif, which makes primarily
non-specific backbone interactions, had similar prevalence of protein-peptide
interactions for all complexes. These results support the idea that these helix 4
residues control coactivator specificity for the 40 nuclear receptors which contain
this conserved motif.
3.4 Conclusions
The data presented herein identifies a mechanism for the selective nature
of NR-coregulator interactions, wherein a specific LxxLL or CoRNR box of a
coregulator makes discriminating interactions with conserved helix 4 residues,
controlling relative affinity. The charge clamp residues exert the greatest effect on
binding energy, but do not discriminate between coactivators, as they bond to the
backbone of the peptide. The hydrophobic interactions of the leucines, isoleucines
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and other hydrophobic residues in the LxxLL motifs also impart affinity but do
not discriminate between the known coactivators, many of which have been
identified by their possession of this hydrophobic motif15,283. We found that the
degree to which helix 4 residues interact with an LxxLL box is proportional to the
affinity of the coactivator complex for both ERα and PPARγ.
We determined that different full agonists induce distinct affinities for
coactivators, in contrast to cell-based transactivation assays, which may suffer
from transcriptional machinery squelching. The most efficacious ligand identified
was the tyrosine derivative GW1929142. In addition, we found that the difference
between GW1929 and another highly efficacious full agonist, rosiglitazone, is
independent of helix 12. Rather, it appears that this ligand better stabilizes the
whole of the LBD of PPARγ in a conformation which is almost identical to that
seen when bound with coactivator. This removes the requirement of major
rearrangement of the protein to allow for coactivator binding thereby increasing
the net binding energy. This effect appears to arise primarily through a large
system of ordered water molecules which allow the ligand to stabilize a much
larger area of the protein than would be expected through water-mediated
hydrogen bonds.
This work reveals the physical mechanism by which NR preferentially
bind certain coregulator proteins and better defines the AF-2 region of NR
proteins. These data indicates that the AF-2 is made up of two distinct regions
which serve different purposes in coactivator binding events. The first comprised
of the C-terminal of helix 3 and helix 12 provides the majority of the binding
energy but none of the selectivity. While the second region, helix 3’ and helix 4,
makes highly specific interactions which determine coactivator specificity. This
could lead to design of drugs which alter the conformation of the second region
specifically and drive the preferential recruitment of desired coactivators to lead
to a more specific functional outcome.
3.5 Methods
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3.5.1 Materials Used
Isopropy-beta-D-thiogalactopyranoside (IPTG) was obtained from
Goldbio (I2481C50). Tris-(2-carboxyethyl)phosphine hydrochloride (TCEP) was
obtained from Biosynth (C-1818). Trizma base (T1503), MOPS (RDD003),
Potassium Chloride (746436), Ethylenediaminetetraacetic acid (EDTA, 798681),
Monobasic potassium phosphate (795488), Dibasic potassium phosphate
(795496), 3-bromo 1,1,1-trifluoroacetone (BTFA, 374059), and Tween 20
(P1379) were obtained from Sigma Aldrich. Sodium Chloride (0241) was
obtained from Amresco. Fatty acid free bovine serum albumin (126575) was
obtained from EMD Millipore. Pierce protease inhibitors (88265) were obtained
from Fisher Scientific.
3.5.2 Protein Purification
A pET-45b plasmid carrying the genes for ampicillin resistance and Nterminally 6xHis tagged PPARγ LBD or containing a tobacco etch virus nuclear
inclusion protease (TEV) recognition site between the His tag and protein of
interest was transformed into chemically competent E. coli BL21(DE3) Gold
cells. Cells were grown in terrific broth (TB). Cells grown in TB were induced at
an OD600 of approximately 0.8 by the addition of 0.5mM IPTG. Induction
proceeded for 16 hours prior to harvesting. Harvested cells were homogenized
into 50mM Phosphate, 300mM KCl, 1mM TCEP pH 8.0 and lysed using a C-5
Emulsiflex high-pressure homogenizer (Avestin). Lysates were then clarified and
passed through two Histrap FF 5ml columns in series (GE Healthcare). Protein
was eluted using a gradient from 15-500µM imidazole. Fast protein liquid
chromatography (FPLC) was performed on either an NGC Scout system (Biorad)
or an ÄKTA Start (GE Healthcare). To eluted protein 2-8mg of recombinant
6xHis tagged TEV was added, approximately 1:40 w/w TEV to PPARγ, followed
by dialysis into 50mM Tris, 200mM NaCl, 1mM TCEP and 1mM EDTA pH 8.0.
To separate cleaved protein from TEV as well as cleaved 6xHis tag the protein
was again passed through HisTrap FF columns. The cleavage step was only
performed on protein which would be used for NMR or FP, protein used for TRFRET did not have the 6xHis tag removed. The protein was then further purified
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by gel filtration using a HiLoad 16/600 Superdex 200 PG or HiLoad 16/600
Superdex 75 PG (GE Healthcare). Size exclusion was performed in 25mM
MOPS, 300mM KCl, 1mM TCEP, 1mM EDTA buffer pH 8.0. Protein was then
dialyzed into 25mM MOPS, 25mM KCl, 1mM EDTA buffer pH 7.4. RxRα-LBD
was purified by the same protocol as PPARγ-LBD with the only difference being
that in all buffers for RxRα purification the TCEP concentration was increased to
5mM to reduce tetramerization. FL PPARγ2 or RxRα was purified in the same
manner with the caveat that the 6xHis tag was not cleaved for this protein as the
cleavage negatively affected protein activity. Protein purity in excess of 95% was
determined by gradient 4-20% SDS-PAGE analysis (NuSep) for the PPARγ-LBD
or the RxRα-LBD. In the case of the FL PPARγ2 or RxRα the presence of
degradation products made assessing purity more difficult.
3.5.3 Expression of 15N-labeled PPARγ LBD
To express 15N-labeled PPARγ LBD E. coli BL21(DE3) gold cells
carrying the same pET-45b vector as above were grown in modified M9 media
containing 15NH4Cl as the sole nitrogen source were grown to an OD of
approximately 1.0 at 37°C and 180 rpm. M9 media was made following the
protocol of Justine M. Hill and amended to include a vitamin extraction. This
vitamin extraction was made by dissolving a centrum for men vitamin tablet in
20ml of 18MΩ water as much as possible. This solution was then centrifuged at
4,000g for 20 minutes and the supernatant was removed. 1.0ml of this supernatant
was added to each liter of M9 medium. Following this the temperature was
dropped to 22°C for one hour prior to induction. Cells were induced with 1mM
IPTG and induction proceeded for 16 hours. PPARγ LBD was then purified as
described above.
3.5.4 Delipidation of PPARγ
To delipidate PPARγ LBD purified protein was diluted to 0.8mg/ml and
batched with Lipidex 1000 (Perkin Elmer) at an equal volume. This mixture was
batched for 1 hour at 37°C and 100 rpm in an incubator. Immediately following
this treatment, protein was pulled through a gravity column by syringe. To
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increase yield, it was found that speed of elution was important, protein could not
remain on the resin at room temperature in excess of 3 minutes. Two more
column volumes of pre-warmed 25mM MOPS, 25mM KCl and 1mM EDTA were
also pulled through in the same manner.
3.5.5 Site-Directed Mutagenesis
Mutations in PPARγ LBD were generated using the Quikchange
Lightning site-directed mutagenesis kit (Agilent). To generate each mutation the
following primers were used: K474C Forward 5’aggttaattattagtacaagtcgcagtagatctcctgcaggagcgg-3’, Reverse 5’ccgctcctgcaggagatctactgcgacttgtactaataattaacct-3’, C285A Forward 5’ccacggagcgaaactgagcgccctgaaagatgcgg-3’, Reverse 5’ccgcatctttcagggcgctcagtttcgctccgtgg-3’., Q294C Forward 5’gcatactctgtgatctcgcacacagcctccacggagc -3’, Reverse 5’gctccgtggaggctgtgtgcgagatcacagagtatgc -3’The presence of expected mutations
and absence of spurious mutations was confirmed by Sanger sequencing
(Eurofins).
3.5.6 Preparation of NMR Samples
NMR samples were prepared to a final concentration of 150µM protein in
470µL volume containing 10% D2O. Addition of drug was done in two separate
injections of compound to reduce precipitation. Injections were spaced 20-30
minutes apart to allow time for binding. All drugs were dissolved in D6dimethylsulfoxide (DMSO). Deuterated solvents were obtained from Cambridge
Isotope Laboratories Inc. and were at least 99% isotopically pure. Final
concentrations of drug for samples of PPARγ-BTFA were 1.25x drug to protein,
187.5µM, with the exception of Troglitazone, Pioglitazone, and BVT.13 which
were loaded to 2.0x, 300µM, due to poor binding affinity. In both cases the
concentration of the drug was controlled to maintain a constant volume of DMSO,
8.80µL for PPARγ-BTFA. Peptide addition to NMR samples was done to 2.0x
peptide to protein, 300µM, of peptide dissolved to 1-1.5mM in buffer.
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Following drug addition to PPARγ-BTFA, samples were labeled with 1.0x
molar equivalents BTFA for non-covalent drugs, the covalent drugs, T0070907
and GW9662, were labeled with 10x BTFA. After labeling the protein was
incubated overnight and then buffer exchanged approximately 100x using 10kDa
Amicon Ultra-15 concentrators (Merck Millipore) to remove excess unbound
BTFA. Following this buffered D2O was added.
3.5.7 Fluorine-19 (19F) NMR spectroscopy
Acquisition of spectra was done on a 700 Mhz Bruker magnet with a QCIF cryoprobe. Various pulse programs were used. Chemical shift was calibrated
using an internal separated KF reference (in 20 mM KPO4 pH 7.4 50 mM KCl)
contained in a coaxial tube inserted into the NMR sample tube. KF was set to be 119.522 ppm, which is the shift of the KF signal with respect to the fluorine basic
transmitter frequency for the instrument (658.8462650 MHz) at 298.2K, the
temperature at which samples were run. Routine 1D fluorine spectra were
acquired utilizing the zgfhigqn.2 pulse program (topspin 3.5), which consists of a
90-degree pulse followed by acquisition with proton decoupling (acquisition=0.7
s). Settings were D1=1.2 s, AQ= 0.82 s. Approximately 500 to 4000 transients
were collected. Saturation transfer experiments were carried out using the stddiff
pulse program. Settings were D1=1.6 s, AQ=0.6 s. For some experiments the total
duration of the saturating pulse (Gaus1.1000, 54.52 dB, 50ms) was 1.6 s (D20)
and the location of the saturating pulse was varied. In other experiments D20 was
varied, the saturating pulse was constant and the rate of exchange was fit using
equation 50 found here234. An off resonance selective saturating pulse was used to
determine the peak intensity at time t=0 and R1 was determined experimentally.
Fits of the saturation transfer data were accomplished with a single free parameter
using these experimentally determined values for initial intensity and R1. 2D
TROSY amide proton nitrogen correlation data was obtained using the
trosyf3gpphsi19.2 pulse program. Transverse and longitudinal relaxation lifetimes
(T1 and T2) were determined by fitting data acquired using the cpmg and t1ir
pulse programs in Prism 7.0b (Graphpad Software, Inc.) using standard formulas.
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We deconvoluted the spectra in an objective manner with models chosen
statistically by a fitting program. All fits were carried out in the same manner with
the same settings in the fitting program, except where noted. Relative phase of
fitted peaks was allowed to vary slightly (π/50 radians) to accommodate imperfect
phasing of these broad signals. The fitting algorithm219 assumes Lorentzian
lineshapes of similar phase. Intermediate exchange effects and field
inhomogeneity are likely present in some of these spectra, which will result in
inaccuracies in the fitted models; however, notwithstanding these limitations, the
deconvolution method provides an objective view of the possible underlying
spectral structure and populations.

3.5.8 Crystallization of PPARγ-LBD
Crystals of PPARγ-LBD bound to GW1929 were grown by sitting drop
with a 1:1 mix of protein to 200mM tri-lithium citrate, 20% w/v PEG 3350 (pH
not fixed). Protein concentration was 10mg/ml (318µM) premixed with a 1.05x
molar excess of GW1929 in D6-DMSO (334µM). Large rock/needle crystals grew
from the mother liquor at 4°C in 3 days. Crystals of PPARγ-LBD complexed with
both MED1-2 and GW1929 were grown by sitting drop with a 1:1 mix of protein
to 100mM HEPES, 25% w/v PEG 2000 MME, pH 7.5. Protein concentration was
10mg/ml premixed with a 1.05x molar excess of both MED1-2 and GW1929.
Large plate crystals grew from the mother liquor at 4°C in three days. The MED12 peptide used in crystallography was comprised of residues 631-655, primary
sequence is Ac-VSSMAGNTKNHPMLMNLLKDNPAQ-NH2, the binding
LxxLL motif is in bold. This peptide was synthesized by Lifetein LLC.
3.5.9 Crystallographic analysis
The PPARγ crystal co-crystallized GW1929 or GW1929 with MED1-2
peptide crystals were cryoprotected by transferred into reservoir solution
containing 15-20% (v/v) glycerol and flash-frozen in a 100K nitrogen gas stream.
Diffraction data were collected at 100K and a wavelength of 0.979 Å at
the Advanced Photon System SBC-CAT 19-BM beamlines equipped with an
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ADSC Q210r CCD detector. Each crystal was collected with an oscillation range
(0.2-0.5o per image) for a total 180-360o per dataset Images were indexed,
integrated, and scaled using HKL2000284.The initial phasing map were
determined by molecular replacement method with Phaser program, integrated in
PHENIX software suite285 using coordinates of the previous published PPARγ
structure (PDB code: 5TTO) as a searching model, against 10-2.5Å experimental
data. The initial models were placed into a likelihood-weighted 2mFo-DFc map
with COOT286 and first subjected to one cycle of rigid-body refinement using
PHENIX. Subsequently, the models were further refined by iterative model
rebuilding with COOT and refinement of atomic positions, real space, occupancy,
and isotropic B-factor parameters with PHENIX using a small set of reflections
(<10%) for calculation of Rfree. Ligand in each structure was located in a SIGMAA weighted mFo-DFc difference omit map287 computed with phases from the
refined model. The models were further refined multiple rounds until Rfree
converged. For Gw1929/MED1-2-bound PPARγ structure, additional TLS
refinement was included in the final round of refinement. The final refined
coordinates and structure factors for GW1929 and Gw1929/MED1-2-bound
PPARγ protein have been deposited in Protein Data Bank (PDB) under ID code of
6D8X and 6D94, respectively. Data collection and refinement statistics of a final
model are shown in Table 1.

3.5.10 Fluorescence polarization
Fluorescence polarization was performed in 25mM MOPS, 25mM KCl,
1mM EDTA, 5mM TCEP, 0.1mg/ml fraction V BSA, 0.01% Tween 20, pH 7.4.
In this assay into 50nM of N-terminally FITC labeled peptide PPARγ loaded
stoichiometrically with ligand was titrated over 12 points covering a range of
24nM-50µM in a 384-well plate. Solutions were incubated for two hours in the
dark at room temperature and then the fluorescence polarization at 528nm was
measured using a Synergy H1 plate reader (Biotek). Fluorescence polarization
data was plotted in GraphPad Prism 7.0 (GraphPad software) and the dissociation
115

constant, Kd, was determined by a non-linear regression. All assay conditions
were run in duplicate.
Peptides used in fluorescence polarization assays are as follows, CBP-1,
residues 62-81, primary sequence is AASKHKQLSELLRGGSGSS, MED1-2,
residues 638-656, primary sequence is NTKNHPMLMNLLKPAQD, PGC1α,
residues 136-155, primary sequence is EAEEPSLLKKLLLAPANTQ, NCoR1-2,
residues 2251-2273, primary sequence is GHSFADPASNLGLEDIIRKALMG.
FITC conjugated peptides of CBP-1 and PGC1α were purchased from Thermo
Fisher, FITC conjugated peptides of MED1-2 and NCoR1-2 were synthesized by
Lifetein LLC.

3.5.11Time-Resolved Fӧrster Resonance Energy Transfer
TR-FRET was performed in the same buffer and plate conditions as
fluorescence polarization. In this assay 8nM of 6xHis tagged PPARγ-LBD and
0.9nM of LanthaScreen Elite Tb Anti His antibody (LifeTechnologies catalogue
number PV5863) was added to either 200nM of FITC-MED1-2 or 1,000nM of
FITC-SRC1-2 in the presence or absence of 1µM ligand. Following addition of all
components plates were incubated in the dark at room temperature for two hours.
TR-FRET was measured with excitation at 330/80nm and emission at 495/10nm
for terbium cryptate and emission of 520/20nm for FITC. Change in TR-FRET
was measured by the ratio of the 520/495 emission.
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Chapter 4: Inverse agonists induce drug specific structure
and function via distinct molecular mechanisms in the
nuclear receptor PPARγ.
Zahra Heidari, Ian M. Chrisman, Scott Novick, Michelle Nemetchek, Theodore
Kamenecka, Patrick Griffin, and Travis Hughes
Data in this chapter is in preparation for publication

4.1 Abstract
The off state of PPARγ in particular and nuclear receptors in general is not well
defined. While there are several published structures of PPARγ in an active/on state
(i.e. bound to a coactivator) to date there is no published structure of PPARγ in an
inactive/off state (i.e. bound to a corepressor). Furthermore, most antagonist and
agonist bound PPARγ structures are very similar to the apo structure. In this study,
we use NMR, hydrogen deuterium exchange mass spectrometry, and extensive
accelerated molecular dynamics simulations of PPARγ alone or bound to several
inverse agonists and antagonists as well as these complexes cobound to a nuclear
receptor corepressor 1 (NCoR1) peptide to demonstrate that PPARγ can adopt
distinct inverse agonist structural states.

We demonstrate that the helix 3

conformational ensemble is ligand and inverse agonist dependent, including the
helix 3 charge clamp. One inverse agonist (T0070907) appears to select/induce just
two primary helix 3 and helix 12 structures, while the other (SR10221)
selects/induces a more conformationally diverse ensemble. One mechanism of
inverse agonism involves disruption of a tripartite salt-bridge which destabilizes
the active conformation via disruption of interactions between the helix 2-3 loop
and helix 3 which aids formation of non-active helix 12 states with high affinity for
corepressors. Finally, we show that these two distinct inverse agonist states induce
differential corepressor peptide affinity.
4.2 Introduction
Peroxisome Proliferator-Activated Receptor γ (PPARγ) is a member of the
nuclear receptor (NR) superfamily of ligand-dependent transcription factors which
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control transcription of a myriad of genes which are implicated in many
physiological processes including lipid homeostasis288,289. Drugs affect the
transcriptional activity of nuclear receptors via recruitment of other proteins,
termed co-regulators, which affect transcription through histone modification, posttranslational modification of the receptor, or through bridging to promoter
associated transcriptional machinery290,291. The vast majority of nuclear receptor
drugs bind deep in a ligand binding pocket within the ligand binding domain (LBD)
allosterically changing the nuclear receptor surface. These changes include changes
to the surface that interacts with most coregulators, the coregulator binding surface
or activation function-2 (AF-2) surface which includes portions of helices 3, 4 and
12. In this way drugs can modify transcription of genes regulated by a given nuclear
receptor282,292. Surprisingly, the AF-2 surface looks very similar in many nuclear
receptor crystal structures bound to antagonists and agonists. Some structures do
show very distinct coregulator binding surfaces, although the influence of crystal
contacts makes interpretation difficult293. Almost 200 crystal structures of PPARγ
bound to various drugs and three different coactivators have been published
indicating that full agonists stabilize helix 12 in a particular on/active
conformation294. However, there is no structure of PPARγ bound to any corepressor
or corepressor peptide (i.e. PPARγ in the transcriptionally off state) and relatively
few studies have investigated the structural mechanism of PPARγ mediated
transcriptional repression161,295,296. In fact, the idea that nuclear receptor inverse
agonists are more than antagonists that displace activating endogenous ligands is
not widely accepted. However, our recently published biophysical work indicates
that bona fide inverse agonists of PPARγ exist282,296. Despite the lack of PPARγ –
corepressor crystal structures important insight regarding the off structural state of
PPARγ can be inferred from structures of other nuclear receptors bound to
corepressors. These structures reveal diversity in the binding modes and structures
of both well characterized corepressors such as silencing mediator of retinoic acid
and thyroid hormone receptor (SMRT) and nuclear receptor corepressor 1
(NCoR)20,200 and less characterized corepressors that do not bind to the traditional
AF2 coregulator binding surface297. Similar to coactivators, each corepressor
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contains several amino acid core motifs, or nuclear receptor boxes (NR boxes), of
about nine residues that mediate binding to nuclear receptors20. SMRT contains
two such motifs while NCoR contains three298. Most of these core corepressor
motifs have been crystalized with various nuclear receptors revealing
characteristically longer alpha helices for corepressors than coactivators. This
increased helix length20 requires a different AF2 structure for optimal binding of
corepressors that often involves displacement of helix 12, such as in PPARα200,
progesterone receptor299 and estrogen related receptor-γ274. In contrast several
nuclear receptor-corepressor crystal structures display helix 12 in a position similar
to the canonical active structure with coactivator bound, positioned roughly
orthogonal to and making some contact with the corepressor helix n-terminus, but
with a shifted helix 12 to accommodate the longer corepressor helix. For example,
the crystal structure of the tetrameric form of the RXRα LBD shows interaction
between helix 12 of a tetrameric partner and bound SMRT300 and glucocorticoid
receptor (GR) bound to an antagonist shows an interaction between helix 12 and
NCoR301.
We detected active-like corepressor bound helix 12 conformations for
PPARγ bound to NCoR using long conventional molecular dynamics simulations
(cMD)282. Simulations of apo PPARγ show that H12 is pushed away from the
coregulatory binding surface. Displacement of helix 12 from the coregulator
binding surface has also been observed in numerous structures of nuclear receptors
bound to corepressor core motifs20,200,298,302. In contrast, simulations of inverse
agonist (T0070907156,282) bound PPARγ show helix 12 aligned orthogonal to the
NCoR peptide with a potentially productive interaction between helix 12 and
NCoR282. The physiological importance of these conformations is unknown as we
observed very slow (μs to second) exchange between different conformations for
many of these complexes, including the PPARγ-T0070907 NCoR complex282. It is
therefore unlikely that these cMD simulations sampled all physiologically relevant
conformations. The sampled structures could instead represent structures from a
local minimum potential energy well that contributes little to the overall
physiologic structural ensemble. We recently presented evidence that two distinct
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inverse agonists (T0070907 and SR10221) induce ligand specific helix 12
structural states that are different from the ligand free state. We also found that one
or a few T0070907 helix 12 states in relatively fast exchange imparts high affinity
for NCoR282,296. However, the structure(s) that compose this high corepressor
affinity structural ensemble remains unknown. In addition, it is not known whether
the structural state of other areas of the PPARγ coregulator binding surface
contribute to the high affinity of this structural state for NCoR.
Here, we develop and experimentally test simulation derived structural
models for these off states of PPARγ utilizing extensive cMD and accelerated MD
(aMD) simulations of PPARγ bound to the covalent PPARγ inverse agonist
T0070907, SR10221 and co-bound to NCoR. Experimental data and the
reconstructed physiological structural ensemble from these more extensive
simulations supports the hypotheses that T0070907, SR10221 and apo have distinct
structural ensembles that bind corepressors differently. It also supports the idea that
T0070907 andSR10221 induce these structural states through different
mechanisms. The molecular mechanism by which the inverse agonist T0070907
induces/selects a conformational ensemble with high affinity for corepressor
binding is explored using simulations, mutagenesis and NMR. The simulations
reveal an n-terminal extension of helix 3 for T0070907 bound PPARγ and
disruption of an ionic bond network involving the n-terminus of helix 3. Together
these changes prevent interaction of the helix 2-3 loop (i.e. the omega loop) with
helix 3 and change the interaction of the helix 11 to 12 loop and helix 12 with the
rest of the molecule. Both the salt bridge network and the omega loop helix 3
interaction have been shown to be important for transcriptional agonism107,303 and
disruption of these interactions would be expected to enhance corepressor affinity.
In line with this expectation, mutation of a key residue involved in this salt bridge
bond network increases NCoR affinity and decreases affinity for a coactivator
peptide across many ligands except for T0070907, which independently disrupts
this salt bridge network. Previous research indicated interaction between SR10221
and helix 3 that destabilizes helix 3. Here we find evidence of that SR10221 directly
interacts with helix 12 to disrupt the active conformation. Thus, we present
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evidence for two separate atomically detailed structural mechanisms of inverse
agonism in PPARγ. Finally, we demonstrate that the distinct structural ensembles
yield distinct functional effects by showing that T0070907 increases affinity for
receptor interaction peptides from both NCoR and SMRT as compared to apo while
SR10221 selectively increases affinity for SMRT peptide relative to apo.
4.3 Results
4.3.1 Accelerated molecular dynamics reveals a diverse apo PPARγ structural
ensemble.
Previously reported adaptive biasing-force simulations of ligand free (apo)
and rosiglitazone bound PPARγ ligand binding domain (LBD) explored the helix
12 energy landscape along defined reaction coordinates and found multiple distinct
low energy conformations for apo PPARγ but just one for rosiglitazone bound
PPARγ304. We refer here to the PPARγ LBD as PPARγ. Other forms of PPARγ will
be referred to explicitly. In contrast to adaptive biasing-force simulations,
accelerated MD simulations (aMD) do not use defined reaction coordinates but
instead smooth the native potential energy landscape making sampling more
efficient without restricting the conformational space that can be explored305. Given
sufficient conformational sampling and a force field that reproduces protein
structure accurately, the deepest wells in the aMD generated potential energy
landscape contain the most prevalent structures found in the physiologic structural
ensemble. Ligand free PPARγ and PPARγ bound to many distinct ligands have
crystalized as a homodimer with each monomer in a distinct conformation,
differentiated principally by the position of helix 12. One helix 12 conformation is
considered active, while the other is considered inactive and of uncertain
physiologic relevance. However, there are apparent contacts between helix 12 and
other crystallographic unit cell members in both conformations in most
structures282. We ran extensive (Supplementary Table 1) aMD simulations of apo
and agonist (rosiglitazone) bound PPARγ starting with helix 12 in the active
position. Similar to the adaptive biasing-force simulations, the agonist bound
simulation produces one relatively narrow energy well, while the apo PPARγ
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energy landscape has several energy minima that would be significantly populated
at physiologic temperature (Figure 1a). Alternatively, we started very extensive
aMD simulations (~57 μs) from the inactive apo structure. These simulations
sample some of the same structures as the active apo simulation and reveal some
similarity in overall energy landscapes, but do not converge completely (Figure
1a). Both apo simulations share one low energy well/conformation, which is found
in the third (1.06 kcal mol-1) and second (0.07 kcal mol-1) lowest energy well in the
inactive and active simulations respectively (Figure 1c and Supplementary
Figure 1). Overall these simulations indicate that the physiologic structural
ensemble of apo PPARγ is very diverse, which is consistent with NMR and
hydrogen

deuterium

exchange

mass

spectrometry

(HDX-MS)

data140,161,166,207,208,221,306. We observe four major classes of helix 12 conformations
in this diverse ensemble, the active conformation, conformations roughly similar to
the active conformation, but with a shifted helix 12 that enlarges the coregulator
binding surface, conformations where helix 12 appears to bind the coregulator
binding surface in a similar manner to a corepressor (which would block all binding
to the coregulator binding surface) and finally conformations where helix 12 lies
parallel to helix 3 (Supplementary Figure 1a and b). Interestingly, in the
corepressor like conformation helix 10/11 is disrupted at 484/456 and 477/449
respectively, bending significantly and allowing LXXLLXXXY residues of helix
12 to bind to the coregulator binding surface. These helix 12 residues are oriented
similarly to the L/IXXIIXXXF/Y/L motif20 of corepressors when aligned to a
PPARα/SMRT structure (Figure 1e). In addition, similar corepressor like binding
of helix 12 to the coregulator binding surface have been observed in rat ERβ307 and
between PPARγ unit crystallographic cell members48,282 (Supplementary Figure
9). Together, these helix 12 conformations appear to be a mix of those favorable
for coactivator or corepressor binding and some that would favor binding of neither.
In addition, both helix 3 and helix 11 show significant structural diversity. In the
lowest and fourth lowest energy wells of inactive apo helix landscape to bind to
some or all of the coregulator binding surface (Figure 1e). Helix 3 is
conformationally diverse and in some cases, helicity is absent in the range of
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residues 316/288 to 320/29 and in general helix 3 is bent at various angles in this
region which leads to diverse positioning of the n-terminus of helix 3 (Figure 1d).
This is consistent with our previously observed slow exchange (1.0 s-1) between
two conformations of a 19F NMR of a probe placed near the location of the bend in
helix 3 (Q322/294) in apo PPARγ282, although this pattern could also be explained
by a population of apo PPARγ with helix 12 bound like a corepressor. Finally, there
is an n-terminal extension of helix 3 observed in some apo structures
(Supplementary Figure 1a and b).
4.3.2 The active helix 12 conformation is not the primary component of the
physiologic apo ensemble.
Simulations started from the active apo structure predict that almost all of
the helix 12 conformations in the physiologic ensemble are similar to the active
structure, whereas the inactive simulation suggests that only ~20% of the
physiologic ensemble has an active-like helix 12 conformation. Bonding between
K347/319 on helix 4 and helix 12 is characteristic of the active helix 12
conformation but not the inactive conformation in PPARγ crystal structures
(Figure 2a). In order to estimate values characteristic of the physiologic structural
ensemble we clustered the structures found near the bottom of the deepest wells in
the aMD generated landscape and started 1 μs cMD simulations from multiple
representative structures for each well. Population weighted average values for
various structural characteristics, including prevalence of the helix 4-12 salt bridge,
were then calculated for each well from these cMD simulations and then these
individual well values combined into one value representative of the putative
physiologic structural ensemble using Boltzmann weighting (see methods). We
refer to these values as Boltzmann averages. Simulations predict high prevalence
(i.e. high Boltzmann average) for bonding between K347/319 and helix 12 in an
active conformation in the PPARγ-rosiglitazone complex. Simulations predict that
apo has either high or low prevalence of this interaction depending on whether the
apo simulation was started in the active or inactive helix 12 conformation (Figure
2b). Simulations indicate that in the absence of helix 12 bonding K347/319 interacts
mainly with solvent (Supplementary Figure 2c). Therefore, a K347A mutation
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should have minimal impact on structure unless there is K347/319 to helix 12
bonding. We compared 2-dimensional protein NMR of wt and K347A mutant
bound to various ligands to determine which PPARγ-ligand complexes have helix
12 in the active conformation. Consistent with the inactive apo and the rosiglitazone
simulations, these NMR data indicate that helix 12 in apo PPARγ does not interact
with K347 while helix 12 of rosiglitazone bound PPARγ does. The K347A
mutation induces many changes to the PPARγ-rosiglitazone structure including
disappearance of helix 12 residue L496/469 and a shift in a residue near the
coregulator binding surface (L429/401) (Figure 2b). In contrast, there are few
changes to the apo PPARγ structure. This indicates that an active-like helix 12
conformation is not a major component of the apo physiologic ensemble. However,
an active-like conformation likely contributes some to the overall ensemble as
demonstrated by the inactive apo simulations and changes in a few amide chemical
shifts upon mutation of K347 (Figure 2b).
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Figure 1. Extensive aMD simulations indicate a diverse PPARγ structural ensemble. Multiple
independent simulations were run for the indicated PPARγ ligand binding domain complexes (see
Supplementary Table 1). a and f) The RMSD of helix 12 was calculated compared to a published
apo PPARγ structure (PDB code: 1PRG) active (chain A) and inactive (chain B) structures. The
energy of each trajectory snapshot was calculated and overlaid on the 2D RMSD to produce the
displayed potential energy landscapes. b and g) The aMD trajectory structures within a 0.2 x 0.2
angstroms RMSD square centered on the lowest energy wells were clustered using k-means
clustering into 5 clusters using CPPTRAJ308. Arbitrary (i.e. CPPTRAJ chosen) representative
structures are shown for the most prevalent clusters. The relative prevalence of the structure is
indicated by the color of helix 12 ranging from dark green for the most prevalent to olive drab,
light green, light blue and then deep sky blue for the least prevalent. For reference, an active
structure (rosiglitazone bound PPARγ; 2PRG chain A) is shown with helix 12 colored dim grey. c)
Representative structures from the third and second lowest energy wells in the inactive and active
apo simulations respectively are shown in orange and dark green. Representative active and
inactive crystal structures (PDB code 1PRG chain a and chain b) are shown in dim grey and light
pink respectively. d) Representative structures from active and inactive apo (white and green) are
shown compared to an active crystal structure (light blue; PDB code 2PRG chain A). e) A
representative structure from a low energy well (well 4 Supplementary Fig. 1; white; PPARγ LBD
and gold; helix 11-12) is compared to the crystal structure of PPARα bound to SMRT (PDB code
1KKQ; white; PPARα LBD, green; helix 12 and light blue; SMRT peptide). Comparison of
relative position of PPARγ helix 12 LXXLLXXXY residues with the SMRT corepressor motif
residues is highlighted. h) Representative structures of PPARγ (green) bound to T0070907 and a
peptide from NCoR (gold) from the lowest energy well. The orange lines indicate hydrogen bonds
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between the helix 12 charge clamp (E499/471) and the NCoR peptide backbone of 1.7 and 2.0
Angstroms as defined by Chimera for this particular trajectory snapshot. i) Comparison of the
active structure (white; rosiglitazone; PDB code 2PRG) bound to a coactivator peptide (SRC2;
grey) with the most prevalent conformation in the lowest energy well from the aMD simulation of
T007-PPARγ-NCoR (green and gold). A shift in helix 12 relative to the active conformation is
indicated by the pink arrow.

4.3.3 aMD indicates that inverse agonists bias the structural ensemble towards
helix 12 conformations favorable for NCoR binding.
We next performed aMD of PPARγ bound to three inverse
agonists/antagonists SR10221161, GW9662155 and T0070907 to determine how
inverse agonist/antagonist structures differ from apo PPARγ and agonist bound
structural ensembles (Figure 1a). These simulations were started from structures
with helix 12 in the inactive conformation. T0070907 and GW9662 covalently
attach to the sole cysteine in the ligand binding domain and differ by one atom; the
benzene ring of GW9662 is a pyridine ring in T0070907, making T0070907 a more
efficacious inverse agonist296. Both covalent ligands increase affinity for a NCoR
peptide over apo while SR10221 does not (Supplementary Table 6), however only
T0070907 and SR10221 act as inverse agonists in a in cell reporter assay296.
Representative structures from the lowest energy wells demonstrate considerable
conformational diversity in helix 3, 11 and 12. Three main low energy helix 12
conformations are detected for the covalent ligands; 1) active-like conformations,
2) active-like conformations with a shifted helix 12 that expands the coregulator
binding surface, 3) conformations where helix 12 lies parallel to and near the nterminus of helix 3, (Figure 1b and Supplementary Figure 1). There is also an nterminal extension of helix 3 observed in some of these structures. Representative
structures from the two lowest energy wells for these complexes feature expanded
coregulator binding surfaces, in contrast helix 12 would sterically clash with NCoR
binding in the lowest energy apo well (Figure 1b). The PPARγ-SR10221 complex
displays distinct low energy conformations. The lowest energy conformation
resembles the active conformation, however helix 12 is shifted along the helical
axis toward helix 11 (Figure 1b). Thus, these simulations indicate that the covalent
ligands select/induce helix 12 conformations expand the coregulator binding
surface in several ways, allowing binding of the longer corepressor peptide. These
simulations also indicate distinct helix 12 conformations are induced/selected by
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SR10221 and GW9662/T0070907, which is supported by fluorine NMR (Figure
3).
To experimentally test these simulation-generated structural hypotheses we
measured the effect of the K347A mutation on PPARγ bound to SR10221,
T0070907, and GW9662. Bonding between K347 and helix 12 is more frequent in
active-like conformations (Supplementary Figure 2e). The K347A mutation has
a large effect on the PPARγ/GW9662 complex, a small effect on the PPARγT0070907 complex and no apparent effect on the PPARγ-SR10221 complex
(Supplementary Figure 2a). Both the GW9662 and T0070907 simulations
indicate prevalent low energy conformations with helix 12 in an active-like
conformation (Supplementary Figure 1) which result in relatively low levels of
K347A to E499 bonding (Figure 2b). The protein NMR suggests that active-like
conformations are more prevalent in the GW9662 complex than the T0070907
complex and that these conformations result in more K347A to helix 12 bonding
than observed in the simulations. This raises the possibility that one of the two
major helix 12 conformations observed using fluorine282 and protein296 NMR
(Supplementary Figure 2b) is similar to the active state. As shown below, fluorine
NMR indicates that 36% of the T0070907 helix 12 structural ensemble is found in
this active-like state while 83-88% of helix 12 in the PPARγ-GW9662 structural
ensemble is in this active-like state282,296. The lack of change in the PPARγSR10221 spectrum supports the idea that this ligand induces a distinct helix 12
conformational ensemble from the other two inverse agonist/antagonist ligands.
Which is also supported by the distinct PPARγ-SR10221 fluorine NMR spectrum
(see below) and distinct low energy conformations observed in simulations
(Supplementary Figure 1).
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Figure 2. The active apo simulation is inconsistent with NMR data. a) Examples of three classes
of helix 4 to helix 12 binding observed in 31 randomly chosen crystal structures with helix 12 in the
active conformation (PDB codes 1PRG, 2PRG and 3R5N). PPARγ LBD structures are commonly
asymmetric homodimers with helix 12 in an active and inactive conformation. The salt bridge
between K347/319 and E499/471 was only seen in 1/31 active structures, while 25/26 active
structures showed bonding between K347/319 and the helix 12 backbone and none of the inactive
conformations showed bonding between helix 4 and helix 12. b) Prevalence of helix 4 (K347/319)
to helix 12 (E499/471) bonding (side chain and backbone), which dominated the helix 4 to helix 12
bonding in active-like structures in simulations. The Boltzmann average is shown as a pink bar while
individual values from cMD simulations started from representative structures in the lowest wells
in the aMD generated energy landscape are shown as closed circles. Only prevalence of E499 to
K347 interaction is shown as this interaction is a good indicator of the active-like conformation
(Supplementary Figure 1g). c) Comparison of wt and K347/319A mutants bound to rosiglitazone
or with no ligand.

4.3.4 Ligands induce/select functionally distinct helix 12 structural ensembles.
We gathered solution structural information for diverse ligand-PPARγ
complexes and apo PPARγ using a fluorine NMR probe, 3-bromo-1,1,1trifluoroacetone (BTFA)309, attached via an introduced cysteine at three locations;
on helix 12 (K502/474C), on Q322/294C between the helix 3 charge clamp lysine
(K329/301) and the site of simulation observed helical disruption (316/288320/292) and on a portion of the omega loop (Q299/271C) near helix 3. We BTFA
label PPARγ ligand binding domain in the presence of bound ligand to minimize or
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eliminate labeling of the only native cysteine (which points into the ligand binding
pocket), alternatively for apo we also use a double mutant that includes a C313A
mutation. Fluorescence polarization-based coregulator peptide recruitment assays
demonstrated that the K502C-BTFA probe does not have a significant effect on
peptide affinity282, Q299C has no apparent effect on NCoR or MED1 binding
(Supplementary Table 2), and Q322C causes a 2 fold median increase in affinity
for MED1 and no apparent change in affinity for NCoR peptide (Supplementary
Table 3).
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F NMR of the K502C-BTFA construct confirmed our previous

observations282 that T0070907, GW9662 and the non-covalent inverse agonist
SR10221161,296 induce distinct helix 12 structural ensembles from each other and
from apo, although T0070907 and GW9662 differ only in relative populations of
the two main structural ensembles (Figure 3a). Given that T0070907 induces
higher affinity than GW9662 for a nuclear receptor interaction domain peptide
from NCoR296 (Supplementary Table 2, 3 and 6) and the T0070907 spectrum
has a larger left (i.e. downfield) population than GW9662, this narrower left peak
likely represents an ensemble of closely related structures with high affinity for
NCoR. This is supported by the fact that addition of SMRT or NCoR increases
the population of the left peak in both GW9662 and T0070907 (Figure 3) as we
previously reported282. Objective deconvolution219 of these spectra indicate that
this left peak is relatively narrow (43 Hz) and similar in width to agonist bound
PPARγ (rosiglitazone; 32 Hz) and the primary SR10221 bound PPARγ peak (41
Hz) and much narrower than the broad deconvoluted apo peaks which range from
97 to 144 Hz (Figure 3). The relatively narrow peaks are consistent with the
hypothesis that these peaks represent structures exchanging on relatively fast
timescales (e.g. ps to lower microsecond lifetimes) between similar helix 12
conformations while the apo peaks indicate exchange between more distinct helix
12 structures exchanging on the μs-ms time scale223. Clearly resolved separate
peaks observed in these spectra indicate very slow exchange (ms-s time scale)
which we previously confirmed for the two prominent PPARγ-T0070907 peaks282
and which is consistent with exchange between conformations with larger
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structural differences223. Together, these data with other NMR and HDXMS207,282,296 indicate that agonist (i.e. rosiglitazone) bound PPARγ has one
primary narrow structural ensemble, while apo PPARγ and PPARγ bound to
T0070907, GW9662 and SR10221 have at least two and very likely more distinct
helix 12 structural ensembles. However, these data also support the idea that
T0070907 and NCoR co-binding to PPARγ induce/select a primary helix 12
structural state composed of similar structures with high affinity for NCoR and
two or more other structural states with lower affinity for NCoR.

4.3.5 The apo helix 3 structural ensemble is composed of structurally and
functionally diverse structures.
While the helix 12 conformational ensemble has a large impact on
coregulator affinity282, we hypothesized that the helix 3 structural ensemble is
influenced by ligands and also plays a role in coregulator affinity. The fluorine
probe on helix 3 of apo PPARγ shows two distinct wide peaks, which chemical
exchange saturation transfer (CEST310) indicates undergo slow exchange at a rate
of less than 0.5 per second for both PPARγQ322C-BTFA (Figure 3 and
Supplementary Figure 3) and PPARγC313A,Q322C-BTFA282. We routinely
delipidate PPARγ, which binds E. coli lipids218. The right (upfield) apo peak
originates, at least partially, from the E. coli lipid bound state and the observed
exchange could be reflective of either lipid exchange or exchange between apo
structural states. In contrast to apo, our previous work indicates that the structure
and dynamics of PPARγ bound to the ligands utilized here is dominated by the
ligands with any residual lipid causing minimal effects282. There is no indication
that the two states have grossly different affinity for NCoR or CBP as both peaks
are in clear slow exchange with the peptide bound peak (Supplementary Figure
3). Regardless, the left apo peak is almost certainly lipid free and is wider (~70
Hz) than spectral peaks for PPARγ bound to efficacious ligands (e.g. rosiglitazone
and T0070907 primary peaks which are ~30 Hz) indicating that the left apo peak
represents two or more distinct structures exchanging on the μs to ms timescale.
The ratio of chemical shift separation between the states (350 Hz) to the rate of
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exchange between states (<0.5 s-1) is <0.001, thus peak broadening is not due to
exchange between the left and right states. Addition of coactivator, corepressor or
a heterodimer partner of PPARγ (RXRα) all lead to peak consolidation (Figure 3
and Supplementary Figure 3), indicating that the structural ensemble of the
portion of helix 3 containing the charge clamp contains a mix of structures with
no clear preference for binding coactivators or corepressors.
Ligands induce/select functionally distinct helix 3 structural ensembles from
the apo ensemble.
Addition of corepressors (NCoR or SMRT) to PPARγQ322C-BTFA led to
narrowing of primary peaks in inverse agonist (T0070907) bound PPARγ spectra
and broadening for labeled PPARγ bound to an agonist (rosiglitazone). Likewise,
the binding of a coactivator peptide (MED1 or CBP) has little effect on the
spectra from agonist bound labeled PPARγ but induces peak splitting and
broadening in inverse agonist/antagonist bound labeled PPARγ (Figure 3 and
Supplementary Figure 3). Heterodimerization with RXRα reduces the affinity of
the PPARγ T0070907 complex for NCoR282 and thus would be expected to have a
similar structural effect to coactivator binding on the PPARγQ322C-BTFA
spectrum. This is what is observed (Supplementary Figure 7a). The
MED1/PPARγQ322C-BTFA/T0070907 complex has the highest dissociation
constant of any of these complexes (20 μM; Supplementary Table 2 and 3).
PPARγ and RXRα have a very low dissociation constant (<10nM). At NMR
concentrations (150 μM protein and 300 μM peptide) even the lowest affinity
complex should be >90% bound. Therefore, peak splitting is not likely due to
unbound and bound species in the case of the poorest affinity peptides and
certainly not in the heterodimer. Rather it appears that binding of coactivators or
RXRα to inverse agonist bound PPARγ shifts the equilibrium towards minor
conformations. This argument is especially compelling in the case of PPARγ
bound to GW9662, where CEST reveals exchange between downfield (left
shifted) minor states with the major state and major downfield peaks appear upon
addition of peptides or RXRα (Supplementary Figure 7). We confirmed
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exchange between the two peaks in the PPARγ/GW9662/RXRα complex
spectrum using CEST (1.7 s-1 95% CI=1.4-2.0; Supplementary Figure 7).
Interestingly, in contrast to PPARγ bound to the most efficacious ligands
(T0070907 and rosiglitazone), binding of either a coactivator or a corepressor
peptide to both apo and a partial agonist (nTZDpa) cause similar changes (Figure
3 and Supplementary Figure 7). These data indicate that efficacious ligands
select/induce distinct states with a strong preference for coactivators or
corepressors, while apo and partial agonist structural ensembles are composed of
structures with no strong preference.
4.3.6 Ligands narrow the energy well of the helix 3 c-terminus.
Representative structures from the lowest energy wells of the inactive apo
PPARγ simulations, with or without NCoR peptide, show more variability in the
position of the c-terminal portion of helix 3, including Q322 and the charge
clamp, than PPARγ bound to ligands with or without NCoR peptide (Figure 3b
and c). The variability in this region is likely functionally significant as it varies
the position of the backbone of the K329 charge clamp (Figure 3d). Simulations
also indicate lower helix 3 helicity for some low energy apo PPARγ structures
than ligand bound PPARγ with or without NCoR bound (Supplementary Figure
3). Consistent with fluorine NMR and simulations, HDX-MS shows much faster
exchange of amide protons in a peptide that spans residues 322 to 326 for the apo
PPARγ/NCoR complex than the PPARγ/T0070907/NCoR complex and slightly
faster exchange in the PPARγ/SR10221/NCoR complex compared to the
T0070907 complex (Figure 4 and Supplementary Figure 8). These data indicate
that ligands that induce the highest affinity for coregulators induce/select a cterminal helix 3 structural ensemble distinct from apo and less efficacious ligands.
Together, these data imply the structure of the c-terminus of helix 3 is ligand
dependent and functionally important; importance that likely lies in positioning
and/or stability of the helix 3 charge clamp.
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Figure 3. 19F NMR, HDX-MS and simulations indicate that helix 3 has a ligand
dependent diverse conformational ensemble that affects the helix 3 charge clamp position. a)
19
F NMR spectra of PPARγ labeled at the indicated residues with BTFA and bound to the
indicated ligands. The lower rows of spectra included an 2x molar ratio of corepressor peptide
derived from NCoR (unlabeled). Asterisk denotes what is likely unfolded PPARγ or BTFA
labeled contaminating protein282. b) The c-terminal portion of helix 3 is highlighted in color. Dark
green, olive drab and light green indicate that the structures are a representative structure from the
lowest, second lowest and third lowest energy wells in the aMD energy landscape for the indicated
PPARγ-ligand or PPARγ/ligand/NCoR complexes. A representative structure from the
rosiglitazone PPARγ simulation is shown in yellow. The side chains of the charge clamp (K329)
and the BTFA probe location (Q322) are shown. c) RMSD of residues 322-329 of individual cMD
simulations that were started from representative structures from the lowest energy wells for the
indicated complexes compared to the same residues in the crystal structure 1PRG (apo PPARγ).
Boltzmann averages are shown as magenta bars. The Boltzmann average is shown as a magenta
bar. d) Comparison of representative structures from the lowest (dark green) and second lowest
(olive drab) energy wells of inactive apo PPARγ. The distance between the alpha carbon atoms for
the charge clamp residue K329 for the two structures is indicated.
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Figure 4. HDX-MS of PPARγ co-bound to T0070907 and a NCoR peptide (2:1 molar ratio
NCoR:PPARγ) compared to PPARγ bound to NCoR alone (right) or cobound with SR10221
(left). The difference in hydrogen deuterium exchange for peptides from the indicated regions of
the protein is shown by the coloring as indicated. The dark grey regions showed no significant
difference, while the white regions were not resolved in the assay.

4.3.7 A single omega loop structure is selected/induced by inverse agonist and
corepressor binding.
The spectrum produced by a probe on the omega loop (Q299/272C) near
the n-terminus of helix 3 of PPARγ produces a narrow peak (72% of signal) and a
wider peak (28% of signal) for the PPARγ-T0070907 complex and more complex
spectra for other complexes (Figure 3a). The dominant narrow peak indicates that
the loop region is stabilized by T0070907 into a single structure in 72% of the
population. Fifteen percent of the GW9662 and apo spectra originates from a peak
with very similar chemical shift and width to this narrow T0070907 peak.
Addition of NCoR or SMRT corepressor peptides drives the omega loop in the
GW9662 and T0070907 complexes to a single peak, which is consistent with an
ensemble of closely related structures, while the changes to apo are difficult to
interpret because of native cysteine labeling (Figure 3a). These data indicate that
the omega loop is allosterically linked to the coregulator binding surface in these
complexes and suggest that a specific omega loop conformation is characteristic
of a structural ensemble with the highest affinity for NCoR. In contrast, the
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spectrum of Q299-BTFA PPARγ bound to the efficacious agonists rosiglitazone
or GW1929 does not change upon addition of coactivators or corepressors
indicating a lack of allosteric linkage between the omega loop and the coregulator
binding surface for this complex (Figure 3a and Supplementary Figure 4).
Simulations indicate that in some low energy apo, GW9662 and T0070907
structures (with or without NCoR) helix 3 extends n-terminally to near the
fluorine probe residue (299; Supplementary figure 4b), which would be
consistent with the narrow PPARγQ299C-BTFA/T0070907 NMR spectrum (Figure
3a). Three of 174 PPARγ crystal structures show a 4-residue helix 3 n-terminal
extension; a few others show shorter extensions (Supplementary Figure 4d).
However overall, there is not a good correlation between the Boltzmann average
and the population of the narrow peak in the 19F NMR spectrum. In addition,
Hydrogen deuterium exchange mass spectrometry (HDX-MS) of an omega loop
peptide that covers this region does not show differences between
PPARγ/T0070907/NCoR and PPARγ/SR10211/NCoR or apo PPARγ/NCoR
complexes (Figure 4, Supplementary Figure 9). Indicating that helical extension
may not be different between these three complexes. The overall helicity of the
region included in the HDX-MS omega loop peptides appears different between
the complexes in the simulations (Supplementary Figure 4f). Either this
difference is not detected by HDX-MS or these simulation structures are
representative of intermediates along the path to an as yet unsampled NCoR
bound structure. One consequence of Helix 3 extension is reduction of the
interaction between the omega loop (i.e. the large loop between helix 2 and helix
3) and helix 3 and/or helix 12 (Supplementary Figure 6). Interaction of the
omega loop with helix 3 residues has been shown to be important for the
transcriptionally active state106,107. In fact, SR10221 may disrupt this helix 3
omega loop interaction by pushing on Phe310161, essentially the same mechanism
via different means. Thus helix 3 extension may free up helix 12 positioning as
one step towards a final structure. Another consequence of helical extension in
both the crystal structures and the simulations appears to be disruption of a critical
tripartite salt bridge which we detail below.
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Figure 5. The reconstructed physiologic ensemble (from aMD inspired cMD) indicates that
helix 12 bonds to NCoR in the T0070907 complex but not the SR10221 complex. a) The
prevalence of the indicated hydrogen and salt bridge bonds in individual 1μs conventional MD
runs of representative structures from low energy wells (black circles) and the overall Boltzmann
weighted average (pink) for the indicated complexes. b) The Boltzmann average prevalence of
hydrogen bonding between the charge clamp residue (K329) and NCoR is significantly higher
than between a helix 4 residue (N340) and NCoR. c) The decrease in affinity is greater for a
mutation abolishing the helix 3 charge clamp (K329A) than for one abolishing the helix 4-NCoR
bonding (N340A). d) Mutation of the helix 12 charge clamp (E499L) leads to ligand dependent
decrease in affinity for NCoR, which correlates with simulation derived prevalence of bonding
between E499 and both NCoR and helix 4 (K347). e) Abolishing the helix 4 to helix 12 and NCoR
interaction through mutation (K347A) reduces affinity for NCoR in a ligand dependent manner,
but only the prevalence of the K347-E499 bonding correlates with the decrease. Fits for panels d
and e were done with a single exponential as this is the correlation expected between the ratio of
dissociation constants and bond prevalence311.

4.3.8 The structural mechanism of distinct corepressor bound affinities.
The PPARγ-T0070907 complex has the highest affinity for the NCoR
peptide out of all the simulated complexes, including the inverse agonist
SR10221296 (Supplementary Table 6). To determine the underlying mechanism
for how T0070907 induces a high affinity structure for NCoR we analyzed aMD
simulations of apo PPARγ, and PPARγ bound to inverse agonist/antagonist
(T0070907, GW9662 and SR10221) co-bound to a peptide from NCoR. These
simulations were started from structures with helix 12 in the inactive conformation
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because docking of NCoR onto PPARγ with helix 12 in the active conformation
results in steric clash between NCoR and helix 12. Representative structures from
the deepest wells indicate that the structure of these PPARγ NCoR complexes are
ligand dependent, with the most prominent differences found in the omega loop,
helices 3, 11 and 12 (Figure 1d and Supplementary Figure 5). As expected from
the PPARα-SMRT structure200, Boltzmann average values indicate prevalent
hydrogen bonding between the NCoR peptide and Lys329/301 of helix 3 and
Asn340/312 of helix 4 (Figure 5a). Interestingly, low energy ensembles of
T0070907/NCoR and GW9662/NCoR, but not SR10221/NCoR, show hydrogen
bonding between the NCoR backbone and helix 12 similar to the active
conformation, but with helix 12 shifted to allow binding of the longer corepressor
helix (Figure 1 and 5 and Supplementary Figure 5). The importance of the charge
clamp residues (Lys329/301 and E499/471) for coactivator binding has been shown
extensively for several different nuclear receptors, including PPARγ22, however the
helix 12 clamp (E499) has not been proposed before to be important for corepressor
binding to nuclear receptors including PPARγ. The helix 12 charge clamp was
shown to interact with, but not hydrogen bond to, NCoR in a glucocorticoid
receptor antagonist structure301, where helix 12 is shifted in a similar manner to
accommodate the longer compressor helix42. In addition, these simulations indicate
that low energy helix 12 conformations include disordered and/or coregulator
binding surface displaced helix 12 conformations similar to those previously
observed in various other corepressor bound crystal structures20,200,299,300,302.
As noted above, simulations indicate that residues K329/301 (Helix 3) and
N340/312 (Helix 4) interact with NCoR, while E499/471 (Helix 12) and
K347/319 (Helix 4) can interact both with NCoR and form a salt bridge with each
other in a ligand dependent manner. A series of point mutants of the PPARγ-LBD
were generated in these four residues to test these simulation-generated structural
hypotheses. In addition we used a deletion mutant, L496stop (referred to herein as
ΔH12), which deletes helix 12312,313 and increases affinity for corepressor
proteins314. The change in affinity upon mutation of K329/301 or N340/312
should correlate (exponentially) with hydrogen bond prevalence as simulations
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indicate that the hydrogen bond partners to these residues on NCoR are solvent
exposed in the mutants (Supplementary Table 4) and these residues do not
interact with other PPARγ residues and are thus less likely to affect the native
state structure (e.g. are non-disruptive315). Simulations indicate that the K329NCoR hydrogen bond is more prevalent than the N340-NCoR hydrogen bond
across the tested complexes (Figure 5b). Consistent with the simulations,
mutation of K329 has a significantly larger effect on affinity for NCoR than
mutation of N340 (Figure 5c).
Interpretation of the E499 and K347 mutation data is less straightforward
because simulations indicate that these two residues not only hydrogen bond to
NCoR but also form a salt bridge with each other in a ligand dependent manner.
Mutation of these residues may impact PPARγ structure in addition to NCoR
binding. The prevalence of both E499-K347 and E499-NCoR hydrogen bonding
alone and summed correlates with the effects of E499L mutation on NCoR
affinity indicating that both interactions contribute to NCoR affinity. In contrast,
the prevalence of K347-NCoR hydrogen bonding does not correlate with
mutagenesis results. However there is the expected exponential correlation316
between K347-E499 bonding prevalence and affinity changes in the K347A
mutant across the four complexes. This suggests that either disruption of the
K347-E499 salt bridge affects helix 12 conformation and may obscure the effects
of K347-NCoR bonding or that the K347-NCoR bonding observed in simulations
is absent or inconsequential in the actual complex. The E499L mutant has
increased affinity for NCoR in the ligand free (apo) and SR10221 bound forms
which are dominated by structures with no hydrogen bonding between
helix4/NCoR and helix 12 (Figure 5a). Thus, the increased affinity of the apo and
SR10221 bound E499L mutant for NCoR is consistent with the E499L mutation
lowering the energetic cost of helix 12 displacement through disruption of the
E499-K347 salt bridge. Consistent with this model, deletion of helix 12 had no
effect on the affinity of the PPARγ-T0070907 complex for NCoR but increased
affinity of NCoR for GW9662 bound PPARγ and dramatically increased affinity
for apo and PPARγ bound to SR10221 (Supplementary Table 5), which is a
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pattern consistent with the prevalence of both the helix 4 to helix 12 (K347 to
E499) salt bridge prevalence and the E499 to NCoR hydrogen bonding prevalence
in these complexes. These data indicate that both displacement of helix 12 from
the coregulator binding surface and positioning of helix 12 that allows direct
binding to a corepressor (Figure 1d and Supplementary Figure 5) can both
increase NCoR affinity.

Figure 6. A tripartite salt bridge that biases towards agonism is disrupted in the T0070907
bound structural ensemble. Prevalence of the helix 6-7 loop to a) helix 11-12 loop and b) helix 3
salt-bridges are shown for the indicated complexes for individual cMD simulations started from
representative structures from the lowest energy wells in the aMD potential energy landscapes
(black circles). The Boltzmann average is shown by a magenta bar. c) The change in affinity
induced by mutation of the helix 3 salt bridge residue (E304) is shown for the indicated
complexes. d) The tripartite salt bridge as detected by chimera in a PPARγ bound to rosiglitazone
crystal structure (PDB code 2PRG). Blue indicate ideal hydrogen bonds, while orange lines
indicate relaxed constraint hydrogen bonds (20 degrees and 0.4 angstroms).

4.3.9 A salt bridge switch for inverse agonism.
We next used the simulations to identify the possible mechanisms by
which T0070907 induces higher affinity for NCoR peptide than apo PPARγ. A
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tripartite salt bridge network was identified in active but not inactive structures in
analysis of >200 PPARγ crystal structures294. A mutation (F388L) found in
familial partial lipodystrophy disrupts this salt bridge network and reduces
transcriptional activation potency for drugs303. This salt bridge network ties
together a very mobile domain of the ligand binding domain140,207 which includes
the n-terminal part of helix 3 (E304/276), the adjacent helix 6-7 loop (R385/357)
and the helix 11-12 loop (E488/460; Figure 6d). The T0070907 complex with or
without NCoR shows the lowest Boltzmann average prevalence for both these salt
bridges (Figure 6 a,b). We analyzed the simulations and found a correlation
between helix 3 extension and interaction of the omega loop with helix 3 and the
integrity of this tripartite salt bridge (Supplementary Figure 6 a,b,e). In addition,
analysis of all available PPARγ crystal structures indicates that this tripartite salt
bridge is more prevalent when helix 12 is in the active conformation than when it
is in an inactive conformation (Supplementary Figure 6d) . It appears that the
PPARγ-T0070907 structural ensembles are biased against the helix 11-12 loop to
helix 6-7 loop salt bridge formation in ways in addition to helix 3 extension as 3/7
of the PPARγ-T0070907 ensembles without helix 3 extension lack this salt
bridge. Thus, T0070907 disrupts this tripartite salt bridge network, which would
be expected to allow alternative conformations of the helix 11-12 loop and
thereby helix 12, impacting coregulator binding.
To experimentally test the importance of E304/276 to coregulator affinity
we generated an E304L mutant and tested the effect on affinity for a FITC-NCoR
peptide using fluorescence polarization. These data confirm the importance of the
E304/276-385/R357 salt bridge for the active high coactivator affinity state as
disruption of this salt bridge increases NCoR affinity and decreases CBP affinity
consistently for all complexes except the T0070907 complex (Figure 6c). These
data are consistent with our simulation generated models which indicate that the
inverse agonist T0070907 disrupts this salt bridge network, inducing a unique
conformation with increased affinity for NCoR.
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4.3.10 The distinct structural ensembles of SR10221 and T0070907 yield
distinct function.
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F NMR of helix 12 and helix 3 (Figure 3 and Supplementary Figure 4

and 10), protein NMR (Supplementary Figure 2) and simulations (Figure 1 and
5) indicate that the inverse agonists SR10221 and T0070907 induce/select distinct
NCoR bound conformations. Comparison of PPARγ co-bound to T0070907 and
NCoR peptide with the apo NCoR and SR10221-NCoR complexes using
hydrogen deuterium exchange mass spectrometry (HDX-MS) also reveals major
structural differences (Figure 4). The T0070907 complex shows much less
exchange in helix 12 and less exchange in helix 10/11 and the 11-12 loop than
both apo/NCoR and SR10221/NCoR co-bound to PPARγ. Together these data
indicate that SR10221 and T0070907 induce different structures and may achieve
inverse agonist effects via distinct mechanisms.
An important functional effect of drug binding to PPARγ is a change in affinity
for coregulators. We tested the effect of SR10221, T0070907 and other PPARγ
ligands on PPARγ affinity for peptides from NCoR and SMRT using fluorescence
polarization. Compared to apo PPARγ, T0070907 binding induces a dramatic
increase in affinity for both NCoR (Supplementary Table 2, 3, 6 ) and SMRT
(Supplementary Table 7) while SR10221 increases affinity for SMRT only
(Supplementary Table 7). Thus, differences in the structural ensemble of helix
12, 3 and possibly other regions of PPARγ lead to differential recruitment of these
corepressor peptides. Differential recruitment of NCoR and SMRT would be
expected to produce unique functional effects in vivo317.
4.4 Discussion
These fluorine and protein NMR, HDX-MS, mutagenesis and extensive enhanced
sampling simulations reveal a very diverse ligand dependent PPARγ
conformational ensemble. These data also demonstrate that helix 3 dynamics and
structure is key to coregulator affinity. They also implicate a particular omega
loop structural state as important for a structural ensemble with high affinity for
the corepressor NCoR. Previous HDX-MS and NMR work indicated that
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stabilization of PPARɣ helix 3 and the βsheet region, and not just helix 12, is
important for transcriptional activity221,318. Remarkably, the PPARγQ299C-BTFA
(omega loop) spectrum dramatically narrows upon binding the inverse agonist
T0070907 or when co-bound to the antagonist GW9662 and NCoR or SMRT
peptides. These narrow NCoR bound spectra are consistent with a helix 3/omega
loop structural ensemble of similar conformations and indicate that T0070907
induces/selects a helix3/omega loop structural ensemble that is well suited to
NCoR binding as we have observed previously for helix 12282 and other areas of
PPARγ296 (Figure 3). These data also indicate that changes to the AF2 surface
can induce changes in the omega loop depending on the ligand bound to PPARγ,
indicating that the omega loop conformation is important to function. These
results, as well as previously obtained data on helix 12 and other areas of the
PPARγ ligand binding domain suggest that T0070907 induces/selects a
conformational ensemble that accommodates NCoR binding better than GW9662
as the structural ensemble induced/selected by GW9662 changes more than that
of T0070907 upon ligand binding282,296. This is consistent with the idea that less
of the NCoR free energy of binding is used in altering the conformational
ensemble of PPARγ-T0070907 than PPARγ-GW9662 resulting in a higher
affinity of NCoR peptide for PPARγ-T0070907.
Simulations indicate that Helix 3 extension would disrupt interaction of the
omega loop with helix 3. Evidence for the importance of helix 3-omega loop
bonding for the transcriptionally active state has been published previously107. In
addition, mutation of F488/460, involved in the ionic bond network that is also
disrupted by helix 3 extension, is associated with familial partial lipodystrophy303.
In addition, one member of a tripartite salt-bridge network is located on the nterminus of helix 3 (near the omega loop). Simulations indicate that T0070907
disrupts this network. Disruption of this network favors corepressor binding.
These changes appear to free helix 3 and 12 to move to a new conformation with
high affinity for NCoR. Together these data indicate that an important
consequence of T0070907 binding is disruption of this tripartite salt bridge.
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Surprisingly, the helix 12 charge clamp (E49922) appears to have some
importance for NCoR binding to inverse agonist (T0070907) bound PPARγ.
Simulations indicate that the lowest energy PPARγ-T0070907-NCoR structure is
similar to the active structure with a shifted helix 12. HDX-MS (Figure 3) and
mutagenesis (Figure 4) are consistent with this model. A similar helix 12 and
corepressor position has been observed via crystallography for glucocorticoid
receptor bound to an NCoR peptide301. This position allows hydrogen bonding
between the helix 12 charge clamp (E499) and the NCoR peptide backbone in a
similar manner to the coactivator helix 12 interaction. However, given that our
aMD simulations are not completely converged, there may be other lower energy
unsampled or poorly sampled structures that are also consistent with our
experimental data. In that case this conformation could represent a minor helix 12
conformation that composes 25% of the NCoR bound PPARγK502C-BTFA
spectrum.
Interestingly, another inverse agonist (SR10221) appears to work as an inverse
agonist by inducing a distinct structural ensemble which does not involve
interaction of helix 12 with NCoR or a single omega loop structure. The distinct
structural ensembles induced by T0070907 and SR10221 produce different
corepressor recruitment profiles. Compared to apo PPARγ T0070907 increases
affinity for both SMRT and NCoR, while SR10221 increases affinity for only
SMRT. This opens the possibility that SR10221 and T0070907 could have
distinct repressive effects in animals and possibly selective physiological effects
similar to what has been observed in selective PPARγ modulators such as MRL24
and SR1664166,306.

4.5 Methods
4.5.1 Protein and ligand 3D-structure preparation
The crystal structure of GW9662-bound PPARγ (PDB code 3B0R) was used as
the initial structure in all simulations of GW9662 bound PPARγ in this study.
This crystal structure was also used to construct the initial 3D structure of
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T0070907 bound PPARγ. In this model, GW9662 was transformed to T0070907
by converting benzene ring of GW9662 to the pyridine ring. In both models, the
chain B conformation was used. In order to construct the 3D structure for nuclear
receptor corepressor 1 (NCoR1) crystal structure with PDB code 2OVM was
used. 1KKQ crystal structure which is the only structure with corepressor
(SMART) was used as a template to design NCoR bound to PPARγ-T0070907.
Both chain A and B of crystal structure with PDB code 1PRG were used for apo
and 10221 (chain B) simulations. To build the initial structure for Rosiglitazone
simulations chain A of 2PRG PDB code along with S enantiomer of Rosiglitazone
at pH 7.2 which has the highest affinity for PPARɣ were used. UCSF Chimera
modeler extension was used to model the missing residues in PDB files.
4.5.2 Molecular Dynamics (MD) simulations
Molecular Dynamics (MD) simulations were performed using two different
methods: conventional (cMD) and accelerated molecular dynamics simulation
(aMD). aMD simulations were performed in order to sample the conformational
spaces better. Both cMD and aMD production runs were carried out using Amber
16 molecular modeling package and the AMBER ff14SB force field and general
Amber force field (GAFF2) parameters were used to describe protein and
ligand241,319. Refined structures were submitted to h++ server
(http://biophysics.cs.vt.edu/H++)237 to generate the protonated states of protein at
pH 7.4. The resulting PDB files were modified using pdb4amber in
AmberTools14238 for use with tleap. The R.E.D server (http://upjv.q4mdforcefieldtools.org/REDServer-Development/)239 was used for the ligand
parameterization and charge calculations. The structures were immersed in an
octahedron box of TIP3P243 water molecules extended to 10 Å from the protein
atoms. Enough Na+ atoms were added to neutralize the structure and KCl (K+
and Cl- ions) was added to 50 mM320. The resulting system was equilibrated using
a nine-step of minimization and restrained simulations protocol as following. In
the first step a force constant of 5 kcal mol–1 Å–2 was applied on the protein heavy
atoms through 2000 steps. Then, the MD simulation was performed for 15 ps
with shake under constant volume periodic boundary conditions (NVT). This was
144

followed by two rounds of 2000 steps of steepest descent minimization with 2 and
0.1 kcal/mol Å2 spring constant. The system was then subjected to a simulation
with no restraints followed by three rounds of simulations with 1, 0.5 and 0.5
kcal/mol Å2 force constant on heavy atoms for 5 ps, 10 ps and 10 ps. Finally, a
simulation without restraints was performed for 200 ps under NPT condition.
Hydrogen mass repartitioning along with SHAKE algorithm were used to
allow an integration time step of 4 fs. Production MD runs of constant pressure
replicates were performed from randomized initial velocities. The pressure was
controlled by a Monte Carlo barostat with a pressure relaxation time (taup) of 2
ps. The Langevin dynamics with a collision frequency (gamma_ln) of 3 ps-1 was
used to keep the temperature at 310 K. The particle mesh Ewald41 with an 8.0 Å
cutoﬀ was carried out to treat electrostatic interactions. The time step of cMD
simulations was 100 ps and three independent ~15-μs-long cMD production runs
were performed on T0070907, GW9662 and SR10221bound PPARγ with and
without NCoR. Three independent simulations with the same length were
performed on Rosiglitazone bound PPARɣ. All of the aMD simulations were
started from the equilibrated structures and average dihedral energy and total
potential energy obtained from cMD simulations were used to calculate the boost
parameters. In this study a dual boosting approach was carried out in which two
separate boost potentials are applied to the torsional and the total potential terms.
aMD simulations for ~2.5 µs with time step of 3fs were performed on T0070907
and GW9662 bound PPARγ with and without NCoR.
All production simulations were performed using pmemd.cuda or
pmemd.cuda.MPI. The simulation results were analyzed using cpptraj program in
the AmberTools 14 Toolbox308. A toolkit of Python scripts “PyReweighting” was
used to reweight the biased aMD frames and to calculate free energy profiles321.
4.5.3 Protein purification
A pET45b plasmid containing the PPARγ-LBD, residues 230-505 as well as an Nterminal 6x His tag and tobacco etch virus nuclear inclusion protease (TEV)
recognition site was transformed into BL21 (DE3) gold cells (Invitrogen). Cells
were grown in either terrific broth or ZYP-5052 autoinduction media. In the case
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of autoinduction media cells were grown for 10 hours at 37°C and then allowed to
induce for an additional 12 hours at 22°C and 180 rpm. Cells in terrific broth were
grown at 37°C and 170 rpm until OD600 of between 0.6-1 was reached. Following
this the incubator was dropped to 20°C for one hour and cells were induced
overnight by the addition of 500µM IPTG. Cells were pelleted by centrifugation
and stored at -20°C until ready for use. Cell pellets were resuspended in 50mM
KPO4, 300mM KCl, 1mM TCEP and 1mM EDTA pH 8.0 and lysed using a C-5
Emulsiflex high pressure homogenizer (Avestin). Initial protein purification was
performed on either an AKTA start (GE Healthcare) or a NGC Scout (Bio Rad)
FPLC using 2 His Trap FF 5ml columns in series (GE Healthcare). Following this
the 6x his tag was removed by the addition of approximately 1:40 w/w 6x his tagged
TEV and overnight incubation. Cleaved tag and TEV protease was removed by
again passing through His Trap FF columns. Size exclusion chromatography was
then performed using a Hiload 16/600 Superdex 75 pg column (GE Healthcare).
Protein purity in excess of 95% was confirmed by SDS-PAGE.
4.5.4 Site-directed mutagenesis
Site-directed mutagenesis was performed using the Quikchange Lightning
mutagenesis kit (Agilent Technologies). All mutations as well as the absence of
spurious mutations were confirmed by Sanger sequencing (Eurofins). Primers used
to generate the mutants used in this work are as follows, C313A: 5'ccacggagcgaaactgagcgccctgaaagatgcgg-3',
Q322C:
5'gcatactctgtgatctcgcacacagcctccacggagc-3',
Q314A:
5'ctccacggagcgaaacgcgcagccctgaaagatg-3',
K329A:
5'tttacaaaaccaggaatgcttgcggcatactctgtgatctcctg-3',
N340A:
5'atttgaggagagttacttggtcggccaagtcaagatttacaaaaccag-3',
K347A:
5'gatctcgtggactccatatgcgaggagagttacttggtcg-3',
E499L:
5'caagtccttgtagatcagctgcaggagcgggtga-3',
ΔH12:
5'tccttgtagatctcctgcagttacgggtgaagactcatgtctg-3'

4.5.5 Preparation of NMR samples
All NMR samples were prepared to a final volume of 470µL and a final
concentration of 150µM. Samples of PPARγC313A,Q322C and PPARγQ322C were
loaded with ligands to a final concentration of 165µM for all ligands except
Pioglitazone, Troglitazone and BVT.13 which were loaded to a final concentration
of 225µM or GW9662 and T0070907 which were added to a final concentration of
300µM. Ligand concentration was varied to fix the DMSO addition to each sample
at 7.8µL, 1.66% final v/v. In the case of PPARγC313A,Q322C the protein was labeled
with a 10-fold excess of BTFA during purification. However, the single mutant
PPARγQ322C was labeled with a 2-fold molar excess of BTFA following drug
addition, with the following exceptions, samples loaded with the covalent ligands
were labeled with a 10-fold molar excess of BTFA while the apo sample was
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labeled with a stoichiometric concentration of BTFA to reduce labeling on the
native cysteine in the ligand binding pocket. Following labeling samples were
incubated for 30 minutes when loaded with ligand or 2 hours for the apo sample
and then buffer exchanged >100x using an amicon ultra centrifugal filter
(Millipore) with a 10kDa molecular weight cut off to remove excess BTFA label.
All peptides were added to NMR samples at a final concentration of 300µM from
stocks of approximately 1mM in the same buffer as the NMR samples. Following
sample preparation 10% of final volume of buffered D2O was added to all samples.
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Chapter 5: Conclusions
Presented in this work were a wide variety of experiments to increase the
understanding of a fundamental property of the significant nuclear receptor
PPARγ. All data in this work revolved around the central theme towards
elucidating the conformational mechanisms by which very diverse ligands cause
their functional outcomes. From this we were able to expand the available
knowledge in this area, but the picture is still incomplete. However, a substantial
contribution is made towards the understanding of this area of study which will
help guide future research.
This work demonstrates that the two-state “on-off” model for PPARγ, and
likely other nuclear receptors, does not appear to be correct. We observed that the
conformations induced by the majority of ligands were highly complex. Even in
the highly efficacious ligands such as the inverse agonist T0070907 or the FDA
approved full agonist pioglitazone there appeared to be two or more significantly
populated conformational states of the protein. In fact, when probing helix 12,
considered the most important region of the AF-2 surface, it was seen that only a
small number of ligands, GW1929, rosiglitazone and SR10221, were generating
only a single dominant conformation. Results were similar when probing the
conformational ensemble of helix 3 which is another portion of the AF-2 surface.
In this case all efficacious agonists or inverse agonists selected for a more specific
local conformation, but the majority of ligands showed multiple conformations
present at high population. Interestingly, it was seen that both agonists and inverse
agonists seemed to select for the same conformation in this region. This has not
previously been observed but is not completely surprising as the helix 3 charge
clamp is significant in the binding of all coregulators.
Additionally, we observed that inverse agonism does not operate through a
single mechanism. This has long been thought to occur in NR through a
displacement of helix 12 which then allows room for the larger footprint of the
CoRNR box to bind on the AF-2 surface. This hypothesis was due to the fact that
when nuclear receptors were crystallized with corepressor peptides helix 12 was
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always unresolved and appeared to point into space. Such a mechanism does
appear to be relevant in PPARγ inverse agonists, namely SR10221 and nTZDpa,
but does not appear to be the exclusive conformation. We identified a second
inverse agonist induced conformation which appears to be unique to the covalent
ligands, T0070907 and GW9662. In this mechanism the small covalent ligand
remodels helix 3 which then exerts allosteric effect on helix 12 through the
disruption of intra-protein non-covalent interactions. This allows helix 12 to
reposition into a new conformation which allows for the binding of a CoRNR box
while retaining productive interactions to the corepressor from the helix 12 charge
clamp. Such a mechanism has not previously been reported and the presence of
these productive helix 12 interactions is likely why T0070907 is the most
efficacious known inverse agonist in this protein, approximately three times more
efficacious than SR10221 in SMRT or NCoR recruitment. Though it should be
noted that in the monomeric PPARγ SR10221 is a selective inverse agonist and
only promotes the recruitment of SMRT not NCoR, while in the PPARγ-RxRα
heterodimer it increases affinity for both corepressors.
Perhaps the most interesting finding in this work was the discovery of the
helix 4 motif that seems to direct specificity in coactivator interactions. This
eight-residue motif makes discriminatory hydrogen bonds from the terminal
residues to the side chains of residues on the coactivator peptide that seem to be
responsible for a large portion of the extreme specificity seen in coactivator
interactions. They also seem to have some significance in corepressor interactions
but not to nearly as large of a degree. It could be envisioned where this could be
exploited towards the design of biased drugs to recruit only specific coactivators
and thereby drive specific signaling events. An example of such would be in
PPARγ where the moderate affinity PGC1α protein is relatively unaffected by
ablation of helix 4 hydrogen bond interactions. This leads to the idea of the
creation of a ligand that specifically alters the conformation of helix 4 while
retaining other agonist characteristics. It is reasonable to hypothesize that this
ligand would than preferentially recruit PGC1α. Such a design could be exploited
similarly in other nuclear receptors to select for desired effects. The caveat would
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be that such a design could lead to negative side effects. For example, it has been
shown that overexpression of PGC1α in mice can lead to increased insulin
resistance in the liver322. As such it would require special care in drug design to
avoid such unforeseen effects. Another caveat is that this could only be exploited
to preferentially recruit coactivators with lower affinity since the disruption of
helix 4 would severely reduce the affinity for the high affinity coactivators, such
as MED1 and CBP. So, while this may be a strategy in drug design which would
be slightly limited it could still be of very significant value provided proper care
was taken.
One interesting question this work was not able to resolve is the
mechanism of action in partial agonists. Literature would suggest that the majority
of the insulin sensitizing effects seen with these arises from the modulation of
phosphorylation on S245/273 but this is not their only effect. Several of these
ligands including MRL24323, INT131163 and SR2088282 have been shown reliably
to increase coactivator recruitment, either through transactivation assays or in
vitro peptide recruitment assays. However, it has previously been shown these
make no interaction on helix 12164, consistent with our own data, and herein we
show they do not generate a conformation in the helix 3 portion of the AF-2
distinguishable from non-agonists. The only portion of the AF-2 this leaves they
could exert an effect on is helix 4 but according to molecular dynamics and
crystallography they do not make significant contacts in this region. It should be
stated that there may be direct effects on this region which are not captured by
these techniques. To verify this NMR studies similar to those performed in
chapters 2 or 3 would need to be employed. Other two or three-dimensional NMR
based techniques would likely not be successful in ascertaining these effects since
partial agonist binding generally results in a very plastic state of the protein
leading to a small amount of resolved peaks which makes assignment impractical
and without assigned backbone residues it would not be possible to determine
what changes are occurring. If as the initial data suggests there are no significant
effects on helix 4 conformation induced by partial agonist binding that would
imply that there must be a significant allosteric mechanism exerted by partial
150

agonists. This would be highly interesting to unravel but may be very challenging.
The difficulty lies in the fact that partial agonists make only minimal direct
contacts to the protein and those contacts are shared with non-agonists. However,
a stepwise mutagenic screen may be able to parse these effects and solve the
underlying mechanism. This would be of great value as these ligands are the
current focus of active research despite having no real understanding of their
mechanism. Such an understanding would allow for the more intelligent design of
non-agonist ligands such as SR1664166, this ligand strongly increases insulin
sensitivity but has very poor bioavailability making it unsuitable for medicinal
use, which could increase insulin sensitivity but have no effect on other protein
signaling pathways. Such drugs would be of great use as potential therapeutics
which could yield the desired medical effects but avoid the very serious sideeffects associated with full agonist activation of PPARγ.
Through this work we have greatly expanded the knowledge base relating
to how ligand binding leads to a functional effect in PPARγ. This is of great value
in future guided studies to either create novel ligands or modify existing ligands
in a more efficient way. Through this the current drug design for this protein
which relies primarily on a somewhat scattershot method of creating hundreds if
not thousands of ligands could be made more efficient leading to the more rapid
release of potential therapeutics which target this important protein for metabolic
and neurodegenerative disease.
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Chapter 7: Appendices
7.1 Supplementary material for chapter 2
Data in this section has been published in Nature Communications DOI:
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Supplementary Figure 1 | The fluorine NMR spectrum of Y505C C313S PPARγ LBD is
largely ligand independent. a) Y505C C313S PPARγ LBD was labeled with BTFA and fluorine
NMR was performed at ~376 MHz at room temperature either in apo form (blue spectrum) or in
the presence of two agonists (rosiglitazone; red and MRL20; green). b) Y505 is located at the
unstructured C-terminus of the PPARγ LBD, which likely contributes to the relative lack of
change upon ligand binding. This protein was not delipidated.
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Supplementary Figure 2 | Influence of crystal packing on PPARγγ LBD helix 12
conformation. The PPARγ LBD often crystalizes as a homodimer where helix 12 of the
symmetry-related B chain (helix 12*) associates with the AF-2 surface of the A chain (a), adopting
a conformation similar to a coactivator peptide bound to the AF-2 surface (b). This crystallization
artifact distorts the conformation of the B chain helix 12* and influences the conformation of the
A chain helix 12 through the formation of “charge clamp” hydrogen bonds with a positively
charged (Lys301) of A chain helix 3 and negatively charged (Glu471) residues of A chain helix
12. This creates a dipolar coactivator mimicking protein-protein interaction (δ+/δ-) between
monomeric subunits that is further stabilized by hydrophobic interactions originating from Leu468
and Ile472 of B chain helix 12*, which biases the observed structure into an “active” (A chain) or
“pseudo-inactive” (B chain) helix 12 conformation. (c) Chain A and (d) chain B forms of PPARγ
(PDB code: 1PRG) with helix12 and the coregulator binding surface highlighted.
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Supplementary Figure 3 | Molecular dynamics simulations indicate that the “agonist” helix
12 crystal conformation results in a solvent exposed side chain zeta nitrogen of residue K502
and terminal carbon of K502C-BTFA. (a) PPARγK502C-BTFA bound to GW1929 was simulated
in explicit water and salts for ~12 μs and clustered into five clusters by label (cysteine-BTFA)
position. Representative structures from the two most populated clusters (1 and 2 89% of total
frames) are shown. The percent of the total simulation time spent in each cluster is highlighted.
The trifluoromethyl of the BTFA label and the ligand are highlighted. Fluorine atoms are green.
The remaining 11% of the frames are similar to those in cluster 1 and 2 except for a cluster of 3%
of the frames where the BTFA is near the ligand and has very low solvent exposure. (b) The CF3
group of K502C-BTFA is on the surface of the protein in these two clusters (c) Solvent exposure
analysis of the PPARγK502C-BTFA simulation. The number of solvent molecules (water and ions)
within 5 angstroms of the trifluoromethyl carbon of BTFA, and terminal carbons on the indicated
amino acids and a randomly chosen water molecule are shown. (d) Three independent simulations
were performed of GW1929 bound to PPARγ LBD totaling ~25 μs. The number of solvent
molecules (water and ions) within 5 angstroms of the zeta Nitrogen of K502, other control lysines,
including one pointing into the ligand binding pocket (buried Lysine), and a randomly chosen
water molecule are also shown. (e) Representative structures from clustering of the PPARγK502CBTFA simulation according to helix 12 RMSD into five clusters along with a crystal structure of
an “active” helix 12 conformation (1PRG chain A; grey).
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Supplementary Figure 4 | 19F NMR indicates that K502C is preferentially labeled over C313
by BTFA and PPARγK502C without BTFA label is not active in TR-FRET. PPARγK502C which
contains a native cysteine (C313), and an introduced cysteine (K502C) was incubated with either
(a) 10x or (b) 2x molar ratio of BTFA. (c) PPARγC313A,K502C which contains a single cysteine
(K502C) was incubated with 10x BTFA. The PPARγC313A,K502C-BTFA spectrum is very similar to
the 2x BTFA treated PPARγK502C in panel b indicating that K502C is labeled preferentially. The
spectra shown in panel b and c are shown in other figures in this manuscript (d) PPARγK502C was
prepared for use in functional assays (TR-FRET and FP) or NMR and loaded with either 1.1 to
1.25 molar equivalents of MRL24 (which contains a CF3 group; left peak). The signal from
MRL24 (left peak) and BTFA (right peak) were integrated (red numbers in figure). The integral of
the left peak indicates the amount of protein, while the right peak indicates the fraction labeled. (e)
Ligand dependent recruitment of NCOR or MED1 peptide to PPARγK502C (no BTFA) or
PPARγK502C-BTFA was measured using TR-FRET for select ligands. The failure of non-BTFA
labeled PPARγK502C to produce a TR-FRET signal was also seen in two other separate TR-FRET
experiments using GW1929. Mean of two technical replicates and standard deviation are shown.
(f) The non-BTFA labeled PPARγK502C used in panel e has the expected affinity for NCOR as
measured by fluorescence polarization (also see Supplementary Figure 7b) (g) Comparison of
PPARγC313A,K502C-BTFA (green; only labeled on C502) with PPARγK502C-BTFA2x that was loaded
first with indicated ligands and then exposed to a 2x molar ratio of BTFA (blue; presumably
labeled only on C502) and PPARγK502C-BTFA10x that was exposed to a 10x molar ratio and then
loaded with the indicated ligands (red; presumably labeled on both C502 and C313). PPARγK502CBTFA2x is more similar to PPARγC313A,K502C-BTFA than PPARγK502C-BTFA10x in all cases
except for the ligands which covalently attach to C313. (Dimethylformamide; DMF and Dimethyl
sulfoxide; DMSO). The narrow peak at ~-83.3 ppm is free BTFA. All spectra displayed in panel g
except for the red spectra are displayed in other figures in this manuscript.
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Supplementary Figure 5 | Covalent ligands do not bind to C502, DMSO has a minimal effect
on TR-FRET, and signal from any BTFA labeled contaminating protein is undetectable. (ab) The indicated molar ratios of a) T0070907 or b) GW9662 were added to PPARγK502C followed
by labeling with 10x BTFA. The percent of the total signal area found in the left peak is indicated
in panel a. (c) TR-FRET demonstrates that ligand vehicle (DMSO) has negligible impact on
coregulator recruitment to apo PPARγ LBD. Three technical replicates are shown along with the
mean. (d) PPARγC313A LBD (no cysteines) without (purple) or with (red) 6x histidine tag was
treated with 10x molar ratio of BTFA and measured with fluorine NMR using the same processing
and acquisition parameters as PPARγC313A,K502C-BTFA not bound to ligand (blue) or bound to
GW1929 (green). Cleavage of the 6x histidine tag increases the purity of the protein because after
cleavage the prep is re-run over the nickel column and contaminating proteins stick to the column
while PPAR flows through. The difference in purity that histidine cleavage makes is large, with
virtually no contaminating protein detected after cleavage. All spectra shown in this work except
supplementary figure 2 used proteins with the histidine tag cleaved off, thus, NMR signal from
impurities would not be expected to be observed, however any signal from protein impurities
would be expected to be broad and centered at ~-84.35ppm as shown here. A small broad upfield
shifted peak around ~-84.35 ppm appears inconsistently in deconvolutions of some spectra. As
demonstrated by this control, it is possible, but not likely, that this signal near -84.35 ppm
originates from a small amount of contaminating protein that is labeled with BTFA. Inset displays
zoomed view of main figure. The * denotes signal from free BTFA. The blue and green spectra in
panel d and the spectra in panel b are displayed in other figures in this manuscript.
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Supplementary Figure 6 | TR-FRET indicates that labeled proteins are functional, that
PPARγK502C-BTFA is most functionally similar to PPARγ. (a) Titration of PPARγC313A,K502CBTFA and PPARγK502C-BTFA with a diverse set of ligands in the TR-FRET assay using NCoR or
MED1 biotinylated peptides and His-tagged PPARγ LBD (EC50 values are shown in
Supplementary Table 3). (b) Titration of PPARγ, PPARγC313A,K502C-BTFA and PPARγK502C-BTFA
with a subset of ligands in the TR-FRET assay using CBP biotinylated peptides and His-tagged
PPARγ LBD (EC50 values are shown in Supplementary Table 4). (c) Titration of the ligands into
protein (as labeled) preloaded with fluorescently labeled ligand (Fluormone Pan-PPAR Green)
was used to determine Ki values for ligands to the proteins. Fitted Ki values are displayed in
Supplementary Table 1. Mean and standard deviation (n=2) are shown along with fitted curve (see
methods). Error bars represent the standard deviation between two technical replicates in a single
experiment. The competition assay to determine Ki values was performed a single time. The TRFRET with PPARγK502C-BTFA and PPARγC313A,K502C-BTFA was performed three times with
similar results. TR-FRET with CBP was performed two times with similar results. (d-f)
Comparison of PPARγ, PPARγK502C-BTFA and PPARγC313A,K502C-BTFA TR-FRET ratios at
saturating ligand concentrations for (d) MED1 (e) CBP and (f) NCoR. Correlation coefficient is
indicated (R2).
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Supplementary Figure 7 | Fluorescence polarization indicates that labeled proteins are
functional, that PPARγK502C-BTFA is most similar to PPARγ and that SMRT binding is
perturbed by labeling. (a) Comparison of PPARγ with PPARγK502C-BTFA and PPARγC313A,K502CBTFA affinity for MED1, NCoR and SMRT peptides either without ligand or saturated with
T0070907, GW1929 or INT-131 as measured by fluorescence polarization. Assays involving
SMRT peptide recruitment also included rosiglitazone and MRL24. Error bars represent standard
deviation of 2 (SMRT and wt NCoR) or 3 (PPARγC313A,K502C-BTFA NCoR and MED1)
independently run assays. Correlation coefficient is indicated (R2). (b) Comparison of peptide
affinities for wt and labeled/mutant versions of PPARγ either ligand free or saturated with the
indicated ligands. Significant differences between wt and the labeled/mutant PPARγ are indicated
by asterisks (p<0.05; unpaired t test with Holm-Sidak correction for multiple comparisons).
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Supplementary Figure 8 | 19F NMR spectra of PPARγC313A,K502C-BTFA bound to 16
pharmacologically distinct ligands is similar to PPARγK502C-BTFA. The PPARγC313A,K502CBTFA spectra are higher signal to noise than the PPARγK502C-BTFA spectra because the C313A
mutation allows complete labeling with higher BTFA concentrations without spurious labeling of
C313 (Supplementary Fig. 4). GQ16 used DMF for a vehicle. All other ligands used DMSO.
DMSO and DMF concentrations are the same in all spectra. This DMSO spectrum is also
displayed in other figures in this manuscript. The estimated degree of saturation with ligand in
these spectra is shown in Supplementary Table 2. Some of these spectra were replicated
(Supplementary Fig. 10)
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Supplementary Figure 9 | NMR indicates that delipidation produces a small difference in
backbone structure and in coregulator recruitment. (a-b) Protein was delipidated (red spectra)
or not (blue spectra) and then loaded with the indicated ligand or not loaded with ligand (Apo). 2D
[1H,15N]-TROSY-HSQC NMR spectra (Bruker pulse program trosyf3gpphsi19.2) of (a) 15Nlabeled PPARγ LBD or (b) 15N-labeled PPARγC313A-BTFA. Apo spectra are shown at two
different contour levels in panel a for clarity of changes vs. liganded states. Insets in panel b show
19
F NMR spectra of the same sample. Sharp upfield shifted peaks marked with an asterisk in panel
b are likely misfolded protein or another artifact. (c) PPARγ LBD was delipidated or not
delipidated prior to measuring coregulator recruitment in response to ligand titration via TRFRET. No significant difference is observed. Mean ± SE shown. Error bars represent the standard
deviation of two technical replicates. TR-FRET was repeated in two independent experiments with
similar results. NMR was done once.
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Supplementary Figure 10 | NMR samples are stable over time and replicate samples from
different protein preparations produce very similar spectra. Fluorine NMR was collected on
(a) PPARγK502C-BTFA or (b) PPARγC313A,K502C-BTFA loaded with the indicated ligands initially
(blue) and then after two to nine days of storage at room temperature (red). The changes in the E.
coli lipid panel are likely due to lipid precipitation after unbinding from PPARγ. The blue spectra
are displayed in other figures in this manuscript. (c-d) Replicate samples from the same or
different protein preparations. (c) replicate samples using PPARγK502C-BTFA and (d)
PPARγC313A,K502C-BTFA (* denote samples from different protein preparations). Spectra are scaled
relative to each other for ease of comparison. All of the spectra in panels c and d are shown
elsewhere in this manuscript except for one of the spectra each of pioglitazone and nTZDpa bound
to PPARγC313A-BTFA.
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Supplementary Figure 11 | PPARγC313A,Q322C-BTFA recruits coregulators with similar
efficacy to that of wild type PPARγ and the apo PPARγC313A,Q322C-BTFA spectrum is stable
over time. (a) TR-FRET ratio change with increased ligand concentration indicates a change in
affinity between the indicated peptide and delipidated PPARγC313A,Q322C-BTFA induced by ligand
binding. (b) 19F NMR spectra of delipidated apo PPARγC313A,Q322C-BTFA initially and then after 3
days at ambient temperature. The * indicates free BTFA signal. Error bars represent the standard
deviation of two technical replicates in a single experiment. TR-FRET was performed twice in two
independent experiments with similar results.
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Supplementary Figure 12 | Chemical exchange occurs between 19F NMR resolved peaks.
Chemical Exchange Saturation Transfer (CEST) was performed on probes on helix 12 (a,d,e) and
on helix 3 (c). (a) Both on (-83.062 ppm) and off (-85.052 ppm) resonance selective saturating
pulses were performed and the height of the smaller peak (-84.07 ppm) in the 19F spectrum of
T0070907-bound PPARγK502C-BTFA was monitored (left panel). The p value of a two-tailed ttest comparing the mean intensity (shown) of the smaller peak with on and off resonance selective
pulses is shown. While exchange is detected, the exchange is likely very slow, resulting in very
small changes in intensity of the small peak. (b) Calculation to determine the detection limits of
CEST in our system. The intensity of a peak (peak A) as a function of the rate of exchange with a
peak that is selectively saturated (peak B) normalized by the intensity of peak A in the absence of
exchange (Ao). Calculations are shown using T1 values of 400 ms (red) and 350 ms (black) and a
1.6 second selective saturation pulse (which is what was used in the CEST figures). Calculation
was done using Equation 50 from (Journal of Biomolecular NMR 2000 18:49-63). Given
experimental noise and peak A and B sharpness in our experiments exchange may be difficult to
reliably detect with exchange rates less than ~0.4 s-1 (I/Io>0.86; indicated by dotted vertical line in
graph). In addition, exchange rates faster than 10 s-1 can be detected but may be difficult to
quantify given that we used 50 ms selective pulses. (c-e) Exchange rates are indicated with 95%
confidence interval in parentheses. An off resonance soft pulse equidistant from the peak of
interest (green) was subtracted from an on resonance soft pulse (red) to yield Veff (purple). Fits
were carried out fixing T1 at the experimentally verified rate (Supplementary Table 5) and
experimentally obtained non-exchange intensity. Thus, only one parameter was fit leaving 6
degrees of freedom in each fit. These experiments were performed once.
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Supplementary Figure 13 | 19F NMR was performed on samples of the indicated protein and
ligand complexes in the presence of 10% (upper panel), 50% (middle panel), or 100% (lower
panel) deuterium oxide (D2O). Vertical lines indicate the chemical shift of select peaks at 10%
D2O concentration and are included to aid in comparison of peak position between different D2O
concentrations. These experiments were performed once.
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Supplementary Figure 14 | Ligand-directed helix 12 ensemble dictates PPARγγC313A,K502CBTFA-coregulator interaction. (a) Plot of mean 19F NMR chemical shift values
(PPARγC313A,K502C-BTFA) versus TR-FRET endpoint data for the recruitment of MED1, NCoR
and CBP peptides to PPARγC313A,K502C-BTFA (top panels) and wt PPARγ LBD (bottom panels) for
the set of 16 pharmacologically distinct synthetic PPARγ ligands and apo-protein (select ligands
for CBP). TR-FRET was performed in three separate experiments for MED1 and NCoR
recruitment and two separate experiments for CBP with similar results. b) Plot of mean 19F NMR
chemical shift values (PPARγC313A,K502C-BTFA) versus MED1, NCoR and SMRT peptide
dissociation constant (Kd) for PPARγK502C-BTFA (top panels) and wt PPARγ LBD (bottom
panels) as measured by fluorescence polarization (FP) for a subset of the ligands in panel a. Mean
and standard deviation for FP represent 2 (NCOR binding to PPARγC313A,K502C-BTFA and SMRT)
or 3 (NCOR binding to wt and MED1) independent replications. Linear regression fit is shown as
a solid line and the correlation coefficient (R2) for the fitted line is indicated. Covalent ligands,
which require C313 for binding are not included in the wt graphs as the NMR chemical shift
would not be expected to correlate with the FP or TR-FRET values.
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Supplementary Figure 15 | Molecular simulations of PPARγ LBD bound to (a) T0070907
(covalent inverse agonist) alone or co-bound to the corepressor peptide NCoR (lower panel)
or (b) apo or apo bound to NCoR (lower panel). The root mean square deviation of helix 12
compared to the conformation of helix 12 in the crystal structure that was used to build these
molecules (chain B of 3B0R and 1PRG). Each color represents an independent simulation started
from the same coordinates but with different initial atom velocities. Apo without NCoR stays the
closest to the starting crystal structure.
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Supplementary Figure 16 | Synthetic PPARγ ligands and 19F label used in this study. a-q)
Chemical structures of the ligands used in this study. r) Chemical structure of the 3-bromo-1,1,1trifluoroacetone label used in this study
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Supplementary Table 1 | Effect of labeling on ligand affinity
Ligand

#EC50 (nM)

*Ki (nM)

Fold increase in Ki compared to
wild-type

wt

PPARγK502CBTFA

PPARγC313A,K502CBTFA

wt

PPARγK502CBTFA

PPARγC313A,K502CBTFA

PPARγK502CBTFA

PPARγC313A,K502CBTFA

Pioglitazone

247

428

412

121

696

1137

6

9

Rosiglitazone

32

81

516

16

132

1422

8

92

Ciglitazone

9930

>50uM

9034

4875

>50uM

24921

36

5

Troglitazone

4699

8723

6387

2306

14177

17619

6

8

INT-131

5

66

22

3

107

60

41

23

nTZDpa

21

19

44

10

31

123

3

12

GQ-16

8481

2171

8873

4163

3528

24477

1

6

BVT.13

10105

7087

7641

4960

11518

21079

2

4

SR10221

292

282

314

143

458

866

3

6

GW1929

2

3

5

1

5

13

5

12

SR2088

33

45

68

16

74

189

5

12

SR2595

110

80

352

54

130

972

2

18

^GW9662

6

14

33204

NA

NA

NA

similar EC50

large change in
EC50

^T0070907

15

25

>50uM

NA

NA

NA

similar EC50

large change in
EC50

SR1664

131

74

551

64

120

1519

2

24

MRL24

0.9

1.3

1.4

0.5

2

4

5

8

median

5

11

mean

9

17

NA = Not applicable

#Given that 8nM protein was used in determining EC50 values in this table any EC50 less than 4 nM indicates that the true EC50
is ≤ 4 nM.

^these are covalent ligands therefore EC50 doesn’t have the same meaning as the non-covalent ligands
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Supplementary Table 2 | Fraction of protein bound by ligand for NMR samples
Assumes all added
ligand is soluble.

Assumes 10 µM
solubility of ligand.

Fraction bound
according to
deconvolution of
NMR signal

PPARγBTFA

PPARγC313
A
-BTFA

PPARγBTFA

PPARγC313
A
-BTFA

PPARγBTFA

PPARγC313A
-BTFA

Pioglitazone

1.00

0.99

0.96

0.94

1.00

0.89

Rosiglitazone

1.00

0.94

0.99

0.93

1.00

0.95

Ciglitazone

0.55

0.81

0.37

0.69

*1.00

*0.96

Troglitazone

0.92

0.85

0.76

0.74

0.74

0.81

INT-131

1.00

1.00

0.99

0.99

1.00

1.00

nTZDpa

1.00

0.99

1.00

0.99

1.00

1.00

GQ-16

0.93

0.71

0.89

0.69

#0.57

#0.29

BVT.13
Pentahydrate

0.84

0.73

0.79

0.71

0.65

0.69

SR10221

0.99

0.96

0.97

0.95

1.00

1.00

GW1929

1.00

1.00

1.00

1.00

1.00

1.00

SR2088

1.00

0.99

0.99

0.98

1.00

ND

SR2595

1.00

0.96

0.99

0.95

1.00

1.00

^GW9662

1.00

NA

1.00

NA

0.90

NA

^T0070907

1.00

NA

1.00

NA

1.00

NA

SR1664

1.00

0.94

0.99

0.93

1.00

1.00

MRL24

1.00

1.00

1.00

1.00

1.00

0.86

##0.21

##0.25

Vehicle (DMSO)

Fraction bound is calculated using Ki values for ligands.
*Discrepancy between NMR and calculation is likely a combination of inaccurate deconvolution and
good solubility of ciglitazone (Cayman Chemical states that ciglitazone is soluble to 1.2mM in 25%
DMSO).
^Covalent ligands were added at 2x and so are assumed to be fully bound based on EC50 values, this
is supported by LC-ESI MS data.
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# GQ16 has very poor solubility, which would explain the low bound fraction observed via NMR.
## This is either residual bound E. coli lipid or an Apo conformation that is shifted to the right.
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Supplementary Table 3 | EC50 values for MED1 and NCOR recruitment
Coregulat
or

MED1 EC50 (nM)**

PPARγ
variant

wt

NCOR EC50 (nM)**

PPARγK50
2C
-BTFA

FC

PPARγC31
3A,K502C
BTFA

FC

wt

PPARγK50
2C
-BTFA

FC

PPARγC31
3A,K502C
BTFA

FC

Pioglitazon 190
e

420

2

970

5

350

2200

6

1,200

3

Rosiglitaz
one

13

29

2

99

8

21

96

5

1,200

57

Ciglitazon
e

4200

7400

2

1800

<1

2,70
0

15,000

6

14,000

5

Troglitazo
ne

580

2600

4

1400

2

1,10
0

6,600

6

4,600

4

INT-131

7

1

<1

18

2

2

3

1

38

19

nTZDpa*

8

<1

<1

<1

<1

4

8

2

47

12

GQ-16

730

1600

2

NC

NA

1,90
0

1,900

1

NC

NA

BVT.13
Pentahyd
rate

>50,0
00

>50,000

N
A

14,000

<1

44,0
00

9,300

<1

19,000

<1

SR10221

8

NC

N
A

4

<1

2

28

14

28

14

GW1929

3

4

1

3

1

2

10

5

91

46

SR2088

23

50

2

37

1

13

34

3

120

9

SR2595

100

NC

N
A

680

7

75

34

<1

590

8

GW9662#

4

NC

N
A

NC

NA

3

37

12

NC

NA

T0070907
#

4

NC

N
A

>50,000

NA

13

66

5

NC

NA

SR1664

180

NC

N
A

5600

31

NC

99

N
A

535

NA

MRL24*

2

1

<1

1

<1

<1

1

1

2

2
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Median
change§

2

1

5

9

Mean
change§

2

5

5

15

NA=not applicable
NC=no significant change in TR-FRET ratio was observed, which does not
allow curve fitting, which is expected for non-agonists and for non-agonists and
inverse agonists in the MED1 assay.
*Data indicates two recruitment events. The EC50 is shown for the initial
peptide recruitment event only. The second recruitment event likely is caused by
binding of a second ligand to the same PPARγ molecule208.
# these ligands form a covalent adduct to C313 and should not bind to
PPARγC313A,K502C-BTFA.
**Given that 8nM protein was used in determining EC50 values in this table any
EC50 less than 4 nM indicates that the true EC50 is ≤ 4 nM.
§not including covalent ligands; values less than 1 (<1) are treated as 1
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Supplementary Table 4 | EC50 values for CBP recruitment
Coregulator

CBP EC50 (nM)**

PPARγ
variant

wt

PPARγK502C-BTFA

Fold
change

PPARγC313A,K502C-BTFA

Fold change

Rosiglitazon
e

2

4

2

11

8

INT-131

<1

<1

1

<1

1

GW1929

<1

<1

1

<1

1

T0070907#

2

4

2

41,000

21,000

MRL24*

<1

1

1

1

1

Median
change

1

§1

Mean
change

1.4

§2.8

*Data indicates two recruitment events. The EC50 is shown for the initial peptide recruitment
event only. The second recruitment event likely is caused by binding of a second ligand to the
same PPARγ molecule208.
# this ligand forms a covalent adduct to C313 and should not bind to PPARγC313A,K502C-BTFA.
**Given that 8nM protein was used in determining EC50 values in this table any EC50 less than 4
nM indicates that the true EC50 is ≤ 4 nM.
§not including covalent ligands; values less than 1 (<1) are treated as 1
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Supplementary Table 5 | NMR derived spin relaxation values are consistent with
deconvolution

Ligand, protein and
peak
Pioglitazone
PPARγC313A,K502C-BTFA

T2 value
(mean and
95%
confidence
interval:
ms)

Predicted
FWHM (Hz)
from T2 value
95% CI
(1/π*T2)

Deconvolution T1 value
FWHM (Hz)*
(mean and 95%
confidence
interval: ms)

4.9 (4.6 to
5.3)

47 to 54

95

365 (348 to
382)

6.2 (5.7 to
6.7)

38 to 46

62

367 (356 to
379)

17.6 (16.9
to 18.4)

16 to 18

22

342 (339 to
344)

3.1 (2.9 to
3.4)

94 to 110

112

404 (360 to
451)

2.2 (2.0 to
2.3)

135 to 152

174

415 (396 to
434)

-84.06 ppm
Pioglitazone
PPARγC313,K502CA-BTFA
-84.33 ppm
GW1929
PPARγC313A,K502C-BTFA
-84.38 ppm
Apo
PPARγC313A,K502C-BTFA
-84.06 ppm
Apo
PPARγC313A,K502C-BTFA
-83.9 ppm
*Decovoluted peak widths are all slightly wider than the T2 predicted linewidth — if they were narrower, this
would indicate over-fitting of the data. Thus, the deconvolution provides a fit with the least number of
possible peaks (i.e. the number of chemical environments, or conformations) sampled by the BTFA probe
attached to helix 12 for these spectra.
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Supplementary Methods

Parameters used in simulations

&cntrl
imin = 0, nstlim = 250000000, dt=0.004,
ntx = 5, irest = 1,
ntwx = 25000, ioutfm = 1, ntxo =2, ntpr = 25000, ntwr = 25000,
iwrap = 1, nscm = 1000,
ntc = 2, ntf = 2, ntb = 2, cut = 8.0,
ntt = 3, ig = -1, gamma_ln = 3, temp0 = 310, tempi = 310,
ntp = 1, taup = 2.0, barostat = 2,
igb = 0, saltcon = 0.0,
ntr = 0,

Prepin file

0 0 2

This is a remark line
molecule.res
CYB INT 0
CORRECT

OMIT DU BEG

0.0000
1 DUMM DU M 0 -1 -2

0.000

.0

.0

.00000

2 DUMM DU M 1 0 -1

1.449

.0

.0

.00000

3 DUMM DU M 2 1 0

1.523 111.21
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.0

.00000

4 N

N

M 3 2 1

5 H

H

E 4 3 2

1.540 111.208 -180.000 -0.415700
1.001 128.253 75.116 0.271900

6 CA CT M 4 3 2

1.453 46.684 -6.789 0.021300

7 HA H1 E 6 4 3

1.085 106.975 -51.989 0.112400

8 CB CT 3 6 4 3

1.532 114.777 70.403 -0.052400

9 HB2 H1 E 8 6 4

1.083 111.004 -48.445 0.125000

10 HB3 H1 E 8 6 4

1.080 109.153 70.321 0.125000

11 SG S

S 8 6 4

1.820 113.917 -171.908 -0.275000

12 CD CT 3 11 8 6

1.812 99.158 84.434 -0.125700

13 HD2 H1 E 12 11 8

1.085 111.557 -58.090 0.067200

14 HD3 H1 E 12 11 8

1.085 110.619 60.963 0.067200

15 CE C

B 12 11 8

16 O1 O

E 15 12 11

17 CZ CT 3 15 12 11

1.510 111.238 -178.762 0.509200
1.181 125.861 -0.134 -0.397100
1.537 114.766 179.713 0.511800

18 F3 F

E 17 15 12

1.323 109.977 58.455 -0.191500

19 F1 F

E 17 15 12

1.305 111.986 179.382 -0.191500

20 F2 F

E 17 15 12

1.324 109.860 -59.791 -0.191500

21 C

C

M 6 4 3

1.534 104.761 -167.409 0.597300

22 O

O

E 21 6 4

1.192 120.251 -90.053 -0.567900

LOOP

IMPROPER
CD CZ CE O1
CA +M C O

199

DONE
STOP

AMBER parameter database derived frcmod file

Remark line goes here
MASS
N 14.010
H 1.008

0.530
0.161

CT 12.010

0.878

H1 1.008

0.135

S 32.060

2.900

C 12.010

0.616

O 16.000

0.434

F 19.000

0.320

BOND
H -N 434.00 1.010
CT-N 337.00 1.449
CT-H1 340.00 1.090
CT-CT 310.00 1.526
C -CT 317.00 1.522
CT-S 227.00 1.810
C -O 570.00 1.229
CT-F 367.00 1.380

ANGLE
200

H1-CT-N 50.000

109.500

CT-CT-N 80.000

109.700

C -CT-N 63.000

110.100

CT-N -H 50.000

118.040

CT-CT-H1 50.000

109.500

CT-CT-S 50.000

114.700

CT-C -O 80.000

120.400

C -CT-H1 50.000

109.500

C -CT-CT 63.000

111.100

CT-S -CT 62.000

98.900

H1-CT-H1 35.000

109.500

H1-CT-S 50.000

109.500

CT-C -CT 63.000

117.000

F -CT-F 77.000

109.100

DIHE
H1-CT-CT-N 9 1.400

0.000

3.000

N -CT-CT-S 9 1.400

0.000

3.000

O -C -CT-N 6 0.000

0.000

2.000

H1-CT-N -H 6 0.000

0.000

2.000

CT-CT-N -H 6 0.000

0.000

2.000

C -CT-N -H 6 0.000

0.000

2.000

CT-CT-S -CT 3 1.000

0.000

3.000

H1-CT-CT-H1 9 1.400

0.000

3.000

H1-CT-CT-S 9 1.400

0.000

3.000

O -C -CT-H1 1 0.800

0.000

-1.000

O -C -CT-H1 1 0.000

0.000

-2.000
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O -C -CT-H1 1 0.080

180.000

O -C -CT-CT 6 0.000

0.000

2.000

H1-CT-S -CT 3 1.000

0.000

3.000

C -CT-S -CT 3 1.000
C -CT-CT-H1 9 1.400

0.000
0.000

3.000

3.000
3.000

C -CT-CT-S 9 1.400

0.000

3.000

O -C -CT-S 6 0.000

0.000

2.000

CT-C -CT-S 6 0.000

0.000

2.000

CT-C -CT-F 6 0.000

0.000

2.000

CT-C -CT-H1 6 0.000
O -C -CT-F 6 0.000

0.000
0.000

2.000
2.000

IMPROPER
CT-CT-C -O
10.5
180.0
2.0
angle X- X- C- O, penalty score= 6.0)

Using general improper torsional

NONBON
N

1.8240 0.1700

H

0.6000 0.0157

CT

1.9080 0.1094

H1

1.3870 0.0157

S

2.0000 0.2500

C

1.9080 0.0860

O

1.6612 0.2100

F

1.7500 0.0610

GAFF parameter database derived frcmod file
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Remark line goes here
MASS
N 14.010
H 1.008

0.530

same as n

0.161

same as hn

CT 12.010

0.878

same as c3

H1 1.008

0.135

same as h1

S 32.060

2.900

same as ss

C 12.010

0.616

same as c

O 16.000

0.434

same as o

F 19.000

0.320

same as f

BOND
H -N 403.20 1.013

same as hn- n, penalty score= 0.0

CT-N 328.70 1.462

same as c3- n, penalty score= 0.0

CT-H1 330.60 1.097

same as c3-h1, penalty score= 0.0

CT-CT 300.90 1.538

same as c3-c3, penalty score= 0.0

C -CT 313.00 1.524

same as c-c3, penalty score= 0.0

CT-S 215.90 1.839

same as c3-ss, penalty score= 0.0

C -O 637.70 1.218

same as c- o, penalty score= 0.0

CT-F 356.90 1.350

same as c3- f, penalty score= 0.0

ANGLE
H1-CT-N 49.840

108.880 same as h1-c3-n , penalty score= 0.0

CT-CT-N 65.910

111.610 same as c3-c3-n , penalty score= 0.0

C -CT-N 67.000

109.060 same as c -c3-n , penalty score= 0.0

CT-N -H 45.800

117.680 same as c3-n -hn, penalty score= 0.0

CT-CT-H1 46.390

109.560 same as c3-c3-h1, penalty score= 0.0
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CT-CT-S 61.300

110.270 same as c3-c3-ss, penalty score= 0.0

CT-C -O 67.400

123.200 same as c3-c -o , penalty score= 0.0

C -CT-H1 47.040

108.220 same as c -c3-h1, penalty score= 0.0

C -CT-CT 63.270

111.040 same as c -c3-c3, penalty score= 0.0

CT-S -CT 60.240

99.240 same as c3-ss-c3, penalty score= 0.0

H1-CT-H1 39.240
H1-CT-S 42.060
C -CT-S 61.850
CT-C -CT 62.040

108.460 same as h1-c3-h1, penalty score= 0.0
108.760 same as h1-c3-ss, penalty score= 0.0
108.840 same as c -c3-ss, penalty score= 0.0
116.500 same as c3-c -c3, penalty score= 0.0

C -CT-F 66.260

110.000 same as c -c3-f , penalty score= 0.0

F -CT-F 70.890

107.360 same as f -c3-f , penalty score= 0.0

DIHE
H1-CT-CT-N 9 1.400
score= 0.0

0.000

3.000

N -CT-CT-S 9 1.400
score= 0.0

0.000

O -C -CT-N 6 0.000
score= 0.0

180.000

2.000

same as X -c -c3-X , penalty

H1-CT-N -H 6 0.000
score= 0.0

0.000

2.000

same as X -c3-n -X , penalty

CT-CT-N -H 6 0.000
score= 0.0

0.000

2.000

same as X -c3-n -X , penalty

C -CT-N -H 6 0.000
score= 0.0

0.000

2.000

same as X -c3-n -X , penalty

CT-CT-S -CT 3 1.000
score= 0.0

0.000

3.000

same as X -c3-ss-X , penalty

H1-CT-CT-H1 9 1.400
score= 0.0

0.000

3.000

same as X -c3-c3-X , penalty

3.000
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same as X -c3-c3-X , penalty

same as X -c3-c3-X , penalty

H1-CT-CT-S 9 1.400
score= 0.0

0.000

3.000

same as X -c3-c3-X , penalty

O -C -CT-H1 1 0.800

0.000

-1.000

same as h1-c3-c -o

O -C -CT-H1 1 0.000

0.000

-2.000

same as h1-c3-c -o

O -C -CT-H1 1 0.080
score= 0.0

180.000

3.000

same as h1-c3-c -o , penalty

O -C -CT-CT 6 0.000
score= 0.0

180.000

2.000

same as X -c -c3-X , penalty

H1-CT-S -CT 3 1.000
score= 0.0

0.000

C -CT-S -CT 3 1.000
score= 0.0
C -CT-CT-H1 9 1.400
score= 0.0

0.000

3.000
3.000

0.000

same as X -c3-ss-X , penalty
same as X -c3-ss-X , penalty

3.000

C -CT-CT-S 9 1.400
score= 0.0

0.000

O -C -CT-S 6 0.000
score= 0.0

180.000

2.000

same as X -c -c3-X , penalty

CT-C -CT-S 6 0.000
score= 0.0

180.000

2.000

same as X -c -c3-X , penalty

CT-C -CT-F 6 0.000
score= 0.0

180.000

2.000

same as X -c -c3-X , penalty

CT-C -CT-H1 6 0.000
score= 0.0
O -C -CT-F 6 0.000
score= 0.0

3.000

same as X -c3-c3-X , penalty

180.000

same as X -c3-c3-X , penalty

2.000

180.000

2.000

same as X -c -c3-X , penalty
same as X -c -c3-X , penalty

IMPROPER
CT-CT-C -O

1.1

180.0

2.0

Using the default value

NONBON
205

N

1.8240 0.1700

same as n

H

0.6000 0.0157

same as hn

CT

1.9080 0.1094

same as c3

H1

1.3870 0.0157

same as h1

S

2.0000 0.2500

same as ss

C

1.9080 0.0860

same as c

O

1.6612 0.2100

same as o

F

1.7500 0.0610

same as f
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7.2 Supplementary material for chapter 3
Data in this section is in final preparation for publication.
Supplementary information for

Helix 4 determines the specificity of coactivator interactions in
nuclear receptors

Ian M Chrisman, Zahra Heidari, Trey Patton, Tung-Chung Mou, Travis S Hughes
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Figure S1. Consensus logos of the helix 4 motif in nuclear receptors. A: The consensus logo of
the 8-residue motif on helix 4 for all 40 NR which are thought to bind coregulators on the AF-2
surface. In one NR, DAX1, this motif has expanded to be 9-residues and cannot be aligned. Of the
remaining seven the motif cannot be located in two and is degenerate in five others. All NR where
the motif is degenerate are not thought to bind coregulators on the AF-2 surface. B: Consensus
logo of the helix 4 motif for the NR1 family of NR. This shows a much higher degree of
conservation in this family relative to other NR families. C: Consensus logo of the helix 4 motif
for the NR2 family. D: Consensus logo of the helix 4 motif for the NR2 family with TR4 omitted.
This protein has a highly degenerate sequence in this region and has been shown not to bind
coregulators on the AF-2 surface. E: Consensus logo of the helix 4 motif for the NR3 family. This
motif is the least conserved in this family which may indicate the least homology in coregulator
interactions within an NR family. This is merely hypothetical however and would require further
research to demonstrate.
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Protein
Androgen receptor
(NR3C4)
Constitutive
androstane
receptor (NR1I3)
Coup TF1 (NR2F1)
Coup TF2 (NR2F2)
ERBAL2 (NR2F6)
DAX1 (NR0B1)
Estrogen receptor
α (NR3A1)
Estrogen receptor
β (NR3A2)
Estrogen related
receptor α
(NR3B1)
Estrogen related
receptor β
(NR3B2)
Estrogen related
receptor γ
(NR3B3)
Farnesoid x
Receptor (NR1H4)
GCNF (NR6A1)
Glucocorticoid
Receptor (NR1C1)

Sequence
DDQMAVIQ
also R
EDQISLLK
also R

Location
731738/726
188195/183

Co-peptide
NCoA2, NCoA4, NCoA3
NCoA1

PDB accession
2Q7J, 3L3X,
4OLM, 1T63
1XV9

TDQVSLLR
TDQVSLLR
ADQVALLR
LDQQLVLVR
HDQVHLLE

246-253
239-246
229-236
280-288
373-380

No structures
No coregulator
No structures
No coregulators
NCoA1, NCoA2

4TUZ, 5KR9

FDQVRLLE

327-332

NCoA1

3OMO

SDQMSVLQ

255-262

PGC1α

3D24

GDQMSLLQ

270-277

No structures

ADQMSLLQ

295-302

NCoA1, NRIP1, SMRT- No
interactions

HEDQIALLK

318-325

NCoA2, NCoA1
No structures
NCoA2, NCoR

DDQMTLLQ
also R

590597/585

HNFα (NR2A1)
HNFγ (NR2A2)
LRH1 (NR5A2)
LXRα (NR1H3)
LXRβ (NR1H2)
Mineralocorticoid
receptor (NR3C2)
NOR1 (NR4A3)
NURR1 (NR4A1)
NUR77 (NR4A2)
PGR (NR3C3)
PNR (NR2E3)
PPARα (NR1C1)
PPARγ (NR1C3)
PPARδ (NR1C2)
PXR (NR1I2)
RARα (NR1B1)

DDQVALLR
DDQVALLR
DDQMKLLQ
EDQIALLK
REDQIALLK
EDQITLIQ

205-212
166-173
372-379
284-291
298-305
796-803

NCoA1
No coregulators
Dax1, SRC2
NCoA1
NCoA1
NCoA1

EDQTLLIE
ADQDLLFE
ADQDLLLE
DDQITLIQ
RDQVILLE
NDQVTLLK
NDQVTLLK
NDQVTLLK
EDQISLLK
ADQITLLK

464-471
433-440
433-440
745-752
247-254
303-310
312-319
276-283
270-277
255-262

RARβ (NR1B2)

ADQITLLK
also T
ADQITLLK

258264/253
257-264

No structures
No coregulators
No coregulators
SMRT
No coregulators
NCoA1
MED1
No coregulators
NCoA1
SMRT, NCoA1- No
interactions
NCoA1

RARγ (NR1B3)

No coregulators
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5WZX/5Q0A/
3OOF
3MNR, 3H52,
4CSJ, 3K22,
3E7C
1PZL
4RWV, 3PLZ
3IPQ
4DK7
5L7E

4OAR
3FEI, 3G8I

5X0R, 2O9I

4DM6, 4JYI

REV-ERBα (NR1D1)
REV-ERBβ (NR1D2)
RORα (NR1F1)
RORβ (NR1F2)
RORγ (NR1F2)

RxRα
RXRβ
RXRγ
SF1
SHP
THRα
THRβ
TLX
TR2
TR4
VDR

(NR2B1)
(NR2B2)
(NR2B3)
(NR5A1)
(NR0B2)
(NR1A1)
(NR1A2)
(NR2C2)
(NR2C1)
(NR2C2)
(NR1I1)

HDQVNLLK
HDQVNLLK
QNDQIVLLK
QNDQILLLK
QNDQIVLLK

466-473
432-439
349-357
288-296
346-354

NCoR- No interactions
No coregulators
NRIP1
NCoA1
NCoA2, NRIP1, SMRT

DDQVILLR
DDQVILLR
EDQVILLR
ADQMTLLQ
QDQRRLLQ
EDQIILLK
EDQIILLK
QDQLMLLE

295-302
366-373
296-303
293-299
82-89
245-252
299-306
202-209

DCNTSLVR
DDQIVLLK

413-420
253-260

NCoA2, TIF2
NCoA2- No interactions
No coregulators
NCoA2, SHP, PGC1α
No coregulators
No coregulators
No coregulators
No coregulators
No structures
No coregulators
MED1

4S15
1NQ7
5YP5, 3L0L,
6FZU, 5NTI,
5X8Q
4RMC, 5MK4

1ZDT

5AWK, 5B41

Figure S2. Conserved helix 4 motif in all nuclear receptors. For all human nuclear receptors,
listed alphabetically in left column, the eight-residue helix 4 sequence is shown along with the
residue numbers this motif covers. Bolded residues are those which are resolved to interact with
coregulator peptides in crystal structures. The coregulators listed are those which show interaction
and the PDB accession numbers for the crystal structures these interactions were identified in are
provided. For those proteins which have been crystallized with coregulators but show no helix 4
interactions (ERRγ, RARα, REV-ERBα and RXRβ) all coregulators that have been crystallized
with this protein are listed. In one case, DAX1, this motif has expanded to include one extra
residue. For the proteins GCNF and TR2 this motif is highly degenerate and cannot be located due
to the lack of crystal structures.
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Species

Estrogen
Glucocorticoid Testicular
Nurr1
Receptor α
Receptor
Receptor 4
NDQVTLLK
HDQVHLLE
DDQMTLLQ
DCNTSLVR
ADQDLLFE
Homo
Sapiens
(Human)
Sus Scrofa NDQVTLLK HDQVHLLE DDQMTLLQ DCNTSLVR ADQDLLFE
(0.98)
(0.92)
(0.89)
(0.99)
(0.99)
(Pig)
Manis
Javanica
(Pangolin)
Physeter
Catodon
(Sperm
Whale)
Gallus
Gallus
(Chicken)
Danio
Rerio
(Zebrafish)
Xenopus
Laevis
(Frog)

PPARγ

NDQVTLLK HDQVHLLE
(0.98)
(0.91)

DDQMTLLQ
(0.95)

DCNTSLVR ADQDLLFE
(0.98)
(0.99)

NDQVTLLK HDQVHLLE
(0.98)
(0.89)

DDQMTLLQ
(0.93)

DCNTSLVR ADQDLLFE
(0.99)
(0.99)

NDQVTLLK HDQVHLLE
(0.87)
(0.79)

DDQMTLLQ
(0.75)

ECNTSLVR TDQDLLFE
(0.93)
(0.95)

NDQVTLLK HDQVQLLE
(0.64)
(0.58)

DDQMTLLQ
(0.49)

ECNTALVR CDQELLFE
(0.80)
(0.92)

NDQVTLLK HDQVHLLE
(0.82)
(0.69)

DDQMTLLQ
(0.63)

DCNTNLVR QDQDLLFE
(0.88)
(0.87)

Figure S3. Sequence conservation of the helix 4 motif. The sequence conservation of the 8residue helix 4 motif for several nuclear receptors was examined across several species which
range from close relatives of humans to distantly related species. Total protein identity is shown in
parentheses for each non-human sequence. For all nuclear receptors shown this motif is fully
conserved among mammals. The only sequences found to not be fully conserved are from proteins
which do not meet the standard motif. Fully conserved residues are shown in bold while residues
which deviate from the human sequence are in red.
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Figure S4. Experimental replicate of the LBD PPARγ-RxRα FP. A: Heatmap from an
experimental replicate of the LBD PPARγ-RxRα. All values shown reflect the average value from
two technical replicates within the single experimental replicate. B: Curve fits used to generate the
heatmap shown in figure 2. C: Curve fits used to generate the heatmap shown in panel A. Error
bars reflect the difference in two technical replicates within the same experimental replicate.
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Figure S5. Experimental replicate of the FL PPARγ-RxRα-SULT2A1 FP. A: Heatmap from
an experimental replicate of the FL PPARγ-RxRα-SULT2A1 PPRE. All values shown reflect the
average value from two technical replicates within the single experimental replicate. B: Curve fits
used to generate the heatmap shown in figure 2. C: Curve fits used to generate the heatmap shown
in panel A. Error bars reflect the difference in two technical replicates within the same
experimental replicate.
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Figure S6. CEST NMR indicates that the central peak observed in 19F NMR of PPARγQ294CBTFA arises from labeling of the native cysteine. A: Variable location CEST NMR of
PPARγQ294C-BTFA reveals that in this variant that the rightmost peak is not in exchange with the
central peak but does exchange with the leftmost. In this spectrum the peak for free BTFA,
denoted with an asterisk, was truncated so as to not drown out the peaks from the protein. This
truncation is why the observed peak is much wider than expected for a small molecule. B: Overlay
of PPARγQ294C-BTFA (Blue) and a sample WT PPARγ-LBD labeled with a 40x molar excess of
BTFA (Red). The WT PPARγ peak nearly perfectly overlays with the central peak of PPAγQ294CBTFA supporting that this peak arises from labeling of C285. In all spectra an * denotes residual
free BTFA.
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Figure S7. 19F NMR of PPARγC285A, Q294C-BTFA. A-L: The 19F NMR spectra of PPARγC285A,
-BTFA in 12 distinct ligand bound states. The covalent ligands T0070907 and GW9662 were
not run with this mutant as they require C285 for function. All NMR spectra were collected once.

Q294C
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Figure S8. Curve fits of Mutant FP. A: The curve fits for FP of point mutants from a single
experimental replicate. B: The curve fits for FP of point mutants from the second experimental
replicate. Error bars signify the difference in two technical replicates within an experimental
replicate.
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Figure S9. TR-FRET evidences the same ligand behavior as is seen in FP data. A: TR-FRET
data for MED1-2 association with more ligands including a partial agonist, INT131, and an
inverse agonist T0070907. This data shows the same pattern of ligand induced affinity as is seen
in the FP assays with this peptide. Data in this panel is from the same experiment as is shown in
figure 4. B: Experimental replicate of the MED1-2 TR-FRET data. Data in this experimental
replicate was collected in a manner identical to that in panel A. C: Experimental replicate of the
SRC1-2 TR-FRET shown in figure 4. Data in this panel was collected identically to that in figure
4. D: Experimental replicate of the SRC1-2 TR-FRET shown in figure 4. Data in this experimental
replicate was collected at a concentration of SRC1-2 half that used in figure 4. The pattern is
identical to that seen at the higher concentration but the signal to noise is significantly worse.
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Figure S10. Molecular dynamics of ERα. A: RMSD of ERα bound to SRC1-2 started from
3UUD. B: : RMSD of ERα bound to SRC1-3 introduced to 3UUD. C: : RMSD of ERα bound to
SRC202 started from 5DX3. D: : RMSD of ERα bound to SRC1-3 introduced to 5DX3. E: :
RMSD of ERαY537S bound to SRC1-2 started from 3UUD. F: RMSD of ERαY537S bound to SRC12 introduced to 3UUD. G: RMSD of ERαY537S bound to SRC2-2 started from 3UUD. H: RMSD of
ERαY537S bound to SRC1-3 introduced to 5DX3. In panel H the first μs of data is omitted due to a
saving error. To allow protein to reach a stable state only the data from 1.5-3.5μs was considered
in this work. I: Fractional charge clamp interaction for all data in this work. In the WT ERα
interaction is always between 100-200% indicating robust interaction and proper peptide location.
In ERαY537S the interaction is not always well populated indicating there may be issues in the
peptide location. J: Fraction of interaction between the helix 4 residues and peptides in ERαY537S.
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Figure S11. Chemical structures of the synthetic ligands and the 19F label used in this work.
A-M: The chemical structures of all PPARγ ligands used in this work. N: The chemical structure
of the BTFA molecule used to add the 19F label to PPARγ.

219

CBP-1
MED12
PGC1α
NCoR-1

T0070907
1,118
602.6
2,953
1,533
2,008
1,586
78.4
100

GW9662
520.7
387.7
1,492
1,036
1,256
1,230
273.1
359.9

Apo
414.5
257.7
861.9
732.9
1,235
1,110
497.5
638.8

SR1664
601.7
459.9
2,093
1,465
1,761
1,868
555.3
738.6

MRL24
381.2
364.5
1,814
1,450
1,029
1,149
1,404
3,194

Troglitazone
280.8
252.9
641.4
567.5
984
1,264
602.6
1,001

Pioglitazone
182.2
199.7
462
494.2
893.4
1,042
875.9
1,387

Rosiglitazone
131
105.9
347.5
237.4
658.4
648.9
2087
3,445

Table S1. Kd values for the LBD PPARγ-RxRα complex with coactivator peptides. The first
experimental replicate is shown in blue while a second experimental replicate is shown in orange.
All Kd values are in nanomolar and were obtained from non-linear curve fits of 12 data points
ranging from 20-41600nM for the first experimental replicate or 21-43000nM for the second
experimental replicate. Each curve was comprised of two technical replicates.
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GW1929
81.8
76.1
145.5
172
257.1
363.6
2,374
3,777

CBP-1
MED12
PGC1α
NCoR-1

T0070907
3,953
5,431
7,240
3,390
8,844
6,075
1,055
455

GW9662
3,211
2,385
6,032
2,592
8,203
3,474
2,628
1,161

Apo
2,227
1,791
4,020
2,149
7,425
4,601
3,022
1,552

SR1664
3,805
2,579
6,753
2,795
10,144
6,471
3,324
1,541

MRL24
3,624
2,020
5,271
2,869
7,720
3,680
3,692
2,183

Troglitazone
1,693
1,375
3,049
1,893
6,408
4,061
4,444
1,946

Pioglitazone
1,444
1,134
2,928
1,507
5,571
3,553
6,015
2,741

Rosiglitazone
1,327
1,161
2,623
1,311
5,340
3,336
6,877
3,710

Table S2. Kd values for the full-length PPARγ-RxRα-DNA complex with coactivator
peptides. The first experimental replicate is shown in blue while a second experimental replicate
is shown in orange. All Kd values are in nanomolar and were obtained from non-linear curve fits of
12 data points ranging from 26-53000nM for the first experimental replicate or 23-47600nM for
the second experimental replicate. Each curve was comprised of two technical replicates.

221

GW1929
1,198
1,015
2,181
1,185
4,034
2,205
6,875
3,785

PPAR:GW1929

PPAR:MED12:GW1929

APS 19BM
0.979
1929
30.31 - 1.90 (1.97
- 1.90)
P 41 21 2

APS 19BM
0.979
MED1+1929
43.81 - 1.90
(1.97 - 1.90)
C 2 2 21

Completeness (%)*

61.9 61.9 167.9
90 90 90
26487 (2520)
8.0 (4.3)
99.22 (97.30)

55.4 87.6 121.6
90 90 90
23571 (2313)
9.8 (6.2)
99.26 (98.72)

Mean I/σ (I)*
Wilson B-factor
Rsym†,*

13.5 (2.3)
23.08
0.11 (0.65)

19.2 (7.6)
25.50
0.09 (0.56)

0.2082 (0.3873)

0.2008 (0.3524)

0.2446 (0.4103)

0.2574 (0.3881)

2217
37
185
276

2295
37
131
286

0.004
0.56

0.012
1.44

97.81/ 2.19/0.00

98.23/1.77/0.00

36.01
44.01
38.05
0

45.24
30.09
45.26
1

Data collection
Beamline
Wavelength (Å)
Ligand
Resolution range (Å)*
Space group
Unit cell dimensions
a, b, c (Å)
α, β, γ (◦)
Unique reflections*
Redundancy*

Refinement
Rwork§,*
Rfree

§,*

Number of total atoms
protein
1929
Solvent
Total protein residues
RMS deviations
Bonds lengths (Å)
Bond angles (◦)
Ramachandran
favored/allowed/outliers (%)††
Average B-factor
Macromolecules
GW1929
water
Number of TLS groups

Table S3. Crystallography data collection and refinement statistics.
*

Data for highest resolution shell are given in brackets. † Rsym=∑hkl ∑i |Ii(hkl)-〈I(hkl)〉|/ ∑hkl ∑i
Ii(hkl), where Ii(hkl) is the ith observation of the intensity of the reflection hkl. § Rwork=∑hkl || Fobs||Fcalc||/ ∑hkl |Fobs|, where Fobs and Fcalc are the observed and calculated structure-factor amplitudes
for each reflection hkl. Rfree was calculated with 5% of the diffraction data that were selected
randomly and excluded from refinement. †† Calculated using MolProbity (Chen et al., 2010).
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WT PPARγ-LBD
Rosiglitazone
WT PPARγ-LBD
GW1929
PPARγK301A
Rosiglitazone
PPARγK301A
GW1929
PPARγN312A
Rosiglitazone
PPARγN312A
GW1929
PPARγ-LBDK319A
Rosiglitazone
PPARγ-LBDK319A
GW1929
PPARγ-LBDE499L
Rosiglitazone
PPARγE499L
GW1929

CBP-1
82.12
125.90
48.71
70.00
2,040
2,135
1,310
1,853
4,787
7,838
3,663
4,886
1,625
1,247
839.5
980.4
>50,000
>50,000
>50,000
>50,000

MED1-2
226.80
194.80
180.80
97.61
12,953
10,894
8,299
8,177
1,674
1,130
1,495
1,127
2,332
1649
2,407
1,379
NBD
NBD
NBD
NBD

PGC1α
884.00
1966.0
413.7
538.70
46,132
>50,000
12,348
12,310
1,590
2,973
675
1,306
2,946
4,249
1,484
751.2
>50,000
>50,000
34,686
>50,000

Table S4. Kd values for the PPARγ mutants with coactivator peptides. The first experimental
replicate is shown in blue while a second experimental replicate is shown in orange. All Kd values
are in nanomolar and were obtained from non-linear curve fits of 12 data points ranging from 2449,500nM for both experimental replicates. Each curve was comprised of two technical replicates.
A value of >50,000 indicates the affinity was lower than the highest concentration used so an
accurate affinity cannot be determined. A value of NBD indicates that there was no indication of
binding at the highest concentration used.
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7.3 Supplementary material for chapter 4
Data in this section is in final preparation for publication
Supplementary material for

Inverse agonists induce drug specific structure and function via
distinct molecular mechanisms in the nuclear receptor PPARγ
Zahra Heidari, Ian Chrisman, Scott Novick, Michelle Nemetchek, Theodore Kamenecka,
Patrick Griffin, Travis Hughes
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Supplementary Figure 1. Accelerated MD reveals a more diverse structural
ensemble for apo PPARγ and PPARγ bound to inverse agonists/antagonists
compared to agonist bound PPARγ. a-f) Representative structures from clustering
based on helix 12 RMSD of structures in the wells indicated in panel g. The identity of the
energy well and the calculated prevalence of each well’s structures within the Boltzmann
ensemble (see methods) is indicated by the number and percent in parentheses
respectively. The prevalence of the structures within a particular well is indicated by the
color of helix 12 ranging from dark green for the most prevalent to olive drab, light green,
light blue and then deep sky blue for the least prevalent. For reference, an active
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structure (rosiglitazone bound PPARγ; 2PRG chain A) is shown with helix 12 colored dim
grey. g) The locations of the wells that were sampled to produce the representative
structures in panels a-f is shown. Supplementary table 9 shows the relative energies of
the wells indicated in panel g.
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Supplementary Table 2. Comparison of coregulator peptide affinity for the ligand
binding domain of wt PPARγ, PPARγQ299C-BTFA
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Supplementary Table 3. Comparison of coregulator peptide affinity for the ligand
binding domain of wt PPARγ, PPARγQ322C-BTFA, and PPARγC313A,Q322C-BTFA.
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Supplementary Figure 2. Protein and 19F NMR of the helix 12 conformational
ensemble. a-c) Comparison of K347A mutant, that would disrupt interaction between
helix 4 and helix 12, and wt PPARγ LBD bound to the indicated ligands. Probable
assignments, based on rosiglitazone bound PPARγ and apo PPARγ assignments, for
residues affected by the mutation are indicated. The mutation consistently affects a
resonance with shifts between 121 and 123 and 8.5 and 8.7 in all forms. Two
rosiglitazone assigned residues are in this area, K347 and L463. L463 is far from the
coregulator binding surface so we assume this resonance is K347 (the residue we
mutated). d) The Boltzmann average values for interaction of the terminal side chain
protons on K347 (i.e. NH3) and all other residues was calculated for PPARγ alone (apo)
or bound to T0070907. When K347 is not interacting with helix 12 it interacts almost
solely with solvent. c) all 58 representative structures shown in Supplementary Figure 1
were subjectively classified as having active-like or inactive-like helix 12 conformations
and prevalence of bonding between helix 12 residues and K347 were calculated from
1μs simulations of each representative structure.
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Supplementary Figure 3. The c-terminal portion of helix 3 is composed of a diverse
structural ensemble in apo that consolidates upon binding coregulators, RXRα or
ligands. a) The spectrum of wt PPARγ-BTFA (red) overlays well with the middle peak of
PPARγQ322C-BTFA, indicating that the middle peak originates from labeling of the native
cysteine (C313). The green arrow indicates signal from C313. b) Examples of spectra
from delipidated PPARγC313A,Q322C-BTFA from different purifications and from nondelipidated PPARγC313A,Q322C-BTFA (bottom panel). The delipidation efficacy is variable
and affects the relative population of apo peaks with delipidation increasing the
population of the left peak. This variability is also observed with spectra of apo bound to
peptides. These data indicate that the left peak in these spectra originates from apo. The
right peak may also be representative of apo PPARγ or E. coli lipid bound PPARγ or the
lipid may simply push the apo helix 3 structure equilibrium towards the right peak. c-d)
Overlay of PPARγQ322C-BTFA (blue), which can be labeled at the native cysteine (C313),
and PPARγC313A,Q322C-BTFA (red) which cannot, reveals the signal originating from C313
when PPARγ is bound to either c) NCoR or d) RXRα (green arrows). NCoR and RXRα
binding consolidate the Q322C-BTFA signal into one main peak. e) Either CBP or NCoR
was titrated into ligand free PPARγC313A,Q322C-BTFA (apo) at the indicated molar ratios of
peptide to PPARγ starting with just PPARγ (0.0). Titration of both peptides again leads to
peak consolidation. f) CEST indicates exchange between the peak denoted by the
orange arrow and the black arrow, but not the central peak (which originates from the
native cysteine). The black circles indicate the location of the saturating peak, while the
height of the circles represent the height of the right peak labeled with the black arrow. g)
Saturating NMR pulses were applied at the orange peak (in panel f) and an off-target
area equidistant from the peak of interest (the right peak labeled with the black arrow in
panel f) and the height of the right peak (panel f) was measured after various durations of
the saturating NMR pulse. The data were then fit to a single exponential, which indicates
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0.5 s-1 exchange (0.3-0.7 95% CI), however this is at the limit of detection and the
exchange rate may be lower. h) Boltzmann averages of the RMSD of helix 3 charge
clamp (K329) indicate higher variance in the position of K329 compared to when bound
to inverse agonists/antagonists or agonists. i) Boltzmann averages of the helicity of a
section of helix 3 near the charge clamp and containing the Q322C BTFA probe shows
higher variance in the helicity in apo PPARγ compared to when bound to inverse
agonists/antagonists or agonists.
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Supplementary Figure 4. The n-terminal portion of helix 3 shows diverse ligand
dependent conformations. a-b) PPARγ-Q299C was labeled with BTFA bound to the
indicated ligands (or apo) and peptides and fluorine NMR spectra were collected. c) The
extent of helix 3 extension beyond the normally observed n-terminus (V305) is indicated
for individual simulations along with the Boltzmann average (pink bar). d) Comparison of
the crystal structure of rosiglitazone bound PPARγ (white; PDB code 2PRG) with
simulation structures of rosiglitazone bound PPARγ (dim grey) and T0070907 bound
PPARγ (gold). The location of the probe (Q299) and the usual n-terminus of helix 3
(V305) is shown. e) Three crystal structures show n-terminal helix 3 extension to residue
301/272 (khaki), which is different from the non-helical form usually observed in this
region (light blue; PDB code 1PRG). The three structures with n-terminal extension are
PPARγ bound to a partial agonist (PDB code 1ZEO) and PPARγ bound to two
antagonists (6C5Q, 6C5T). f) Overall Boltzmann average (pink bars) and average helicity
(black circles) of a region (291-306) where n-terminal extension is observed in some
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simulations. This region was chosen for analysis as it is the same region as observed
peptides from the HDX-MS analysis (Supplementary Figure 8)

Supplementary Figure 5. Accelerated molecular simulations indicate that two
inverse agonists induce different conformations when bound to a peptide from the
corepressor peptide NCoR. aMD simulations were run of PPARγ bound to the indicated
ligands and a NCoR peptide. a) Representative structures from clustering based on helix
12 RMSD of structures in the wells indicated in panel g. The identity of the energy well
and the calculated prevalence of each well’s structures within the Boltzmann ensemble
(see methods) is indicated by the number and percent in parentheses respectively. The
prevalence of the structures within a particular well is indicated by the color of helix 12
ranging from dark green for the most prevalent to olive drab, light green, light blue and
then deep sky blue for the least prevalent. For reference, an active structure
(rosiglitazone bound PPARγ; 2PRG chain A) is shown with helix 12 colored dim grey.
The relative energies of the wells indicated in panel b are shown in Supplementary
Table 9.
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Supplementary Table 5. Fold change in corepressor (NCoR) affinity compared to WT
PPARγ LBD

Fold change for each construct and ligand is shown relative to the same condition in WT
PPARγ LBD. Significance is determined by T-test corrected for multiple comparison using
the Holm-Sidak method
P ≤ 0.05. A blue arrow indicates a loss of affinity relative to
WT while a red arrow indicates a higher affinity. NS indicates that the value is not
statistically significant.
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Supplementary Table 6, Kd values for PPARγ constructs and NCoR when bound to
each ligand used in this study

Construct
WT PPARγ
Q314A
K329A
N340A
K347A
E499L
Deletion of
Helix 12

PPARγ (apo)

PPARγT0070907

PPARγSR10221

PPARγGW9662

388.25±38.86
480.10±86.27
3474.35±18.88
572.70±53.03
1056.55±64.42
318.43±5.80
70.13±35.64

97.33±5.07
255.75±107.27
703.05±90.16
142.40±5.80
307.45±32.74
158.93±16.05
97.35±61.36

424.83±124.86
296.50±16.40
2985.00±791.96
503.25±29.34
473.9±13.01
104.82±15.24
53.65±29.05

255.93±23.21
1114.20±307.73
1556.50±40.31
369.95±1.77
632.5±55.44
396.80±84.00
90.15±56.35

Values are reported in nanomolar. Error represents the standard deviation of n separate
experiments for each condition. For WT PPARγ n = 4, for Q314A n = 2, for K329A n = 2,
for N340A n = 2, for K347A n = 2, for E499L n = 3, for Deletion of helix 12 n = 4. Kd
values were determined from non-linear regression four-parameter variable slope fit of 12
data points with concentrations ranging from 25 – 50,000nM ligand and protein. All fits
were performed in GraphPad Prism 7.02.
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Supplementary Figure 6. Helix 3 extension reduces omega loop-helix 3 interaction
and salt-bridge interactions. a) Comparison of the total number of hydrogen bonds
between the omega loop and helix 3 for simulations of various complexes and b)
comparison between the Boltzmann average of the root mean square deviation between
helix 3 and the omega loop and helix 3 extension. c) Comparison of the prevalence of
hydrogen bonding between beta sheet residues for the indicated complexes. Bars
represent Boltzmann averages, dots represent values of the individual aMD inspired cMD
simulations.
d) Analysis of the indicated salt bridge formation for all available crystal structures of
PPARγ .e) Comparison of the prevalence of the indicated salt bridges and helical
extension for the indicated complexes and for all available crystal structures. The helix 67 loop (R385/357) to helix 11-12 loop (E488/460) salt bridge is not observed for the 13
structural ensembles with an n-terminal helix 3 extension of 2 or more residues beyond
V305/277 (i.e. the n-terminus of helix 3 normally observed in crystal structures) while it is
observed in 22 of 27 structures that lack helix 3 extension. 12 of 13 structural ensembles
with an extended helix 3 lack the R385 to E304 salt bridge while it is present in 26 of 27
structural ensembles without an extended helix 3.
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Supplementary Figure 7. 19F NMR reveals structurally and functionally distinct
states in the charge clamp region of helix 3.
a-b) PPARγQ322C covalently bound to T0070907 or GW9662 (which bind to the sole native
cysteine, C313) was labeled with high concentration of BTFA (40x the protein
concentration of ~150 μM) to yield high signal to noise spectra with no possibility of
labeling the native cysteine. The indicated coregulators or RXRα were added at a 2:1
molar ratio. These spectra yield evidence of multiple peaks even without other proteins or
peptides bound, most obviously for PPARγQ322C-BTFA bound to GW9662 (panel b). d-f)
PPARγQ322C-BTFA was loaded with the indicated ligands and 19F NMR spectra were
acquired followed by deconvolution. g) Saturating pulses (circles) were applied at the
minor peak chemical shift (on; black circles) and at a control location equidistant from the
main peak (off; blue circles) for various durations. The normalized intensity of the main
peak was monitored and plotted against the duration of the pulses and fit to determine
the exchange rate (1.7 s-1; 95% CI=1.5-2.0). h) CEST indicates exchange between the
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minor left peak and the major peak in PPARγQ322C-BTFA (top spectrum; panel b). The
position of the black circles indicate the region of saturation and their y position indicates
the height of the major peak (black arrow) upon saturation. A small deviation is noted
when saturating near the minor peak (red arrow) indicating exchange between the minor
and major peak. i) deconvolution of the GW9662 spectrum indicated the presence of
signal downfield (left) of the readily visible peaks. We tested for exchange of these peaks
with the major peak using selective saturating pulses in this region (orange arrows) and
control upfield pulses equidistant from the major peak (black arrows). The intensity of the
major peak was measured after saturating pulses at these locations and compared. This
was repeated 4 times on the same sample at each location. A two-tailed t-test indicates
that the downfield peaks exist and exchange with the major peak.
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Supplementary Figure 8. HDX-MS data of PPARγ bound to NCoR peptide alone or cobound to T0070907 or SR10221. Detected peptide sequences residue numbers and
change in HDX is shown. A decrease in exchange in the T0070907 complex peptide
compared to the indicated complexes is shown as a negative number while an increase
is shown as a positive number. Standard deviation is shown in parantheses. Peptides
with significant differences are shown in color, while insignificant are shown in grey and
have an asterisk. NA means matching peptides were not found.
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Supplementary Figure 9. Helix 12 binds to the coregulator surface in many crystal
structures in a similar manner to NCoR and Helix 12 in simulations. Representative
structures from the fifth lowest energy well in apo PPARγ where helix 12 binds to the
coregulator binding surface (left; gold) and the second lowest energy well from the
PPARγ cobound to SR10221 and NCoR (right; gold) simulations are aligned with the unit
cell of an antagonist bound structure (PDB code 6c5q).
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Supplementary Figure 10. SMRT induces similar changes to helix 12 as NCoR for
PPARγ bound to the indicated ligands. PPARγK502C-BTFA was saturated with the
indicated ligands and a 2:1 molar ratio of SMRT peptide was added. Fluorine NMR was
then performed.
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